US5783181A - Therapeutic uses of fusion proteins between mutant IL 4/IL13 antagonists and immunoglobulins - Google Patents

Therapeutic uses of fusion proteins between mutant IL 4/IL13 antagonists and immunoglobulins Download PDF

Info

Publication number
US5783181A
US5783181A US08/470,299 US47029995A US5783181A US 5783181 A US5783181 A US 5783181A US 47029995 A US47029995 A US 47029995A US 5783181 A US5783181 A US 5783181A
Authority
US
United States
Prior art keywords
dna
seq
igg4
disease
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
US08/470,299
Inventor
Michael Joseph Browne
Peter Ronald Young
Allan Richard Shatzman
Kay Elizabeth Murphy
Conrad Gerald Chapman
Helen Elizabeth Clinkenbeard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Ltd
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd, SmithKline Beecham Corp filed Critical SmithKline Beecham Ltd
Assigned to SMITHKLINE BEECHAM CORPORATION, SMITHKLINE BEECHAM CORPORATION reassignment SMITHKLINE BEECHAM CORPORATION ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SHATZMAN, ALLAN RICHARD, YOUNG, PETER RONALD, BROWNE, MICHAEL JOSEPH, CHAPMAN, CONRAD GERALD, CLINKENBEARD, HELEN ELIZABETH, MURPHY, KAY ELIZABETH
Application granted granted Critical
Publication of US5783181A publication Critical patent/US5783181A/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5406—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Definitions

  • the present invention relates to antagonists of human interleukin 4 (IL4) and/or human interleukin 13 (IL13) for the treatment of conditions resulting from undesirable actions of IL4 and/or IL13 such as certain IgE mediated allergic diseases, T cell mediated autoimmune conditions and inappropriate immune responses to infectious agents.
  • IL4 human interleukin 4
  • IL13 human interleukin 13
  • Interleukins are secreted peptide mediators of the immune response. Each of the known interleukins has many effects on the development, activation, proliferation and differentiation of cells of the immune system.
  • IL4 has a physiological role in such functions, but can also contribute to the pathogenesis of disease.
  • IL4 is associated with the pathway of B lymphocyte development that leads to the generation of IgE antibodies that are the hallmark of allergic diseases such as extrinsic asthma, rhinitis, allergic conjunctivitis, atopic dermatitis and anaphylaxis.
  • IL4 can also act as a general growth and differentiation factor for T lymphocytes that may contribute to tissue damage in certain autoimmune conditions such as insulin dependent diabetes, multiple sclerosis and rheumatoid arthritis and in graft rejection. IL4 can also suppress the generation of cell-mediated responses required for the control of infectious disease. Antagonism of the effect of IL4 on T or B lymphocytes can therefore be expected to have beneficial effects on such diseases.
  • IL13 has been recently identified and shares similarity in many of the biological properties of IL4 (Minty, A. et al (1993), Nature 362, 248-250) including some aspect(s) of receptor structure/function (Aversa, G. et al (1993), J. Exp. Med. 178, 2213-2218).
  • Human IL4 consists of a single polypeptide chain of 129 amino acids with 2 possible N-glycosylation sites and 6 cysteines involved in 3 disulphide bridges (Le, H. V. et. al., (1988), J. Biol. Chem. 263, 10817-10823).
  • the amino acid sequence of IL4 and the positions of these disulphide bridges are known (Carr, C. et al., (1991) Biochemistry 30, 1515-1523) SEQ ID NO:21. ##
  • the disulphide bridges are between residues 3 and 127, 24 and 65, and 46 and 99.
  • the molecular weight of IL4 varies with the extent of glycosylation from 15 KDa (no glycosylation) to 60 KDa or more (hyperglycosylated IL4).
  • WO 93/10235 describes certain mutants of IL4 which are IL4 antagonists or partial antagonists.
  • EP-A-0 464 533 discloses fusion proteins comprising various portions of the constant region of immunoglobulin molecules together with another human protein or part thereof.
  • the present invention provides a soluble protein having IL4 and/or IL13 antagonist or partial antagonist activity, comprising an IL4 mutant or variant fused to least one human immunoglobulin constant domain or fragment thereof.
  • mutant or variant encompasses any molecule such as a truncated or other derivative of the IL4 protein which retains the ability to antagonise IL4 and/or IL13 following internal administration to a human.
  • Such other derivatives can be prepared by the addition, deletion, substitution, or rearrangement of amino acids or by chemical modifications thereof.
  • DNA polymers which encode mutants or variants of IL4 may be prepared by site-directed mutagenesis of the cDNA which codes for IL4 by conventional methods such as those described by G. Winter et al in Nature 1982, 299, 756-758 or by Zoller and Smith 1982; Nucl. Acids Res., 10, 6487-6500, or deletion mutagenesis such as described by Chan and Smith in Nucl. Acids Res., 1984, 12, 2407-2419 or by G. Winter et al in Biochem. Soc. Trans., 1984; 12, 224-225 or polymerase chain reaction such as described by Mikaelian and Sergeant in Nucleic Acids Research, 1992, 20, 376.
  • IL4 and/or IL13 antagonist or partial antagonist activity means that, in the assay described by Spits et al (J. Immunology 139, 1142 (1987)), IL4-stimulated T cell proliferation is inhibited in a dose-dependent manner.
  • Suitable IL4 mutants are disclosed in WO 93/10235, wherein at least one amino acid, naturally occurring in wild type IL4 at any one of positions 120 to 128 inclusive, is replaced by a different natural amino acid.
  • the tyrosine naturally occurring at position 124 may be replaced by a different natural amino acid, such as glycine or, more preferably, aspartic acid.
  • the immunoglobulin may be of any subclass (IgG, IgM, IgA, IgE), but is preferably IgG, such as IgG1, IgG3 or IgG4.
  • the said constant domain(s) or fragment thereof may be derived from the heavy or light chain or both.
  • the invention encompasses mutations in the immunoglobulin component which eliminate undesirable properties of the native immunoglobulin, such as Fc receptor binding and/or introduce desirable properties such as stability. For example, Angal S., King D. J., Bodmer M. W., Turner A., Lawson A. D. G., Roberts G., Pedley B.
  • the constant domain(s) or fragment thereof is preferably the whole or a substantial part of the constant region of the heavy chain of human IgG, most preferably IgG4.
  • the IgG component consists of the CH2 and CH3 domains and the hinge region of IgG1 including cysteine residues contributing to inter-heavy chain disulphide bonding, for example residues 11 and 14 of the IgG1 hinge region (Frangione B. and Milstein C., Nature vol216pp939-941, 1967).
  • the IgG1 component consists of amino acids corresponding to residues 1-4 and 6-15 of the hinge, 1-110 of CH2 and 1-107 of CH3 of IgG1 described by Ellison J., Berson B. and Hood L.
  • the hinge is changed from cysteine in the published IgG1 sequence to alanine by alteration of TGT to GCC in the nucleotide sequence.
  • the IgG component is derived from IgG4, comprising the CH2 and CH3 domains and the hinge region including cysteine residues contributing to inter-heavy chain disulphide bonding, for example residues 8 and 11 of the IgG4 hinge region (Pinck J. R. and Milstein C., Nature vol216pp941-942, 1967).
  • the IgG4 component consists of amino acids corresponding to residues 1-12 of the hinge, 1-110 of CH2 and 1-107 of CH3 of IgG4 described by Ellison J., Buxbaum J. and Hood L., DNA vol1pp11-18, 1981.
  • residue 10 of the hinge (residue 241, Kabat numbering) is altered from serine (S) in the wild type to proline (P) and residue 5 of CH2 (residue 248, Kabat numbering) is altered from leucine (L) in the wild type to glutamate (E).
  • Fusion of the IL4 mutant or variant to the Ig constant domain or fragment is by C-terminus of one component to N-terminus of the other.
  • the IL4 mutant or variant is fused via its C-terminus to the N-terminus of the Ig constant domain or fragment.
  • amino acid sequence of the fusion protein of the invention is represented by SEQ ID No:4, SEQ ID No:7 or SEQ ID No:10.
  • the invention provides a process for preparing a compound according to the invention which process comprises expressing DNA encoding said compound in a recombinant host cell and recovering the product.
  • the DNA polymer comprising a nucleotide sequence that encodes the compound also forms part of the invention.
  • the DNA polymer comprises or consists of the sequence of SEQ ID No:3, SEQ ID No:6 or SEQ ID No:9.
  • the process of the invention may be performed by conventional recombinant techniques such as described in Maniatis et. al., Molecular Cloning--A Laboratory Manual; Cold Spring Harbor, 1982 and DNA Cloning vols I, II and III (D. M. Glover ed., IRL Press Ltd).
  • the process may comprise the steps of:
  • the invention also provides a process for preparing the DNA polymer by the condensation of appropriate mono-, di- or oligomeric nucleotide units.
  • the preparation may be carried out chemically, enzymatically, or by a combination of the two methods, in vitro or in vivo as appropriate.
  • the DNA polymer may be prepared by the enzymatic ligation of appropriate DNA fragments, by conventional methods such as those described by D. M. Roberts et al in Biochemistry 1985, 24, 5090-5098.
  • the DNA fragments may be obtained by digestion of DNA containing the required sequences of nucleotides with appropriate restriction enzymes, by chemical synthesis, by enzymatic polymerisation on DNA or RNA templates, or by a combination of these methods.
  • Digestion with restriction enzymes may be performed in an appropriate buffer at a temperature of 20°-70° C., generally in a volume of 50 ⁇ l or less with 0.1-10 ⁇ g DNA.
  • Enzymatic polymerisation of DNA may be carried out in vitro using a DNA polymerase such as DNA polymerase I (Klenow fragment) in an appropriate buffer containing the nucleoside triphosphates dATP, dCTP, dGTP and dTTP as required at a temperature of 10°-37° C., generally in a volume of 50 ⁇ l or less.
  • a DNA polymerase such as DNA polymerase I (Klenow fragment) in an appropriate buffer containing the nucleoside triphosphates dATP, dCTP, dGTP and dTTP as required at a temperature of 10°-37° C., generally in a volume of 50 ⁇ l or less.
  • Enzymatic ligation of DNA fragments may be carried out using a DNA ligase such as T4 DNA ligase in an appropriate buffer at a temperature of 4° C. to ambient, generally in a volume of 50 ⁇ l or less.
  • a DNA ligase such as T4 DNA ligase in an appropriate buffer at a temperature of 4° C. to ambient, generally in a volume of 50 ⁇ l or less.
  • the chemical synthesis of the DNA polymer or fragments may be carried out by conventional phosphotriester, phosphite or phosphoramidite chemistry, using solid phase techniques such as those described in ⁇ Chemical and Enzymatic Synthesis of Gene Fragments--A Laboratory Manual ⁇ (ed. H. G. Gassen and A. Lang), Verlag Chemie, Weinheim (1982),or in other scientific publications, for example M. J. Gait, H. W. D. Matthes, M. Singh, B. S. Sproat, and R. C. Titmas, Nucleic Acids Research, 1982, 10, 6243; B. S. Sproat and W. Bannwarth, Tetrahedron Letters, 1983, 24, 5771; M. D.
  • the DNA polymer is preferably prepared by ligating two or more DNA molecules which together comprise a DNA sequence encoding the compound.
  • a particular process in accordance with the invention comprises ligating a first DNA molecule encoding a said IL4 mutant or variant and a second DNA molecule encoding a said immunoglobulin domain or fragment thereof.
  • the DNA molecules may be obtained by the digestion with suitable restriction enzymes of vectors carrying the required coding sequences or by use of polymerase chain reaction technology.
  • DNA molecules The precise structure of the DNA molecules and the way in which they are obtained depends upon the structure of the desired product.
  • the design of a suitable strategy for the construction of the DNA molecule coding for the compound is a routine matter for the skilled worker in the art.
  • the expression of the DNA polymer encoding the compound in a recombinant host cell may be carried out by means of a replicable expression vector capable, in the host cell, of expressing the DNA polymer.
  • the expression vector is novel and also forms part of the invention.
  • the replicable expression vector may be prepared in accordance with the invention, by cleaving a vector compatible with the host cell to provide a linear DNA segment having an intact replicon, and combining said linear segment with one or more DNA molecules which, together with said linear segment, encode the compound, under ligating conditions.
  • the ligation of the linear segment and more than one DNA molecule may be carried out simultaneously or sequentially as desired.
  • the DNA polymer may be preformed or formed during the construction of the vector, as desired.
  • the choice of vector will be determined in part by the host cell, which may be prokaryotic, such as E. coli, or eukaryotic, such as mouse C127, mouse myeloma, chinese hamster ovary or Hela cells, fungi e.g. filamentous fungi or unicellular yeast or an insect cell such as Drosophila.
  • the host cell may also be a transgenic animal.
  • Suitable vectors include plasmids, bacteriophages, cosmids and recombinant viruses derived from, for example, baculoviruses, vaccinia or Semliki Forest virus.
  • the preparation of the replicable expression vector may be carried out conventionally with appropriate enzymes for restriction, polymerisation and ligation of the DNA, by procedures described in, for example, Maniatis et al., cited above. Polymerisation and ligation may be performed as described above for the preparation of the DNA polymer. Digestion with restriction enzymes may be performed in an appropriate buffer at a temperature of 20°-70° C., generally in a volume of 50 ⁇ l or less with 0.1-10 ⁇ g DNA.
  • the recombinant host cell is prepared, in accordance with the invention, by transforming a host cell with a replicable expression vector of the invention under transforming conditions.
  • Suitable transforming conditions are conventional and are described in, for example, Maniatis et al., cited above, or "DNA Cloning" Vol. II, D. M. Glover ed., IRL Press Ltd, 1985.
  • a bacterial host such as E. coli may be treated with a solution of CaCl 2 (Cohen et al, Proc. Nat. Acad. Sci., 1973, 69, 2110) or with a solution comprising a mixture of RbCl, MnCl 2 , potassium acetate and glycerol, and then with 3- N-morpholino!propane-sulphonic acid, RbCl and glycerol.
  • Mammalian cells in culture may be transformed by calcium co-precipitation of the vector DNA onto the cells.
  • the invention also extends to a host cell transformed with a replicable expression vector of the invention.
  • Culturing the transformed host cell under conditions permitting expression of the DNA polymer is carried out conventionally, as described in, for example, Maniatis et al and "DNA Cloning" cited above.
  • the cell is supplied with nutrient and cultured at a temperature below 45° C.
  • the expression product is recovered by conventional methods according to the host cell.
  • the host cell is bacterial, such as E. coli it may be lysed physically, chemically or enzymatically and the protein product isolated from the resulting lysate. If the product is to be secreted from the bacterial cell it may be recovered from the periplasmic space or the nutrient medium. Where the host cell is mammalian, the product may generally be isolated from the nutrient medium.
  • the DNA polymer may be assembled into vectors designed for isolation of stable transformed mammalian cell lines expressing the product; e.g. bovine papillomavirus vectors or amplified vectors in chinese hamster ovary cells (DNA cloning Vol.11 D. M. Glover ed. IRL Press 1985; Kaufman, R. J. et al., Molecular and Cellular Biology 5, 1750-1759, 1985; Pavlakis G. N. and Hamer, D. H., Proceedings of the National Academy of Sciences (USA) 80, 397-401, 1983; Goeddel, D. V. et al., European Patent Application No. 0093619, 1983).
  • bovine papillomavirus vectors or amplified vectors in chinese hamster ovary cells
  • Compounds of the present invention have IL4 and/or IL13 antagonist activity and are therefore of potential use in the treatment of conditions resulting from undesirable actions of IL4 and/or IL13 such as IgE mediated allergic diseases and T cell mediated autoimmune conditions or chronic microbial infection.
  • the invention therefore further provides a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of the invention and a pharmaceutically acceptable carrier.
  • the compound will normally be employed in the form of a pharmaceutical composition in association with a human pharmaceutical carrier, diluent and/or excipient, although the exact form of the composition will depend on the mode of administration.
  • the compound may, for example, be employed in the form of aerosol or nebulisable solution for inhalation or sterile solutions for parenteral administration.
  • the dosage ranges for administration of the compounds of the present invention are those to produce the desired effect on the IL4 and/or IL13 mediated condition, for example whereby IgE antibody mediated symptoms are reduced or progression of the autoimmune disease is halted or reversed.
  • the dosage will generally vary with age, extent or severity of the medical condition and contraindications, if any.
  • the unit dosage can vary from less than 1 mg to 300 mg, but typically will be in the region of 1 to 20 mg per dose, in one or more doses, such as one to six doses per day, such that the daily dosage is in the range 0.02-40 mg/kg.
  • compositions suitable for injection may be in the form of solutions, suspensions or emulsions, or dry powders which are dissolved or suspended in a suitable vehicle prior to use.
  • Fluid unit dosage forms are prepared utilising the compound and a pyrogen-free sterile vehicle.
  • the compound depending on the vehicle and concentration used, can be either dissolved or suspended in the vehicle. Solutions may be used for all forms of parenteral administration, and are particularly used for intravenous infection. In preparing solutions the compound can be dissolved in the vehicle, the solution being made isotonic if necessary by addition of sodium chloride and sterilised by filtration through a sterile filter using aseptic techniques before filling into suitable sterile vials or ampoules and sealing. Alternatively, if solution stability is adequate, the solution in its sealed containers may be sterilised by autoclaving. Advantageously additives such as buffering, solubilising, stabilising, preservative or bactericidal, suspending or emulsifying agents and/or local anaesthetic agents may be dissolved in the vehicle.
  • Dry powders which are dissolved or suspended in a suitable vehicle prior to use may be prepared by filling pre-sterilised drug substance and other ingredients into a sterile container using aseptic technique in a sterile area.
  • the drug and other ingredients may be dissolved in an aqueous vehicle, the solution is sterilised by filtration and distributed into suitable containers using aseptic technique in a sterile area. The product is then freeze dried and the containers are sealed aseptically.
  • Parenteral suspensions suitable for intramuscular, subcutaneous or intradermal injection, are prepared in substantially the same manner, except that the sterile compound is suspended in the sterile vehicle, instead of being dissolved and sterilisation cannot be accomplished by filtration.
  • the compound may be isolated in a sterile state or alternatively it may be sterilised after isolation, e.g. by gamma irradiation.
  • a suspending agent for example polyvinylpyrrolidone is included in the composition to facilitate uniform distribution of the compound.
  • compositions suitable for administration via the respiratory tract include aerosols, nebulisable solutions or microfine powders for insufflation. In the latter case, particle size of less than 50 microns, especially less than 10 microns, is preferred. Such compositions may be made up in a conventional manner and employed in conjunction with conventional administration devices.
  • a method of treating conditions resulting from undesirable actions of IL4 and/or IL13 which comprises administering to the sufferer an effective amount of a compound of the invention.
  • the invention further provides a compound of the invention for use as an active therapeutic substance, in particular for use in treating conditions resulting from undesirable actions of IL4 and/or IL13.
  • the invention also provides the use of a compound of the invention in the manufacture of a medicament for treating conditions resulting from undesirable actions of IL4 and/or IL13.
  • PCR primers were designed to include restriction enzyme sites, flanked by 10-15 nucleotide base pairs to "anchor" the primers at each end.
  • the primer sequences were as follows: ##STR2##
  • Primers were used at a final concentration of 5 ng/ ⁇ l, and dNTPs were added at a final concentration of 0.2 mM in a total reaction volume of 100 ⁇ l. 31 cycles of PCR were performed. Cycles consisted of a denaturation step of 1 minute at 94° C., an annealing step of 1 minute 30 seconds at 50° C., and an elongation step of 1 minute 30 seconds at 72° C. On cycle 1 denaturation was extended to 5 minutes and on the final cycle elongation was extended to 7 minutes. 2.5 units of the Taq polymerase enzyme from Advanced Biotechnologies were used in the PCR reaction. A PCR product of 587 bp was produced.
  • the 570 bp band was purified by the GenecleanTM procedure, and ligated into Bluescript KS + TM which was prepared by digestion with EcoRI and KpnI followed by GenecleanTM. A Bluescript KS + /IL4.Y124D recombinant was thus generated. Large amounts of this recombinant DNA were produced using the Promega "Magic Maxiprep" method.
  • the IL4.Y124D insert was excised from the Bluescript recombinant using SmaI and KpnI. 20 ⁇ g recombinant DNA was incubated with 25 units SmaI in react buffer 4, at 30° C. overnight. 25 units of KpnI were then added to the digest, which was incubated at 37° C. for 5 hours. The resulting fragment of approximately 580 bp was purified by Geneclean TM to generate an IL4.Y124D/SmaI/KpnI fragment.
  • the COSFcLink vector (Table 1) contains human IgG1 cDNA encoding amino acids 1-4 and 6-15 of the hinge, 1-110 of CH2 and 1-108 of CH3 described by Ellison J., Berson B. and Hood L. E., Nucleic Acids Research vol10, pp4071-4079, 1982. Residue 5 of the hinge is changed from cysteine in the published IgG1 sequence to alanine by alteration of TGT to GCC in the nucleotide sequence. This was cloned from the human IgG plasma cell leukemia ARH-77 (American Type Tissue Collection), using RT-PCR and fully sequenced to confirm identity with the publish ed sequence patent application publication WO 92/00985!.
  • COSFc The construction of COSFc began with a pUC 18 vector containing the human IgG1 cDNA above (pUC18-Fc), which was digested with KpnI and SacII, deleting the CH1, hinge and part of CH2. The deleted region was replaced with a PCR amplified fragment containing the hinge-CH2 region as follows. Using the following PCR primers: ##STR3##
  • a DNA fragment containing the hinge-CH2 region was amplified from pUC18-Fc, digested with KpnI and SacII, gel purified and cloned into the KpnI/SacII digested pUC18-Fc vector.
  • the Cys which occurs at position 230 (Kabat numbering; Kabat et al., "Sequences of Proteins of Immunological Interest, 5th Edition, US Department of Health and Human Services, NIH Publication No. 91-3242 (1991)) of the IgG1 heavy chain, was altered to an Ala through a TGT to GCC substitution in the nucleotide sequence.
  • the entire hinge-CH2-CH3 insert in pUC18-Fcmod was removed in a single DNA fragment with KpnI and XbaI, gel purified, and ligated into SFcR1Cos4 cut with KpnI and XbaI to create COSFc.
  • SFcR1Cos4 is a derivative of pST4DHFR (Deen, K., McDougal, J. S., Inacker, R., Folena-Wasserman, G., Arthos, J., Rosenberg, J., Maddon, P. J., Axel, R., and Sweet, R. W.
  • sFcR1 soluble Fc receptor type I
  • BGH bovine growth hormone
  • DHFR dihydrofolate reductase
  • the COSFcLink vector was made from COSFc by inserting an oligonucleotide linker at the unique EcoRI site of the vector, which recreates this EcoRI site, and also introduces BstEII, PstI and EcoRV cloning sites.
  • the oligonucleotides used were: ##STR4##
  • the junction was sequenced to confirm orientation in the vector.
  • the size of the final vector is 6.37 kb.
  • the COSFcLink vector was prepared by digesting with EcoRV and KpnI as follows: 5 ⁇ g DNA was incubated with 15 units EcoRV in react 2 at 37° C. for 5 hours, followed by ethanol precipitation. The resulting DNA was digested with KpnI in react 4 at 37° C. for 3 hours, and ethanol precipitated. The IL4.Y124D/SmaI/KpnI and the COSFcLink/EcoRV/KpnI fragments were ligated together to form plasmid pDB951, which encodes the IL4.Y124D/IgG1 fusion protein.
  • the ligation was achieved using an Amersham DNA ligation kit, product code RPN 1507, the reactions being incubated at 16° C. overnight.
  • the ligation reaction products were transformed into Promega JM109 competent cells (high efficiency) and plated onto Luria Broth agar containing ampicillin at 50 ⁇ g/ml. Transformants were cultured in Luria Broth (containing ampicillin at 50 ⁇ g/ml) and DNA prepared using Promega "Magic Minipreps". Production of an IL4.Y124D/COSFcLink recombinant DNA was verified by restriction digests and DNA sequencing. The complete IL4.Y124D sequence and the junctions with the COSFcLink DNA were confirmed by DNA sequencing (Table 2).
  • the coding sequence of the recombinant IL4.Y124D/IgG1 DNA is shown in Table 3 and the amino acid sequence of the fusion protein is shown in Table 4.
  • the IL4.Y124D/COSFcLink recombinant DNA was prepared and purified using caesium chloride gradients and the DNA used to transiently transfect HeLa cells.
  • HeLa cells were grown in MEM ⁇ medium (Gibco) with 10% foetal calf serum and 1% glutamine.
  • MEM ⁇ medium Gibco
  • 1 ⁇ 10 6 HeLa cells were seeded in 15 mls RPMI-1640 medium with 10% newborn calf serum, 1% glutamine ("seeding medium"), in a 75 cm 2 flask, four days prior to transfection. On the day prior to transfection, a further 12.5 mls seeding medium was added to each flask. On the day of transfection, the medium was changed to 15 mls of "transfection medium” (MEM medium with Earle's salts containing 10% newborn calf serum and 1% non essential amino acids), at time zero.
  • transfection medium MEM medium with Earle's salts containing 10% newborn calf serum and 1% non essential amino acids
  • the IL4.Y124D/IgG1 chimera inhibited 3 H thymidine incorporation by human peripheral blood T lymphocytes stimulated with 133pM IL4 in a dose dependent manner.
  • PCR was performed to amplify the IL4.Y124D coding region and introduce a silent nucleotide substitution at the 3' end which creates a XhoI site.
  • substrate for the PCR reaction 20 ng of linearised pDB951 plasmid (Example 1.1(c)) was used.
  • the oligonucleotide primers used were as follows: ##STR5##
  • a second PCR reaction was performed to amplify the hinge-CH2-CH3 fragment of the human IgG4 heavy chain.
  • the substrate for this was a synthetic human IgG4 heavy chain cDNA, the sequence of which is described in Table 5, and is based on the Genbank sequence GB:HUMIGCD2 (Ellison J., Buxbaum J. and Hood L. E., DNA 1:11-18, 1981). Numerous silent substitutions were made to the published nucleotide sequence.
  • the gene was assembled by combining two 0.5 Kb synthetic DNA fragments. Each 0.5 Kb fragment was made by annealing a series of overlapping oligonucleotides and then filling in the gaps by PCR.
  • the two 0.5 Kb fragments were joined at the SacII site and inserted into the pCR2 vector.
  • a 1.0 Kb ApaI-BglII fragment containing the entire constant region was isolated and ligated into an expression vector, pCD, containing a humanized IL4 specific variable region. This construct was used as the PCR substrate to amplify the hinge-CH2-CH3 region of IgG4.
  • oligonucleotide primers used for amplification of the IgG4 hinge-CH2-CH3 region were as follows: ##STR6##
  • PCR products of approximately 700 bp (hinge-CH2-CH3 of IgG4) and 400 bp (IL4.Y124D) were obtained and purified using the Promega "Magic PCR cleanup" kit.
  • the purified PCR reactions were then digested with the following enzymes to create "sticky ends": XhoI and XbaI for IgG4 and EcoRV and XhoI for IL4.Y124D.
  • the digests were incubated at 37° C. for 3 hours and then ethanol precipitated.
  • the resulting DNAs were analysed by gel electrophoresis and gave sizes of approximately 690 bp (hinge-CH2-CH3 of IgG4) and 370bp (IL4.Y124D).
  • a vector was prepared into which to ligate the hinge-CH2-CH3 of IgG4 and IL4.Y124D PCR fragments by digesting pDB951 (IL4.Y124D in COSFcLink) with EcoRV and XbaI to remove most of the IL4.Y124D/IgG1 fusion molecule. The only part remaining is approximately 75 bp at the 5' end of ILA, which is not present in the IL4.Y124D EcoRV/XhoI fragment produced by PCR amplification. 5 ⁇ g of pDB951 DNA was digested in a total volume of 30 ⁇ l using react 2 buffer (GibcoBRL). The resulting 5.8 Kb DNA fragment was purified using the GenecleanTM procedure.
  • the three fragments described (IL4.Y124D EcoRV/XhoI, hinge-CH2-CH3 of IgG4 XhoI/XbaI and the 5.8 Kb fragment resulting from EcoRV/XbaI digestion of pDB951) were ligated together to form plasmid pDB952, which encodes the IL4.Y124D/IgG4 fusion protein.
  • the ligation was carried out using a DNA ligation kit from Amersham (product code RPN 1507), incubating the reactions at 16° C. overnight.
  • the ligation reaction products were transformed into Promega JM109 competent cells (high efficiency) and plated onto Luria Broth agar containing ampicillin at 50 ⁇ g/ml.
  • Transformants were cultured in Luria Broth (containing ampicillin at 50 ⁇ g/ml) and DNA prepared using Promega "Magic Minipreps”. Production of an IL4.Y124D/IgG4 recombinant DNA was verified by restriction digests, and the complete IL4.Y124D and hinge-CH2-CH3 IgG4 regions were verified by DNA sequencing. Table 6 describes the sequence of the coding region only of the IL4.Y124D/IgG4 fusion molecule, and Table 7 contains the amino acid sequence of the fusion protein. The IL4.Y124D/IgG4 recombinant DNA was prepared and purified using caesium chloride gradients and the DNA used to transiently transfect HeLa cells.
  • HeLa cells were grown in MEM ⁇ medium (Gibco) with 10% foetal calf serum and 1% glutamine.
  • MEM ⁇ medium Gibco
  • 1 ⁇ 10 6 HeLa cells were seeded in 15 mls RPMI-1640 medium with 10% newborn calf serum, 1% glutamine ("seeding medium"), in a 75cm 2 flask, four days prior to transfection. On the day prior to transfection, a further 12.5 mls seeding medium was added to each flask. On the day of transfection, the medium was changed to 15 mls of "transfection medium” (MEM medium with Earle's salts containing 10% newborn calf serum and 1% non essential amino acids), at time zero.
  • transfection medium MEM medium with Earle's salts containing 10% newborn calf serum and 1% non essential amino acids
  • the IL4.Y124D/IgG4 chimera inhibited 3 H thymidine incorporation by human peripheral blood T lymphocytes stimulated with 133pM IL4 in a dose dependent manner.
  • PCR is performed to amplify the IL4.Y124D coding region and introduce a silent nucleotide substitution at the 3' end which creates a XhoI site as described in Example 2.
  • a second PCR reaction is performed to amplify the hinge-CH2-CH3 fragment of the human IgG4 heavy chain PE variant.
  • residue 10 of the hinge (residue 241, Kabat numbering) is altered from serine (S) in the wild type to proline (P) and residue 5 of CH2 (residue 248, Kabat numbering) is altered from leucine (L) in the wild type to glutamate (E).
  • the IgG4 PE variant was created using PCR mutagenesis on the synthetic human IgG4 heavy chain cDNA described in Table 5, and was then ligated into the pCD expression vector. It was this plasmid which was used as the substrate for the PCR reaction amplifying the hinge-CH2-CH3 fragment of IgG4 PE.
  • the sequence of the IgG4 PE variant is described in Table 8.
  • the residues of the IgG4 nucleotide sequence which were altered to make the PE variant are as follows:
  • residue 322 has been altered to "C" in the PE variant from “T” in the wild type;
  • residue 333 has been altered to "G" in the PE variant from "A” in the wild type.
  • residues 343-344 have been altered to "GA" in the PE variant from "CT” in the wild type.
  • Oligonucleotide primers are used for amplification of the IgG4 PE variant hinge-CH2-CH3 region as described for the derivation of pDB952.
  • PCR products of approximately 700 bp (hinge-CH2-CH3 of IgG4 PE mutant) and 400 bp (IL4.Y124D) are obtained and purified using the Promega "Magic PCR cleanup" kit.
  • the purified PCR reactions are then digested with the following enzymes to create "sticky ends": XhoI and XbaI for IgG4 PE and EcoRV and XhoI for IL4.Y124D.
  • the digests are incubated at 37° C. for 3 hours and then ethanol precipitated.
  • the resulting DNAs are of sizes of approximately 690 bp (hinge-CH2-CH3 of IgG4 PE) and 370bp (IL4.Y124D).
  • the purified and digested PCR products are ligated into Bluescript KS + TM which is prepared by digestion with either XhoI and XbaI for the hinge-CH2-CH3 of IgG4 PE fragment or EcoRV and XhoI for the IL4.Y124D fragment, followed by GenecleanTM.
  • Bluescript KS + /hinge-CH2-CH3 of IgG4 PE recombinant and a Bluescript KS + /IL4.Y124D recombinant are thus generated. Large amounts of these DNAs are produced using the Promega "Magic Maxiprep" method.
  • the IgG4 PE hinge-CH2-CH3 fragment is excised from the Bluescript recombinant using XhoI and XbaI.
  • the resulting fragment of approximately 690 bp is purified by GenecleanTM to generate large amounts of the IgG4 PE hinge-CH2-CH3 XhoI/XbaI fragment.
  • the IL4.Y124D fragment is excised from the Bluescript recombinant using EcoRV and XhoI and the resulting fragment of approximately 370 bp is purified by GenecleanTM.
  • a vector is prepared into which to ligate the hinge-CH2-CH3 of IgG4 PE and IL4.Y124D fragments by digesting pDB951 with EcoRV and XbaI as described for the derivation of pDB952.
  • the three fragments described (IL4.Y124D EcoRV/XhoI, hinge-CH2-CH3 of IgG4 PE variant XhoI/XbaI and the 5.8 Kb fragment resulting from EcoRV/XbaI digestion of pDB951) are ligated together to form plasmid pDB953 using a DNA ligation kit from Amersham (product code RPN 1507), incubating the reactions at 16° C. overnight.
  • the ligation reaction products are transformed into Promega JM109 competent cells (high efficiency) and plated onto Luria Broth agar containing ampicillin at 50 ⁇ g/ml.
  • Transformants are cultured in Luria Broth (containing ampicillin at 50 ⁇ g/ml) and DNA prepared using Promega "Magic Minipreps".
  • Production of an IL4.Y124D/IgG4 PE variant recombinant DNA is verified by restriction digests, and the complete IL4.Y124D and hinge-CH2-CH3 IgG4 PE variant regions are verified by DNA sequencing.
  • Table 9 describes the sequence of the coding region only of the IL4. Y124D/IgG4 PE fusion molecule, and Table 10 contains the amino acid sequence of the fusion protein.
  • the IL4.Y124D/IgG4 PE recombinant DNA is prepared and purified using caesium chloride gradients and the DNA used to transiently transfect HeLa cells.
  • HeLa cells were grown in MEM ⁇ medium (Gibco) with 10% foetal calf serum and 1% glutamine.
  • MEM ⁇ medium Gibco
  • 1 ⁇ 10 6 HeLa cells were seeded in 15mls RPMI-1640 medium with 10% newborn calf serum, 1% glutamine ("seeding medium"), in a 75 cm 2 flask, four days prior to transfection. On the day prior to transfection, a further 12.5 mls seeding medium was added to each flask. On the day of transfection, the medium was changed to 15 mls of "transfection medium" (MEM medium with Earle's salts containing 10% newborn calf serum and 1% non essential amino acids), at time zero. At time +3 hours, 25 ⁇ g of the appropriate DNA in 0.
  • transfection medium MEM medium with Earle's salts containing 10% newborn calf serum and 1% non essential amino acids
  • 125M CaCl 2 , 1 ⁇ HBS HEPES buffered saline
  • 1 ⁇ HBS HEPES buffered saline
  • the cells were subjected to a glycerol shock (15% v/v) and then left to incubate overnight in 12.5 mls seeding medium containing 5 mM sodium butyrate.
  • PBS Dulbecco's phosphate buffered saline
  • 12.5 mls "harvest medium” RPMI-1640 with 2% of a 7.5% stock sodium bicarbonate solution
  • the IL4.Y124D/IgG4 PE chimera inhibited 3 H thymidine incorporation by human peripheral blood T lymphocytes stimulated with 133pM IL4 in a dose dependent manner.
  • the pCDN vector (Aiyar, N., Baker, E., Wu, H.-L., Nambi, P., Edwards, R. M., Trill, J. J., Ellis, C., Bergsma, D. Molecular and Cellular Biochemistry 131:75-86, 1994) contains the CMV promoter, a polylinker cloning region, and the BGH polyadenylation region.
  • This vector also contains a bacterial neomycin phosphotransferase gene (NEO) inserted between the ⁇ -globin promoter and SV40 polyadenylation region for GeneticinTM selection, the DHFR selection cassette inserted between the ⁇ -globin promoter and BGH polydenylation region for methotrexate (MTX) amplification, an ampicillin resistance gene for growth in bacteria, and a SV40 origin of replication.
  • NEO bacterial neomycin phosphotransferase gene
  • the pCDN vector was prepared by digesting with Nde1 and BstX1 as follows: 15 ⁇ g of DNA was incubated with 30 units of BstX1 in react 2 (Gibco-BRL) at 55° C. for 1 hour, and ethanol precipitated. The resulting DNA was digested with Nde1 in react 2 at 37° C. for 1 hour, and ethanol precipitated.
  • the IL4.Y124D/IgG4 PE fragment was prepared from pDB953 (Example 3.1) by digesting with BstX1 and Nde1 as follows: 15 ⁇ g of DNA was incubated with 30 units of BstX1 in react 2 at 55° C. for 1 hour, and ethanol precipitated. The resulting DNA was digested with Nde1 in react 2 at 37° C. for 1 hour, and ethanol precipitated.
  • the IL4.Y124D/IgG4 PE Nde1/BstX1 and pCDN Nde1/BstX1 fragments were ligated together to form the plasmid pCDN-IL4.Y124D/IgG4 PE.
  • the ligation was achieved using 2 units of T4 DNA Ligase (Gibco BRL) with T4 DNA Ligase buffer. The reactions were incubated at 16° C. overnight.
  • the ligation reaction products were transformed into Gibco-BRL DH5a competent cells (subcloning efficiency) and plated onto Luria Broth agar containing 75 ug/ml ampicillin.
  • Transformants were cultured in Luria Broth (containing ampicillin at 50 ug/ml) and DNA prepared by alkaline lysis. Production of a pCDN-IL4.Y124D/IgG4 PE DNA was confirmed by restriction digests. The complete sequence of the recombinant IL4.Y124D/IgG4 PE DNA was confirmed by sequencing. The pCDN-IL4.Y124D/IgG4 PE recombinant DNA was prepared and purified using Qiagen columns and the DNA was used to transiently infect COS cells and electroporated into CHO cells to create stable clones.
  • COS-1 cells were grown in DMEM medium with 10% fetal bovine serum.
  • cells were seeded at 2 ⁇ 10 5 cells into a 35 mm tissue culture dish 24 hours prior.
  • a solution containing 1 ⁇ g of DNA in 100 ⁇ l of DMEM without serum is added to a solution containing 6 ⁇ l of LIPOFECTAMINE Reagent (Gibco-BRL) in 100 ⁇ l of DMEM without serum, gently swirled and incubated at room temperature for 45 minutes.
  • the cells are washed once with serum free DMEM.
  • 0.8ml of serum free DMEM is added to the DNA-LIPOFECTAMINE SOLUTION, mixed gently and the diluted solution is overlayed on the cells.
  • the cells are incubated at 37° C. for 5 hours, then 1 ml of DMEM containing 20% fetal bovine serum is added.
  • the cells are assayed 48-72 hours later to determine expression levels.
  • CHO cells ACC-098 (a suspension cell line derived from CHO DG-44, Urlaub, G., Kas, E., Carothers, A. M. and Chasin, L. A. Cell, 33. 405-412, 1983) were grown in serum free growth medium WO 92/05246.
  • 15 ⁇ g of the pCDN-IL4.Y124D/IgG4 PE plasmid was digested using 30 units of Not1 at 37° C. for 3 hours to linearize the plasmid, and precipitated with ethanol.
  • the resulting DNA was resuspended in 50 ul of 1 ⁇ TE (10 mM Tris, pH 8.0, 1 mM EDTA).
  • the DNA was electroporated into 1 ⁇ 10 7 ACC-098 cells, using a Bio Rad Gene Pulser set at 380V and 25 ⁇ Fd.
  • the cells were resuspended into growth medium at 2.5 ⁇ 10 4 cells/ml, and 200 ⁇ l of the cell suspension was plated into each well of a 96 well plate. 48 hours later the medium was switched to growth medium containing 400 ⁇ g/ml G418 (Geneticin). Twenty one days post selection, conditioned medium from the colonies which arose were screened by Elisa assay. The highest expressing colonies were transferred to 24 well plates in order to be scaled up.

Abstract

A soluble protein having IL4 and/or IL13 antagonist or partial antagonist activity comprises an IL4 mutant or variant fused to least one human immunoglobulin constant domain or fragment thereof.

Description

The present invention relates to antagonists of human interleukin 4 (IL4) and/or human interleukin 13 (IL13) for the treatment of conditions resulting from undesirable actions of IL4 and/or IL13 such as certain IgE mediated allergic diseases, T cell mediated autoimmune conditions and inappropriate immune responses to infectious agents.
Interleukins are secreted peptide mediators of the immune response. Each of the known interleukins has many effects on the development, activation, proliferation and differentiation of cells of the immune system. IL4 has a physiological role in such functions, but can also contribute to the pathogenesis of disease. In particular IL4 is associated with the pathway of B lymphocyte development that leads to the generation of IgE antibodies that are the hallmark of allergic diseases such as extrinsic asthma, rhinitis, allergic conjunctivitis, atopic dermatitis and anaphylaxis. IL4 can also act as a general growth and differentiation factor for T lymphocytes that may contribute to tissue damage in certain autoimmune conditions such as insulin dependent diabetes, multiple sclerosis and rheumatoid arthritis and in graft rejection. IL4 can also suppress the generation of cell-mediated responses required for the control of infectious disease. Antagonism of the effect of IL4 on T or B lymphocytes can therefore be expected to have beneficial effects on such diseases. IL13 has been recently identified and shares similarity in many of the biological properties of IL4 (Minty, A. et al (1993), Nature 362, 248-250) including some aspect(s) of receptor structure/function (Aversa, G. et al (1993), J. Exp. Med. 178, 2213-2218).
Human IL4 consists of a single polypeptide chain of 129 amino acids with 2 possible N-glycosylation sites and 6 cysteines involved in 3 disulphide bridges (Le, H. V. et. al., (1988), J. Biol. Chem. 263, 10817-10823). The amino acid sequence of IL4 and the positions of these disulphide bridges are known (Carr, C. et al., (1991) Biochemistry 30, 1515-1523) SEQ ID NO:21. ##STR1##
The disulphide bridges are between residues 3 and 127, 24 and 65, and 46 and 99. The molecular weight of IL4 varies with the extent of glycosylation from 15 KDa (no glycosylation) to 60 KDa or more (hyperglycosylated IL4).
The DNA sequence for human IL4 has also been described by Yokota, T. et. al., P.N.A.S. 1986 83 5894-5898.
WO 93/10235 describes certain mutants of IL4 which are IL4 antagonists or partial antagonists.
EP-A-0 464 533 discloses fusion proteins comprising various portions of the constant region of immunoglobulin molecules together with another human protein or part thereof.
The present invention provides a soluble protein having IL4 and/or IL13 antagonist or partial antagonist activity, comprising an IL4 mutant or variant fused to least one human immunoglobulin constant domain or fragment thereof.
The term "mutant or variant" encompasses any molecule such as a truncated or other derivative of the IL4 protein which retains the ability to antagonise IL4 and/or IL13 following internal administration to a human. Such other derivatives can be prepared by the addition, deletion, substitution, or rearrangement of amino acids or by chemical modifications thereof.
DNA polymers which encode mutants or variants of IL4 may be prepared by site-directed mutagenesis of the cDNA which codes for IL4 by conventional methods such as those described by G. Winter et al in Nature 1982, 299, 756-758 or by Zoller and Smith 1982; Nucl. Acids Res., 10, 6487-6500, or deletion mutagenesis such as described by Chan and Smith in Nucl. Acids Res., 1984, 12, 2407-2419 or by G. Winter et al in Biochem. Soc. Trans., 1984; 12, 224-225 or polymerase chain reaction such as described by Mikaelian and Sergeant in Nucleic Acids Research, 1992, 20, 376.
As used herein, "having IL4 and/or IL13 antagonist or partial antagonist activity" means that, in the assay described by Spits et al (J. Immunology 139, 1142 (1987)), IL4-stimulated T cell proliferation is inhibited in a dose-dependent manner.
Suitable IL4 mutants are disclosed in WO 93/10235, wherein at least one amino acid, naturally occurring in wild type IL4 at any one of positions 120 to 128 inclusive, is replaced by a different natural amino acid. In particular, the tyrosine naturally occurring at position 124 may be replaced by a different natural amino acid, such as glycine or, more preferably, aspartic acid.
The immunoglobulin may be of any subclass (IgG, IgM, IgA, IgE), but is preferably IgG, such as IgG1, IgG3 or IgG4. The said constant domain(s) or fragment thereof may be derived from the heavy or light chain or both. The invention encompasses mutations in the immunoglobulin component which eliminate undesirable properties of the native immunoglobulin, such as Fc receptor binding and/or introduce desirable properties such as stability. For example, Angal S., King D. J., Bodmer M. W., Turner A., Lawson A. D. G., Roberts G., Pedley B. and Adair R., Molecular Immunology vol30pp105-108, 1993, describe an IgG4 molecule where residue 241 (Kabat numbering) is altered from serine to proline. This change increases the serum half-life of the IgG4 molecule. Canfield S. M. and Morrison S. L., Journal of Experimental Medicine vol173pp1483-1491, describe the alteration of residue 248 (Kabat numbering) from leucine to glutamate in IgG3 and from glutamate to leucine in mouse IgG2b. Substitution of leucine for glutamate in the former decreases the affinity of the immunoglobulin molecule concerned for the FcγRI receptor, and substitution of glutamate for leucine in the latter increases the affinity. EP0307434 discloses various mutations including an L to E mutation at residue 248 (Kabat numbering) in IgG.
The constant domain(s) or fragment thereof is preferably the whole or a substantial part of the constant region of the heavy chain of human IgG, most preferably IgG4. In one aspect the IgG component consists of the CH2 and CH3 domains and the hinge region of IgG1 including cysteine residues contributing to inter-heavy chain disulphide bonding, for example residues 11 and 14 of the IgG1 hinge region (Frangione B. and Milstein C., Nature vol216pp939-941, 1967). Preferably the IgG1 component consists of amino acids corresponding to residues 1-4 and 6-15 of the hinge, 1-110 of CH2 and 1-107 of CH3 of IgG1 described by Ellison J., Berson B. and Hood L. E., Nucleic Acids Research vol10, pp4071-4079, 1982. Residue 5 of the hinge is changed from cysteine in the published IgG1 sequence to alanine by alteration of TGT to GCC in the nucleotide sequence. In another aspect the IgG component is derived from IgG4, comprising the CH2 and CH3 domains and the hinge region including cysteine residues contributing to inter-heavy chain disulphide bonding, for example residues 8 and 11 of the IgG4 hinge region (Pinck J. R. and Milstein C., Nature vol216pp941-942, 1967). Preferably the IgG4 component consists of amino acids corresponding to residues 1-12 of the hinge, 1-110 of CH2 and 1-107 of CH3 of IgG4 described by Ellison J., Buxbaum J. and Hood L., DNA vol1pp11-18, 1981. In one example of a suitable mutation in IgG4, residue 10 of the hinge (residue 241, Kabat numbering) is altered from serine (S) in the wild type to proline (P) and residue 5 of CH2 (residue 248, Kabat numbering) is altered from leucine (L) in the wild type to glutamate (E).
Fusion of the IL4 mutant or variant to the Ig constant domain or fragment is by C-terminus of one component to N-terminus of the other. Preferably the IL4 mutant or variant is fused via its C-terminus to the N-terminus of the Ig constant domain or fragment.
In a preferred aspect, the amino acid sequence of the fusion protein of the invention is represented by SEQ ID No:4, SEQ ID No:7 or SEQ ID No:10.
In a further aspect, the invention provides a process for preparing a compound according to the invention which process comprises expressing DNA encoding said compound in a recombinant host cell and recovering the product.
The DNA polymer comprising a nucleotide sequence that encodes the compound also forms part of the invention.
In a preferred aspect the DNA polymer comprises or consists of the sequence of SEQ ID No:3, SEQ ID No:6 or SEQ ID No:9.
The process of the invention may be performed by conventional recombinant techniques such as described in Maniatis et. al., Molecular Cloning--A Laboratory Manual; Cold Spring Harbor, 1982 and DNA Cloning vols I, II and III (D. M. Glover ed., IRL Press Ltd).
In particular, the process may comprise the steps of:
i) preparing a replicable expression vector capable, in a host cell, of expressing a DNA polymer comprising a nucleotide sequence that encodes said compound;
ii) transforming a host cell with said vector;
iii) culturing said transformed host cell under conditions permitting expression of said DNA polymer to produce said compound; and
iv) recovering said compound.
The invention also provides a process for preparing the DNA polymer by the condensation of appropriate mono-, di- or oligomeric nucleotide units.
The preparation may be carried out chemically, enzymatically, or by a combination of the two methods, in vitro or in vivo as appropriate. Thus, the DNA polymer may be prepared by the enzymatic ligation of appropriate DNA fragments, by conventional methods such as those described by D. M. Roberts et al in Biochemistry 1985, 24, 5090-5098.
The DNA fragments may be obtained by digestion of DNA containing the required sequences of nucleotides with appropriate restriction enzymes, by chemical synthesis, by enzymatic polymerisation on DNA or RNA templates, or by a combination of these methods.
Digestion with restriction enzymes may be performed in an appropriate buffer at a temperature of 20°-70° C., generally in a volume of 50 μl or less with 0.1-10 μg DNA.
Enzymatic polymerisation of DNA may be carried out in vitro using a DNA polymerase such as DNA polymerase I (Klenow fragment) in an appropriate buffer containing the nucleoside triphosphates dATP, dCTP, dGTP and dTTP as required at a temperature of 10°-37° C., generally in a volume of 50 μl or less.
Enzymatic ligation of DNA fragments may be carried out using a DNA ligase such as T4 DNA ligase in an appropriate buffer at a temperature of 4° C. to ambient, generally in a volume of 50 μl or less.
The chemical synthesis of the DNA polymer or fragments may be carried out by conventional phosphotriester, phosphite or phosphoramidite chemistry, using solid phase techniques such as those described in `Chemical and Enzymatic Synthesis of Gene Fragments--A Laboratory Manual` (ed. H. G. Gassen and A. Lang), Verlag Chemie, Weinheim (1982),or in other scientific publications, for example M. J. Gait, H. W. D. Matthes, M. Singh, B. S. Sproat, and R. C. Titmas, Nucleic Acids Research, 1982, 10, 6243; B. S. Sproat and W. Bannwarth, Tetrahedron Letters, 1983, 24, 5771; M. D. Matteucci and M. H Caruthers, Tetrahedron Letters, 1980, 21, 719; M. D. Matteucci and M. H. Caruthers, Journal of the American Chemical Society, 1981, 103, 3185; S. P. Adams et al., Journal of the American Chemical Society,1983, 105, 661; N. D. Sinha, J. Biernat, J. McMannus, and H. Koester, Nucleic Acids Research, 1984, 12, 4539; and H. W. D. Matthes et al., EMBO Journal, 1984, 3, 801. Preferably an automated DNA synthesizer is employed.
The DNA polymer is preferably prepared by ligating two or more DNA molecules which together comprise a DNA sequence encoding the compound. A particular process in accordance with the invention comprises ligating a first DNA molecule encoding a said IL4 mutant or variant and a second DNA molecule encoding a said immunoglobulin domain or fragment thereof.
The DNA molecules may be obtained by the digestion with suitable restriction enzymes of vectors carrying the required coding sequences or by use of polymerase chain reaction technology.
The precise structure of the DNA molecules and the way in which they are obtained depends upon the structure of the desired product. The design of a suitable strategy for the construction of the DNA molecule coding for the compound is a routine matter for the skilled worker in the art.
The expression of the DNA polymer encoding the compound in a recombinant host cell may be carried out by means of a replicable expression vector capable, in the host cell, of expressing the DNA polymer. The expression vector is novel and also forms part of the invention.
The replicable expression vector may be prepared in accordance with the invention, by cleaving a vector compatible with the host cell to provide a linear DNA segment having an intact replicon, and combining said linear segment with one or more DNA molecules which, together with said linear segment, encode the compound, under ligating conditions.
The ligation of the linear segment and more than one DNA molecule may be carried out simultaneously or sequentially as desired.
Thus, the DNA polymer may be preformed or formed during the construction of the vector, as desired.
The choice of vector will be determined in part by the host cell, which may be prokaryotic, such as E. coli, or eukaryotic, such as mouse C127, mouse myeloma, chinese hamster ovary or Hela cells, fungi e.g. filamentous fungi or unicellular yeast or an insect cell such as Drosophila. The host cell may also be a transgenic animal. Suitable vectors include plasmids, bacteriophages, cosmids and recombinant viruses derived from, for example, baculoviruses, vaccinia or Semliki Forest virus.
The preparation of the replicable expression vector may be carried out conventionally with appropriate enzymes for restriction, polymerisation and ligation of the DNA, by procedures described in, for example, Maniatis et al., cited above. Polymerisation and ligation may be performed as described above for the preparation of the DNA polymer. Digestion with restriction enzymes may be performed in an appropriate buffer at a temperature of 20°-70° C., generally in a volume of 50 μl or less with 0.1-10 μg DNA.
The recombinant host cell is prepared, in accordance with the invention, by transforming a host cell with a replicable expression vector of the invention under transforming conditions. Suitable transforming conditions are conventional and are described in, for example, Maniatis et al., cited above, or "DNA Cloning" Vol. II, D. M. Glover ed., IRL Press Ltd, 1985.
The choice of transforming conditions is determined by the host cell. Thus, a bacterial host such as E. coli may be treated with a solution of CaCl2 (Cohen et al, Proc. Nat. Acad. Sci., 1973, 69, 2110) or with a solution comprising a mixture of RbCl, MnCl2, potassium acetate and glycerol, and then with 3- N-morpholino!propane-sulphonic acid, RbCl and glycerol. Mammalian cells in culture may be transformed by calcium co-precipitation of the vector DNA onto the cells.
The invention also extends to a host cell transformed with a replicable expression vector of the invention.
Culturing the transformed host cell under conditions permitting expression of the DNA polymer is carried out conventionally, as described in, for example, Maniatis et al and "DNA Cloning" cited above. Thus, preferably the cell is supplied with nutrient and cultured at a temperature below 45° C.
The expression product is recovered by conventional methods according to the host cell. Thus, where the host cell is bacterial, such as E. coli it may be lysed physically, chemically or enzymatically and the protein product isolated from the resulting lysate. If the product is to be secreted from the bacterial cell it may be recovered from the periplasmic space or the nutrient medium. Where the host cell is mammalian, the product may generally be isolated from the nutrient medium.
The DNA polymer may be assembled into vectors designed for isolation of stable transformed mammalian cell lines expressing the product; e.g. bovine papillomavirus vectors or amplified vectors in chinese hamster ovary cells (DNA cloning Vol.11 D. M. Glover ed. IRL Press 1985; Kaufman, R. J. et al., Molecular and Cellular Biology 5, 1750-1759, 1985; Pavlakis G. N. and Hamer, D. H., Proceedings of the National Academy of Sciences (USA) 80, 397-401, 1983; Goeddel, D. V. et al., European Patent Application No. 0093619, 1983).
Compounds of the present invention have IL4 and/or IL13 antagonist activity and are therefore of potential use in the treatment of conditions resulting from undesirable actions of IL4 and/or IL13 such as IgE mediated allergic diseases and T cell mediated autoimmune conditions or chronic microbial infection.
The invention therefore further provides a pharmaceutical composition comprising a compound of the invention and a pharmaceutically acceptable carrier.
In use the compound will normally be employed in the form of a pharmaceutical composition in association with a human pharmaceutical carrier, diluent and/or excipient, although the exact form of the composition will depend on the mode of administration. The compound may, for example, be employed in the form of aerosol or nebulisable solution for inhalation or sterile solutions for parenteral administration.
The dosage ranges for administration of the compounds of the present invention are those to produce the desired effect on the IL4 and/or IL13 mediated condition, for example whereby IgE antibody mediated symptoms are reduced or progression of the autoimmune disease is halted or reversed. The dosage will generally vary with age, extent or severity of the medical condition and contraindications, if any. The unit dosage can vary from less than 1 mg to 300 mg, but typically will be in the region of 1 to 20 mg per dose, in one or more doses, such as one to six doses per day, such that the daily dosage is in the range 0.02-40 mg/kg.
Compositions suitable for injection may be in the form of solutions, suspensions or emulsions, or dry powders which are dissolved or suspended in a suitable vehicle prior to use.
Fluid unit dosage forms are prepared utilising the compound and a pyrogen-free sterile vehicle. The compound, depending on the vehicle and concentration used, can be either dissolved or suspended in the vehicle. Solutions may be used for all forms of parenteral administration, and are particularly used for intravenous infection. In preparing solutions the compound can be dissolved in the vehicle, the solution being made isotonic if necessary by addition of sodium chloride and sterilised by filtration through a sterile filter using aseptic techniques before filling into suitable sterile vials or ampoules and sealing. Alternatively, if solution stability is adequate, the solution in its sealed containers may be sterilised by autoclaving. Advantageously additives such as buffering, solubilising, stabilising, preservative or bactericidal, suspending or emulsifying agents and/or local anaesthetic agents may be dissolved in the vehicle.
Dry powders which are dissolved or suspended in a suitable vehicle prior to use may be prepared by filling pre-sterilised drug substance and other ingredients into a sterile container using aseptic technique in a sterile area. Alternatively the drug and other ingredients may be dissolved in an aqueous vehicle, the solution is sterilised by filtration and distributed into suitable containers using aseptic technique in a sterile area. The product is then freeze dried and the containers are sealed aseptically.
Parenteral suspensions, suitable for intramuscular, subcutaneous or intradermal injection, are prepared in substantially the same manner, except that the sterile compound is suspended in the sterile vehicle, instead of being dissolved and sterilisation cannot be accomplished by filtration. The compound may be isolated in a sterile state or alternatively it may be sterilised after isolation, e.g. by gamma irradiation. Advantageously, a suspending agent for example polyvinylpyrrolidone is included in the composition to facilitate uniform distribution of the compound.
Compositions suitable for administration via the respiratory tract include aerosols, nebulisable solutions or microfine powders for insufflation. In the latter case, particle size of less than 50 microns, especially less than 10 microns, is preferred. Such compositions may be made up in a conventional manner and employed in conjunction with conventional administration devices.
In a further aspect there is provided a method of treating conditions resulting from undesirable actions of IL4 and/or IL13 which comprises administering to the sufferer an effective amount of a compound of the invention.
The invention further provides a compound of the invention for use as an active therapeutic substance, in particular for use in treating conditions resulting from undesirable actions of IL4 and/or IL13.
The invention also provides the use of a compound of the invention in the manufacture of a medicament for treating conditions resulting from undesirable actions of IL4 and/or IL13.
No unexpected toxicological effects are expected when compounds of the invention are administered in accordance with the present invention.
The following Examples illustrate the invention.
EXAMPLE 1
IL4.Y124D/IgG1 fusion protein
The construction of an IL4.Y124D/IgG1 chimeric cDNA, the expression of the corresponding protein in a mammalian expression system and its activity are described.
1. Construction of DNA coding for fusion protein
(a) Construction of IL4.Y124D coding region
A variant of the human IL4 gene, which has been described (Kruse, N, Tony, H-P and Sebald, W. EMBO Journal 11: 3237 1992!) in which residue 124 in the protein has been mutated from tyrosine in the wild type to aspartic acid, was produced by PCR mutagenesis of the human IL4 cDNA (purchased from British Biotechnology). The IL4.Y124D cDNA was inserted into the expression vector pTR312, using the HindIII and BglII sites, (M. J. Browne, J. E. Carey, C. G. Chapman, A. W. R. Tyrrell, C. Entwisle, G. M. P. Lawrence, B. Reavy, I. Dodd, A. Esmail & J. H. Robinson. Journal of Biological Chemistry 263: 1599, 1988!) to form the plasmid pDB906.
To amplify the IL4.Y124D molecule and add convenient restriction sites at each end for subcloning, a PCR reaction was performed using 20 ng of the pDB906 plasmid as the substrate. PCR primers were designed to include restriction enzyme sites, flanked by 10-15 nucleotide base pairs to "anchor" the primers at each end. The primer sequences were as follows: ##STR2##
Primers were used at a final concentration of 5 ng/μl, and dNTPs were added at a final concentration of 0.2 mM in a total reaction volume of 100 μl. 31 cycles of PCR were performed. Cycles consisted of a denaturation step of 1 minute at 94° C., an annealing step of 1 minute 30 seconds at 50° C., and an elongation step of 1 minute 30 seconds at 72° C. On cycle 1 denaturation was extended to 5 minutes and on the final cycle elongation was extended to 7 minutes. 2.5 units of the Taq polymerase enzyme from Advanced Biotechnologies were used in the PCR reaction. A PCR product of 587 bp was produced. This was purified using the Promega "Magic PCR cleanup" kit, and then digested with EcoRI and KpnI in react buffer 4 (all restriction enzymes were obtained from GibcoBRL.), to generate `sticky ends`. After 4 hours 30 minutes at 37° C., the reaction was heated to 70° C. for 10 minutes and then ethanol precipitated. Analysis of the resulting DNA by agarose gel electrophoresis showed the presence of three bands of approximately 570 bp, 463 bp and 100 bp. The 570 bp fragment represents the full-length IL4.Y124D variant of IL4 and was present because the digest was incomplete. The two smaller fragments were produced due to the presence of an EcoRI site within the IL4.Y124D cDNA. The 570 bp band was purified by the Geneclean™ procedure, and ligated into Bluescript KS+ ™ which was prepared by digestion with EcoRI and KpnI followed by Geneclean™. A Bluescript KS+ /IL4.Y124D recombinant was thus generated. Large amounts of this recombinant DNA were produced using the Promega "Magic Maxiprep" method. The IL4.Y124D insert was excised from the Bluescript recombinant using SmaI and KpnI. 20 μg recombinant DNA was incubated with 25 units SmaI in react buffer 4, at 30° C. overnight. 25 units of KpnI were then added to the digest, which was incubated at 37° C. for 5 hours. The resulting fragment of approximately 580 bp was purified by Geneclean TM to generate an IL4.Y124D/SmaI/KpnI fragment.
(b) Construction of IgG1 coding region
The COSFcLink vector (Table 1) contains human IgG1 cDNA encoding amino acids 1-4 and 6-15 of the hinge, 1-110 of CH2 and 1-108 of CH3 described by Ellison J., Berson B. and Hood L. E., Nucleic Acids Research vol10, pp4071-4079, 1982. Residue 5 of the hinge is changed from cysteine in the published IgG1 sequence to alanine by alteration of TGT to GCC in the nucleotide sequence. This was cloned from the human IgG plasma cell leukemia ARH-77 (American Type Tissue Collection), using RT-PCR and fully sequenced to confirm identity with the publish ed sequence patent application publication WO 92/00985!.
The construction of COSFc began with a pUC 18 vector containing the human IgG1 cDNA above (pUC18-Fc), which was digested with KpnI and SacII, deleting the CH1, hinge and part of CH2. The deleted region was replaced with a PCR amplified fragment containing the hinge-CH2 region as follows. Using the following PCR primers: ##STR3##
A DNA fragment containing the hinge-CH2 region was amplified from pUC18-Fc, digested with KpnI and SacII, gel purified and cloned into the KpnI/SacII digested pUC18-Fc vector. The Cys, which occurs at position 230 (Kabat numbering; Kabat et al., "Sequences of Proteins of Immunological Interest, 5th Edition, US Department of Health and Human Services, NIH Publication No. 91-3242 (1991)) of the IgG1 heavy chain, was altered to an Ala through a TGT to GCC substitution in the nucleotide sequence. An altered DNA sequence in one of the PCR primers introduced a unique KpnI site at the 5' end of the hinge. The resulting plasmid was called pUC18Fcmod, and the junctions and PCR amplified region were sequenced for confirmation.
The entire hinge-CH2-CH3 insert in pUC18-Fcmod was removed in a single DNA fragment with KpnI and XbaI, gel purified, and ligated into SFcR1Cos4 cut with KpnI and XbaI to create COSFc.
SFcR1Cos4 is a derivative of pST4DHFR (Deen, K., McDougal, J. S., Inacker, R., Folena-Wasserman, G., Arthos, J., Rosenberg, J., Maddon, P. J., Axel, R., and Sweet, R. W. Nature 331: 82 1988!) and contains the soluble Fc receptor type I (sFcR1) inserted between the cytomegalovirus (CMV) promoter and bovine growth hormone (BGH) polyadenylation regions, and also contains the dihydrofolate reductase (DHFR) cDNA inserted between the β-globin promoter and SV40 polyadenylation regions, an SV40 origin of replication, and an ampicillin resistance gene for growth in bacteria. Cutting the vector with KpnI and XbaI removes the sFcR1 coding region, so that the COSFc vector contains the hinge-CH2-CH3 region inserted between the CMV promoter and BGH polyA regions.
The COSFcLink vector was made from COSFc by inserting an oligonucleotide linker at the unique EcoRI site of the vector, which recreates this EcoRI site, and also introduces BstEII, PstI and EcoRV cloning sites. The oligonucleotides used were: ##STR4##
The junction was sequenced to confirm orientation in the vector. The size of the final vector is 6.37 kb.
(c) Construction of DNA coding for fusion protein.
To insert the IL4.Y124D cDNA, the COSFcLink vector was prepared by digesting with EcoRV and KpnI as follows: 5 μg DNA was incubated with 15 units EcoRV in react 2 at 37° C. for 5 hours, followed by ethanol precipitation. The resulting DNA was digested with KpnI in react 4 at 37° C. for 3 hours, and ethanol precipitated. The IL4.Y124D/SmaI/KpnI and the COSFcLink/EcoRV/KpnI fragments were ligated together to form plasmid pDB951, which encodes the IL4.Y124D/IgG1 fusion protein. The ligation was achieved using an Amersham DNA ligation kit, product code RPN 1507, the reactions being incubated at 16° C. overnight. The ligation reaction products were transformed into Promega JM109 competent cells (high efficiency) and plated onto Luria Broth agar containing ampicillin at 50 μg/ml. Transformants were cultured in Luria Broth (containing ampicillin at 50 μg/ml) and DNA prepared using Promega "Magic Minipreps". Production of an IL4.Y124D/COSFcLink recombinant DNA was verified by restriction digests and DNA sequencing. The complete IL4.Y124D sequence and the junctions with the COSFcLink DNA were confirmed by DNA sequencing (Table 2). The coding sequence of the recombinant IL4.Y124D/IgG1 DNA is shown in Table 3 and the amino acid sequence of the fusion protein is shown in Table 4. The IL4.Y124D/COSFcLink recombinant DNA was prepared and purified using caesium chloride gradients and the DNA used to transiently transfect HeLa cells.
2. Expression of the fusion protein
HeLa cells were grown in MEMα medium (Gibco) with 10% foetal calf serum and 1% glutamine. For the assay, 1×106 HeLa cells were seeded in 15 mls RPMI-1640 medium with 10% newborn calf serum, 1% glutamine ("seeding medium"), in a 75 cm2 flask, four days prior to transfection. On the day prior to transfection, a further 12.5 mls seeding medium was added to each flask. On the day of transfection, the medium was changed to 15 mls of "transfection medium" (MEM medium with Earle's salts containing 10% newborn calf serum and 1% non essential amino acids), at time zero. At time +3 hours, 25 μg of the appropriate DNA in 0.125M CaCl2, 1×HBS (HEPES buffered saline) was added to the cells. At time +7 hours, the cells were subjected to a glycerol shock (15%v/v) and then left to incubate overnight in 12.5 mls seeding medium containing 5 mM sodium butyrate. The next day the cells were washed with PBS (Dulbecco's phosphate buffered saline) and 12.5 mls "harvest medium" (RPMI-1640 with 2% of a 7.5% stock sodium bicarbonate solution) was added. After a further 24 hour incubation, the supernatants were removed, centrifuged at 1000 rpm for 5 minutes to remove cell debris and stored at either 4° C. or -20° C.
3. Biological Activity
For assay of supernatant for IL4 antagonist activity: using the method described in Spits et al., J. Immunology 139, 1142 (1987), human peripheral blood lymphocytes were incubated for three days with phytohaemagluttinin, a T cell mitogen, to upregulate the IL4 receptor. The resultant blast cells were then stimulated for a further three days with IL4. Proliferation was measured by the incorporation of 3H thymidine.
The IL4.Y124D/IgG1 chimera inhibited 3 H thymidine incorporation by human peripheral blood T lymphocytes stimulated with 133pM IL4 in a dose dependent manner.
EXAMPLE 2
IL4.Y124D/IgG4 fusion protein
1. Construction of DNA coding for fusion protein
PCR was performed to amplify the IL4.Y124D coding region and introduce a silent nucleotide substitution at the 3' end which creates a XhoI site. As substrate for the PCR reaction 20 ng of linearised pDB951 plasmid (Example 1.1(c)) was used. The oligonucleotide primers used were as follows: ##STR5##
A second PCR reaction was performed to amplify the hinge-CH2-CH3 fragment of the human IgG4 heavy chain. The substrate for this was a synthetic human IgG4 heavy chain cDNA, the sequence of which is described in Table 5, and is based on the Genbank sequence GB:HUMIGCD2 (Ellison J., Buxbaum J. and Hood L. E., DNA 1:11-18, 1981). Numerous silent substitutions were made to the published nucleotide sequence. The gene was assembled by combining two 0.5 Kb synthetic DNA fragments. Each 0.5 Kb fragment was made by annealing a series of overlapping oligonucleotides and then filling in the gaps by PCR. The two 0.5 Kb fragments were joined at the SacII site and inserted into the pCR2 vector. A 1.0 Kb ApaI-BglII fragment containing the entire constant region was isolated and ligated into an expression vector, pCD, containing a humanized IL4 specific variable region. This construct was used as the PCR substrate to amplify the hinge-CH2-CH3 region of IgG4.
The oligonucleotide primers used for amplification of the IgG4 hinge-CH2-CH3 region were as follows: ##STR6##
The conditions for both PCR reactions were as described for the derivation of pDB951. Briefly, primers were used at 5 ng/μl, and dNTPs at a final concentration of 0.2 mM in a total reaction volume of 100 μl. 2.5 Units of Taq polymerase enzyme from Advanced Biotechnologies were used and 31 cycles of PCR performed. Cycles consisted of a denaturation step of 1 minute at 94° C., an annealing step of 1 minute 30 seconds at 50° C., and an elongation step of 1 minute 30 seconds at 72° C. On cycle 1 denaturation was extended to 5 minutes and on the final cycle elongation was extended to 7 minutes.
PCR products of approximately 700 bp (hinge-CH2-CH3 of IgG4) and 400 bp (IL4.Y124D) were obtained and purified using the Promega "Magic PCR cleanup" kit. The purified PCR reactions were then digested with the following enzymes to create "sticky ends": XhoI and XbaI for IgG4 and EcoRV and XhoI for IL4.Y124D. The digests were incubated at 37° C. for 3 hours and then ethanol precipitated. The resulting DNAs were analysed by gel electrophoresis and gave sizes of approximately 690 bp (hinge-CH2-CH3 of IgG4) and 370bp (IL4.Y124D).
A vector was prepared into which to ligate the hinge-CH2-CH3 of IgG4 and IL4.Y124D PCR fragments by digesting pDB951 (IL4.Y124D in COSFcLink) with EcoRV and XbaI to remove most of the IL4.Y124D/IgG1 fusion molecule. The only part remaining is approximately 75 bp at the 5' end of ILA, which is not present in the IL4.Y124D EcoRV/XhoI fragment produced by PCR amplification. 5 μg of pDB951 DNA was digested in a total volume of 30 μl using react 2 buffer (GibcoBRL). The resulting 5.8 Kb DNA fragment was purified using the Geneclean™ procedure.
The three fragments described (IL4.Y124D EcoRV/XhoI, hinge-CH2-CH3 of IgG4 XhoI/XbaI and the 5.8 Kb fragment resulting from EcoRV/XbaI digestion of pDB951) were ligated together to form plasmid pDB952, which encodes the IL4.Y124D/IgG4 fusion protein. The ligation was carried out using a DNA ligation kit from Amersham (product code RPN 1507), incubating the reactions at 16° C. overnight. The ligation reaction products were transformed into Promega JM109 competent cells (high efficiency) and plated onto Luria Broth agar containing ampicillin at 50 μg/ml. Transformants were cultured in Luria Broth (containing ampicillin at 50 μg/ml) and DNA prepared using Promega "Magic Minipreps". Production of an IL4.Y124D/IgG4 recombinant DNA was verified by restriction digests, and the complete IL4.Y124D and hinge-CH2-CH3 IgG4 regions were verified by DNA sequencing. Table 6 describes the sequence of the coding region only of the IL4.Y124D/IgG4 fusion molecule, and Table 7 contains the amino acid sequence of the fusion protein. The IL4.Y124D/IgG4 recombinant DNA was prepared and purified using caesium chloride gradients and the DNA used to transiently transfect HeLa cells.
2. Expression of the fusion protein
HeLa cells were grown in MEMα medium (Gibco) with 10% foetal calf serum and 1% glutamine. For the assay, 1×106 HeLa cells were seeded in 15 mls RPMI-1640 medium with 10% newborn calf serum, 1% glutamine ("seeding medium"), in a 75cm2 flask, four days prior to transfection. On the day prior to transfection, a further 12.5 mls seeding medium was added to each flask. On the day of transfection, the medium was changed to 15 mls of "transfection medium" (MEM medium with Earle's salts containing 10% newborn calf serum and 1% non essential amino acids), at time zero. At time +3 hours, 25 μg of the appropriate DNA in 0.125M CaCl2, 1×HBS (HEPES buffered saline) was added to the cells. At time +7 hours, the cells were subjected to a glycerol shock (15%v/v) and then left to incubate overnight in 12.5 mls seeding medium containing 5 mM sodium butyrate. The next day the cells were washed with PBS (Dulbecco's phosphate buffered saline) and 12.5 mls "harvest medium" (RPMI-1640 with 2% of a 7.5% stock sodium bicarbonate solution) was added. After a further 24 hour incubation, the supernatants were removed, centrifuged at 1000 rpm for 5 minutes to remove cell debris and stored at either 4° C. or -20° C.
3. Biological Activity
For assay of supernatant for IL4 antagonist activity: using the method described in Spits et al., J. Immunology 139, 1142 (1987), human peripheral blood lymphocytes were incubated for three days with phytohaemagluttinin, a T cell mitogen, to upregulate the IL4 receptor. The resultant blast cells were then stimulated for a further three days with IL4. Proliferation was measured by the incorporation of 3H thymidine.
The IL4.Y124D/IgG4 chimera inhibited 3 H thymidine incorporation by human peripheral blood T lymphocytes stimulated with 133pM IL4 in a dose dependent manner.
EXAMPLE 3
IL4.Y124D/IgG4 PE fusion protein
1. Construction of DNA coding for fusion protein
PCR is performed to amplify the IL4.Y124D coding region and introduce a silent nucleotide substitution at the 3' end which creates a XhoI site as described in Example 2.
A second PCR reaction is performed to amplify the hinge-CH2-CH3 fragment of the human IgG4 heavy chain PE variant. In IgG4 PE, residue 10 of the hinge (residue 241, Kabat numbering) is altered from serine (S) in the wild type to proline (P) and residue 5 of CH2 (residue 248, Kabat numbering) is altered from leucine (L) in the wild type to glutamate (E). Angal S., King D. J., Bodmer M. W., Turner A., Lawson A. D. G., Roberts G., Pedley B. and Adair R., Molecular Immunology vol30pp105-108, 1993, describe an IgG4 molecule where residue 241 (Kabat numbering) is altered from serine to proline. This change increases the serum half-life of the IgG4 molecule.
The IgG4 PE variant was created using PCR mutagenesis on the synthetic human IgG4 heavy chain cDNA described in Table 5, and was then ligated into the pCD expression vector. It was this plasmid which was used as the substrate for the PCR reaction amplifying the hinge-CH2-CH3 fragment of IgG4 PE. The sequence of the IgG4 PE variant is described in Table 8. The residues of the IgG4 nucleotide sequence which were altered to make the PE variant are as follows:
referring to Table 8:
residue 322 has been altered to "C" in the PE variant from "T" in the wild type;
residue 333 has been altered to "G" in the PE variant from "A" in the wild type; and
residues 343-344 have been altered to "GA" in the PE variant from "CT" in the wild type.
Oligonucleotide primers are used for amplification of the IgG4 PE variant hinge-CH2-CH3 region as described for the derivation of pDB952.
PCR products of approximately 700 bp (hinge-CH2-CH3 of IgG4 PE mutant) and 400 bp (IL4.Y124D) are obtained and purified using the Promega "Magic PCR cleanup" kit. The purified PCR reactions are then digested with the following enzymes to create "sticky ends": XhoI and XbaI for IgG4 PE and EcoRV and XhoI for IL4.Y124D. The digests are incubated at 37° C. for 3 hours and then ethanol precipitated. The resulting DNAs are of sizes of approximately 690 bp (hinge-CH2-CH3 of IgG4 PE) and 370bp (IL4.Y124D).
To obtain larger amounts of the IgG4 PE variant hinge-CH2-CH3 fragment and the IL4.Y124D fragment, the purified and digested PCR products are ligated into Bluescript KS+ ™ which is prepared by digestion with either XhoI and XbaI for the hinge-CH2-CH3 of IgG4 PE fragment or EcoRV and XhoI for the IL4.Y124D fragment, followed by Geneclean™. A Bluescript KS+ /hinge-CH2-CH3 of IgG4 PE recombinant and a Bluescript KS+ /IL4.Y124D recombinant are thus generated. Large amounts of these DNAs are produced using the Promega "Magic Maxiprep" method. The IgG4 PE hinge-CH2-CH3 fragment is excised from the Bluescript recombinant using XhoI and XbaI. The resulting fragment of approximately 690 bp is purified by Geneclean™ to generate large amounts of the IgG4 PE hinge-CH2-CH3 XhoI/XbaI fragment. The IL4.Y124D fragment is excised from the Bluescript recombinant using EcoRV and XhoI and the resulting fragment of approximately 370 bp is purified by Geneclean™.
A vector is prepared into which to ligate the hinge-CH2-CH3 of IgG4 PE and IL4.Y124D fragments by digesting pDB951 with EcoRV and XbaI as described for the derivation of pDB952.
The three fragments described (IL4.Y124D EcoRV/XhoI, hinge-CH2-CH3 of IgG4 PE variant XhoI/XbaI and the 5.8 Kb fragment resulting from EcoRV/XbaI digestion of pDB951) are ligated together to form plasmid pDB953 using a DNA ligation kit from Amersham (product code RPN 1507), incubating the reactions at 16° C. overnight. The ligation reaction products are transformed into Promega JM109 competent cells (high efficiency) and plated onto Luria Broth agar containing ampicillin at 50 μg/ml. Transformants are cultured in Luria Broth (containing ampicillin at 50 μg/ml) and DNA prepared using Promega "Magic Minipreps". Production of an IL4.Y124D/IgG4 PE variant recombinant DNA is verified by restriction digests, and the complete IL4.Y124D and hinge-CH2-CH3 IgG4 PE variant regions are verified by DNA sequencing. Table 9 describes the sequence of the coding region only of the IL4. Y124D/IgG4 PE fusion molecule, and Table 10 contains the amino acid sequence of the fusion protein. The IL4.Y124D/IgG4 PE recombinant DNA is prepared and purified using caesium chloride gradients and the DNA used to transiently transfect HeLa cells.
2. Expression of the fusion protein
HeLa cells were grown in MEMα medium (Gibco) with 10% foetal calf serum and 1% glutamine. For the assay, 1×106 HeLa cells were seeded in 15mls RPMI-1640 medium with 10% newborn calf serum, 1% glutamine ("seeding medium"), in a 75 cm2 flask, four days prior to transfection. On the day prior to transfection, a further 12.5 mls seeding medium was added to each flask. On the day of transfection, the medium was changed to 15 mls of "transfection medium" (MEM medium with Earle's salts containing 10% newborn calf serum and 1% non essential amino acids), at time zero. At time +3 hours, 25 μg of the appropriate DNA in 0. 125M CaCl2, 1×HBS (HEPES buffered saline) was added to the cells. At time +7 hours, the cells were subjected to a glycerol shock (15% v/v) and then left to incubate overnight in 12.5 mls seeding medium containing 5 mM sodium butyrate. The next day the cells were washed with PBS (Dulbecco's phosphate buffered saline) and 12.5 mls "harvest medium" (RPMI-1640 with 2% of a 7.5% stock sodium bicarbonate solution) was added. After a further 24 hour incubation, the supernatants were removed, centrifuged at 1000 rpm for 5 minutes to remove cell debris and stored at either 4° C. or -20° C.
3. Biological Activity
For assay of supernatant for IL4 antagonist activity: using the method described in Spits et al., J. Immunology 139, 1142 (1987), human peripheral blood lymphocytes were incubated for three days with phytohaemagluttinin, a T cell mitogen, to upregulate the IL4 receptor. The resultant blast cells were then stimulated for a further three days with IL4. Proliferation was measured by the incorporation of 3H thymidine.
The IL4.Y124D/IgG4 PE chimera inhibited 3 H thymidine incorporation by human peripheral blood T lymphocytes stimulated with 133pM IL4 in a dose dependent manner.
EXAMPLE 4
Mammalian Expression vector containing DNA coding for IL4.Y124D/IgG4 PE
1. Construction of DNA
The pCDN vector (Aiyar, N., Baker, E., Wu, H.-L., Nambi, P., Edwards, R. M., Trill, J. J., Ellis, C., Bergsma, D. Molecular and Cellular Biochemistry 131:75-86, 1994) contains the CMV promoter, a polylinker cloning region, and the BGH polyadenylation region. This vector also contains a bacterial neomycin phosphotransferase gene (NEO) inserted between the β-globin promoter and SV40 polyadenylation region for Geneticin™ selection, the DHFR selection cassette inserted between the β-globin promoter and BGH polydenylation region for methotrexate (MTX) amplification, an ampicillin resistance gene for growth in bacteria, and a SV40 origin of replication.
To insert the IL4.Y124D/IgG4 PE cDNA, the pCDN vector was prepared by digesting with Nde1 and BstX1 as follows: 15 μg of DNA was incubated with 30 units of BstX1 in react 2 (Gibco-BRL) at 55° C. for 1 hour, and ethanol precipitated. The resulting DNA was digested with Nde1 in react 2 at 37° C. for 1 hour, and ethanol precipitated. The IL4.Y124D/IgG4 PE fragment was prepared from pDB953 (Example 3.1) by digesting with BstX1 and Nde1 as follows: 15μg of DNA was incubated with 30 units of BstX1 in react 2 at 55° C. for 1 hour, and ethanol precipitated. The resulting DNA was digested with Nde1 in react 2 at 37° C. for 1 hour, and ethanol precipitated.
The IL4.Y124D/IgG4 PE Nde1/BstX1 and pCDN Nde1/BstX1 fragments were ligated together to form the plasmid pCDN-IL4.Y124D/IgG4 PE. The ligation was achieved using 2 units of T4 DNA Ligase (Gibco BRL) with T4 DNA Ligase buffer. The reactions were incubated at 16° C. overnight. The ligation reaction products were transformed into Gibco-BRL DH5a competent cells (subcloning efficiency) and plated onto Luria Broth agar containing 75 ug/ml ampicillin. Transformants were cultured in Luria Broth (containing ampicillin at 50 ug/ml) and DNA prepared by alkaline lysis. Production of a pCDN-IL4.Y124D/IgG4 PE DNA was confirmed by restriction digests. The complete sequence of the recombinant IL4.Y124D/IgG4 PE DNA was confirmed by sequencing. The pCDN-IL4.Y124D/IgG4 PE recombinant DNA was prepared and purified using Qiagen columns and the DNA was used to transiently infect COS cells and electroporated into CHO cells to create stable clones.
2. Expression of the Fusion Protein
a) Transient Expression in COS
COS-1 cells were grown in DMEM medium with 10% fetal bovine serum. For the transfection, cells were seeded at 2×105 cells into a 35 mm tissue culture dish 24 hours prior. A solution containing 1 μg of DNA in 100 μl of DMEM without serum is added to a solution containing 6 μl of LIPOFECTAMINE Reagent (Gibco-BRL) in 100 μl of DMEM without serum, gently swirled and incubated at room temperature for 45 minutes. The cells are washed once with serum free DMEM. 0.8ml of serum free DMEM is added to the DNA-LIPOFECTAMINE SOLUTION, mixed gently and the diluted solution is overlayed on the cells. The cells are incubated at 37° C. for 5 hours, then 1 ml of DMEM containing 20% fetal bovine serum is added. The cells are assayed 48-72 hours later to determine expression levels.
b) Electroporation into CHO cells
CHO cells, ACC-098 (a suspension cell line derived from CHO DG-44, Urlaub, G., Kas, E., Carothers, A. M. and Chasin, L. A. Cell, 33. 405-412, 1983) were grown in serum free growth medium WO 92/05246. 15 μg of the pCDN-IL4.Y124D/IgG4 PE plasmid was digested using 30 units of Not1 at 37° C. for 3 hours to linearize the plasmid, and precipitated with ethanol. The resulting DNA was resuspended in 50 ul of 1×TE (10 mM Tris, pH 8.0, 1 mM EDTA). The DNA was electroporated into 1×107 ACC-098 cells, using a Bio Rad Gene Pulser set at 380V and 25 μFd. The cells were resuspended into growth medium at 2.5×104 cells/ml, and 200 μl of the cell suspension was plated into each well of a 96 well plate. 48 hours later the medium was switched to growth medium containing 400 μg/ml G418 (Geneticin). Twenty one days post selection, conditioned medium from the colonies which arose were screened by Elisa assay. The highest expressing colonies were transferred to 24 well plates in order to be scaled up.
                                  TABLE 1                                 
__________________________________________________________________________
DNA sequence of COSFcLink vector, 6367bp                                  
SEQ ID No: 1                                                              
__________________________________________________________________________
GACGTCGACGGATCGGGAGATCGGGGATCGATCCGTCGACGTACGACTAGTTATTAATAG              
                                           60                             
TAATCAATTACGGGGTCATTAGTTCATAGCCCATATATGGAGTTCCGCGTTACATAACTT              
                                           120                            
ACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGCCCATTGACGTCAATAATG              
                                           180                            
ACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGACGTCAATGGGTGGACTAT              
                                           240                            
TTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCCAAGTACGCCCCCT              
                                           300                            
ATTGACGTCAATGACGGTAAATGGCCCGCCTGGCATTATGCCCAGTACATGACCTTATGG              
                                           360                            
GACTTTCCTACTTGGCAGTACATCTACGTATTAGTCATCGCTATTACCATGGTGATGCGG              
                                           420                            
TTTTGGCAGTACATCAATGGGCGTGGATAGCGGTTTGACTCACGGGGATTTCCAAGTCTC              
                                           480                            
CACCCCATTGACGTCAATGGGAGTTTGTTTTGGCACCAAAATCAACGGGACTTTCCAAAA              
                                           540                            
TGTCGTAACAACTCCGCCCCATTGACGCAAATGGGCGGTAGGCGTGTACGGTGGGAGGTC              
                                           600                            
TATATAAGCAGAGCTGGGTACGTGAACCGTCAGATCGCCTGGAGACGCCATCGAATTCGG              
                                           660                            
TTACCTGCAGATATCAAGCTAATTCGGTACCGAGCCCAAATCGGCCGACAAAACTCACAC              
                                           720                            
ATGCCCACCGTGCCCAGCACCTGAACTCCTGGGGGGACCGTCAGTCTTCCTCTTCCCCCC              
                                           780                            
AAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGA              
                                           840                            
CGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCA              
                                           900                            
TAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGGGTGGTCAGCGT              
                                           960                            
CCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAA              
                                           1020                           
CAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGA              
                                           1080                           
ACCACAGGTGTACACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAGGTCAGCCT              
                                           1140                           
GACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGG              
                                           1200                           
GCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTT              
                                           1260                           
CCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATG              
                                           1320                           
CTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCC              
                                           1380                           
GGGTAAATGAGTGTAGTCTAGAGCTCGCTGATCAGCCTCGACTGTGCCTTCTAGTTGCCA              
                                           1440                           
GCCATCTGTTGTTTGCCCCTCCCCCGTGCCTTCCTTGACCCTGGAAGGTGCCACTCCCAC              
                                           1500                           
TGTCCTTTCCTAATAAAATGAGGAAATTGCATCGCATTGTCTGAGTAGGTGTCATTCTAT              
                                           1560                           
TCTGGGGGGTGGGGTGGGGCAGGACAGCAAGGGGGAGGATTGGGAAGACAATAGCAGGCA              
                                           1620                           
TGCTGGGGATGCGGTGGGCTCTATGGAACCAGCTGGGGCTCGAGGGGGGATCTCCCGATC              
                                           1680                           
CCCAGCTTTGCTTCTCAATTTCTTATTTGCATAATGAGAAAAAAAGGAAAATTAATTTTA              
                                           1740                           
ACACCAATTCAGTAGTTGATTGAGCAAATGCGTTGCCAAAAAGGATGCTTTAGAGACAGT              
                                           1800                           
GTTCTCTGCACAGATAAGGACAAACATTATTCAGAGGGAGTACCCAGAGCTGAGACTCCT              
                                           1860                           
AAGCCAGTGAGTGGCACAGCATTCTAGGGAGAAATATGCTTGTCATCACCGAAGCCTGAT              
                                           1920                           
TCCGTAGAGCCACACCTTGGTAAGGGCCAATCTGCTCACACAGGATAGAGAGGGCAGGAG              
                                           1980                           
CCAGGGCAGAGCATATAAGGTGAGGTAGGATCAGTTGCTCCTCACATTTGCTTCTGACAT              
                                           2040                           
AGTTGTGTTGGGAGCTTGGATAGCTTGGACAGCTCAGGGCTGCGATTTCGCGCCAAACTT              
                                           2100                           
GACGGCAATCCTAGCGTGAAGGCTGGTAGGATTTTATCCCCGCTGCCATCATGGTTCGAC              
                                           2160                           
CATTGAACTGCATCGTCGCCGTGTCCCAAAATATGGGGATTGGCAAGAACGGAGACCTAC              
                                           2220                           
CCTGGCCTCCGCTCAGGAACGAGTTCAAGTACTTCCAAAGAATGACCACAACCTCTTCAG              
                                           2280                           
TGGAAGGTAAACAGAATCTGGTGATTATGGGTAGGAAAACCTGGTTCTCCATTCCTGAGA              
                                           2340                           
AGAATCGACCTTTAAAGGACAGAATTAATATAGTTCTCAGTAGAGAACTCAAAGAACCAC              
                                           2400                           
CACGAGGAGCTCATTTTCTTGCCAAAAGTTTGGATGATGCCTTAAGACTTATTGAACAAC              
                                           2460                           
CGGAATTGGCAAGTAAAGTAGACATGGTTTGGATAGTCGGAGGCAGTTCTGTTTACCAGG              
                                           2520                           
AAGCCATGAATCAACCAGGCCACCTTAGACTCTTTGTGACAAGGATCATGCAGGAATTTG              
                                           2580                           
AAAGTGACACGTTTTTCCCAGAAATTGATTTGGGGAAATATAAACTTCTCCCAGAATACC              
                                           2640                           
CAGGCGTCCTCTCTGAGGTCCAGGAGGAAAAAGGCATCAAGTATAAGTTTGAAGTCTACG              
                                           2700                           
AGAAGAAAGACTAACAGGAAGATGCTTTCAAGTTCTCTGCTCCCCTCCTAAAGCTATGCA              
                                           2760                           
TTTTTATAAGACCATGCTAGCTTGAACTTGTTTATTGCAGCTTATAATGGTTACAAATAA              
                                           2820                           
AGCAATAGCATCACAAATTTCACAAATAAAGCATTTTTTTCACTGCATTCTAGTTGTGGT              
                                           2880                           
TTGTCCAAACTCATCAATGTATCTTATCATGTCTGGATCAACGATAGCTTATCTGTGGGC              
                                           2940                           
GATGCCAAGCACCTGGATGCTGTTGGTTTCCTGCTACTGATTTAGAAGCCATTTGCCCCC              
                                           3000                           
TGAGTGGGGCTTGGGAGCACTAACTTTCTCTTTCAAAGGAAGCAATGCAGAAAGAAAAGC              
                                           3060                           
ATACAAAGTATAAGCTGCCATGTAATAATGGAAGAAGATAAGGTTGTATGAATTAGATTT              
                                           3120                           
ACATACTTCTGAATTGAAACTAAACACCTTTAAATTCTTAAATATATAACACATTTCATA              
                                           3180                           
TGAAAGTATTTTACATAAGTAACTCAGATACATAGAAAACAAAGCTAATGATAGGTGTCC              
                                           3240                           
CTAAAAGTTCATTTATTAATTCTACAAATGATGAGCTGGCCATCAAAATTCCAGCTCAAT              
                                           3300                           
TCTTCAACGAATTAGAAAGAGCAATCTGCAAACTCATCTGGAATAACAAAAAACCTAGGA              
                                           3360                           
TAGCAAAAACTCTTCTCAAGGATAAAAGAACCTCTGGTGGAATCACCATGCCTGACCTAA              
                                           3420                           
AGCTGTACTACAGAGCAATTGTGATAAAAACTGCATGGTACTGATATAGAAACGGACAAG              
                                           3480                           
TAGACCAATGGAATAGAACCCACACACCTATGGTCACTTGATCTTCAACAAGAGAGCTAA              
                                           3540                           
AACCATCCACTGGAAAAAAGACAGCATTTTCAACAAATGGTGCTGGCACAACTGGTGGTT              
                                           3600                           
ATCATGGAGAAGAATGTGAATTGATCCATTCCAATCTCCTTGTACTAAGGTCAAATCTAA              
                                           3660                           
GTGGATCAAGGAACTCCACATAAAACCAGAGACACTGAAACTTATAGAGGAGAAAGTGGG              
                                           3720                           
GAAAAGCCTCGAAGATATGGGCACAGGGGAAAAATTCCTGAATAGAACAGCAATGGCTTG              
                                           3780                           
TGCTGTAAGATCGAGAATTGACAAATGGGACCTCATGAAACTCCAAAGCTATCGGATCAA              
                                           3840                           
TTCCTCCAAAAAAGCCTCCTCACTACTTCTGGAATAGCTCAGAGGCCGAGGCGGCCTCGG              
                                           3900                           
CCTCTGCATAAATAAAAAAAATTAGTCAGCCATGCATGGGGCGGAGAATGGGCGGAACTG              
                                           3960                           
GGCGGAGTTAGGGGCGGGATGGGCGGAGTTAGGGGCGGGACTATGGTTGCTGACTAATTG              
                                           4020                           
AGATGCATGCTTTGCATACTTCTGCCTGCTGGGGAGCCTGGGGACTTTCCACACCTGGTT              
                                           4080                           
GCTGACTAATTGAGATGCATGCTTTGCATACTTCTGCCTGCTGGGGAGCCTGGGGACTTT              
                                           4140                           
CCACACCCTAACTGACACACATTCCACAGAATTAATTCCCGATCCCGTCGACCTCGAGAG              
                                           4200                           
CTTGGCGTAATCATGGTCATAGCTGTTTCCTGTGTGAAATTGTTATCCGCTCACAATTCC              
                                           4260                           
ACACAACATACGAGCCGGAAGCATAAAGTGTAAAGCCTGGGGTGCCTAATGAGTGAGCTA              
                                           4320                           
ACTCACATTAATTGCGTTGCGCTCACTGCCCGCTTTCCAGTCGGGAAACCTGTCGTGCCA              
                                           4380                           
GCTGCATTAATGAATCGGCCAACGCGCGGGGAGAGGCGGTTTGCGTATTGGGCGCTCTTC              
                                           4440                           
CGCTTCCTCGCTCACTGACTCGCTGCGCTCGGTCGTTCGGCTGCGGCGAGCGGTATCAGC              
                                           4500                           
TCACTCAAAGGCGGTAATACGGTTATCCACAGAATCAGGGGATAACGCAGGAAAGAACAT              
                                           4560                           
GTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTT              
                                           4620                           
CCATAGGCTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCG              
                                           4680                           
AAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTC              
                                           4740                           
TCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGT              
                                           4800                           
GGCGCTTTCTCAATGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAA              
                                           4860                           
GCTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCGACCGCTGCGCCTTATCCGGTAACTA              
                                           4920                           
TCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAA              
                                           4980                           
CAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAA              
                                           5040                           
CTACGGCTACACTAGAAGGACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTT              
                                           5100                           
CGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTT              
                                           5160                           
TTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGAT              
                                           5220                           
CTTTTCTACGGGGTCTGACGCTCAGTGGAACGAAAACTCACGTTAAGGGATTTTGGTCAT              
                                           5280                           
GAGATTATCAAAAAGGATCTTCACCTAGATCCTTTTAAATTAAAAATGAAGTTTTAAATC              
                                           5340                           
AATCTAAAGTATATATGAGTAAACTTGGTCTGACAGTTACCAATGCTTAATCAGTGAGGC              
                                           5400                           
ACCTATCTCAGCGATCTGTCTATTTCGTTCATCCATAGTTGCCTGACTCCCCGTCGTGTA              
                                           5460                           
GATAACTACGATACGGGAGGGCTTACCATCTGGCCCCAGTGCTGCAATGATACCGCGAGA              
                                           5520                           
CCCACGCTCACCGGCTCCAGATTTATCAGCAATAAACCAGCCAGCCGGAAGGGCCGAGCG              
                                           5580                           
CAGAAGTGGTCCTGCAACTTTATCCGCCTCCATCCAGTCTATTAATTGTTGCCGGGAAGC              
                                           5640                           
TAGAGTAAGTAGTTCGCCAGTTAATAGTTTGCGCAACGTTGTTGCCATTGCTACAGGCAT              
                                           5700                           
CGTGGTGTCACGCTCGTCGTTTGGTATGGCTTCATTCAGCTCCGGTTCCCAACGATCAAG              
                                           5760                           
GCGAGTTACATGATCCCCCATGTTGTGCAAAAAAGCGGTTAGCTCCTTCGGTCCTCCGAT              
                                           5820                           
CGTTGTCAGAAGTAAGTTGGCCGCAGTGTTATCACTCATGGTTATGGCAGCACTGCATAA              
                                           5880                           
TTCTCTTACTGTCATGCCATCCGTAAGATGCTTTTCTGTGACTGGTGAGTACTCAACCAA              
                                           5940                           
GTCATTCTGAGAATAGTGTATGCGGCGACCGAGTTGCTCTTGCCCGGCGTCAATACGGGA              
                                           6000                           
TAATACCGCGCCACATAGCAGAACTTTAAAAGTGCTCATCATTGGAAAACGTTCTTCGGG              
                                           6060                           
GCGAAAACTCTCAAGGATCTTACCGCTGTTGAGATCCAGTTCGATGTAACCCACTCGTGC              
                                           6120                           
ACCCAACTGATCTTCAGCATCTTTTACTTTCACCAGCGTTTCTGGGTGAGCAAAAACAGG              
                                           6180                           
AAGGCAAAATGCCGCAAAAAAGGGAATAAGGGCGACACGGAAATGTTGAATACTCATACT              
                                           6240                           
CTTCCTTTTTCAATATTATTGAAGCATTTATCAGGGTTATTGTCTCATGAGCGGATACAT              
                                           6300                           
ATTTGAATGTATTTAGAAAAATAAACAAATAGGGGTTCCGCGCACATTTCCCCGAAAAGT              
                                           6360                           
GCCACCT                                    6367                           
__________________________________________________________________________

                                  TABLE 2                                 
__________________________________________________________________________
DNA sequence of encoded Y124D-IgG1 fusion molecule in COSFcLink vector,   
6926bp                                                                    
SEQ ID No: 2                                                              
__________________________________________________________________________
GACGTCGACGGATCGGGAGATCGGGGATCGATCCGTCGACGTACGACTAGTTATTAATAG              
                                           60                             
TAATCAATTACGGGGTCATTAGTTCATAGCCCATATATGGAGTTCCGCGTTACATAACTT              
                                           120                            
ACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGCCCATTGACGTCAATAATG              
                                           180                            
ACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGACGTCAATGGGTGGACTAT              
                                           240                            
TTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCCAAGTACGCCCCCT              
                                           300                            
ATTGACGTCAATGACGGTAAATGGCCCGCCTGGCATTATGCCCAGTACATGACCTTATGG              
                                           360                            
GACTTTCCTACTTGGCAGTACATCTACGTATTAGTCATCGCTATTACCATGGTGATGCGG              
                                           420                            
TTTTGGCAGTACATCAATGGGCGTGGATAGCGGTTTGACTCACGGGGATTTCCAAGTCTC              
                                           480                            
CACCCCATTGACGTCAATGGGAGTTTGTTTTGGCACCAAAATCAACGGGACTTTCCAAAA              
                                           540                            
TGTCGTAACAACTCCGCCCCATTGACGCAAATGGGCGGTAGGCGTGTACGGTGGGAGGTC              
                                           600                            
TATATAAGCAGAGCTGGGTACGTGAACCGTCAGATCGCCTGGAGACGCCATCGAATTCGG              
                                           660                            
TTACCTGCAGATGGGCTGCAGGAATTCCGCATTGCAGAGATAATTGTATTTAAGTGCCTA              
                                           720                            
GCTCGATACAATAAACGCCATTTGACCATTCACCACATTGGTGTGCACCTCCAAGCTTAC              
                                           780                            
CTGCCATGGGTCTCACCTCCCAACTGCTTCCCCCTCTGTTCTTCCTGCTAGCATGTGCCG              
                                           840                            
GCAACTTTGTCCACGGACACAAGTGCGATATCACCTTACAGGAGATCATCAAAACTTTGA              
                                           900                            
ACAGCCTCACAGAGCAGAAGACTCTGTGCACCGAGTTGACCGTAACAGACATCTTTGCTG              
                                           960                            
CCTCCAAGAACACAACTGAGAAGGAAACCTTCTGCAGGGCTGCGACTGTGCTCCGGCAGT              
                                           1020                           
TCTACAGCCACCATGAGAAGGACACTCGCTGCCTGGGTGCGACTGCACAGCAGTTCCACA              
                                           1080                           
GGCACAAGCAGCTGATCCGATTCCTGAAACGGCTCGACAGGAACCTCTGGGGCCTGGCGG              
                                           1140                           
GCTTGAATTCCTGTCCTGTGAAGGAAGCCAACCAGAGTACGTTGGAAAACTTCTTGGAAA              
                                           1200                           
GGCTAAAGACGATCATGAGAGAGAAAGACTCAAAGTGTTCGAGCGGTACCGAGCCCAAAT              
                                           1260                           
CGGCCGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAACTCCTGGGGGGACCGT              
                                           1320                           
CAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGG              
                                           1380                           
TCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACG              
                                           1440                           
TGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCA              
                                           1500                           
CGTACCGGGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGT              
                                           1560                           
ACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAG              
                                           1620                           
CCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGATGAGCTGA              
                                           1680                           
CCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCG              
                                           1740                           
TGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGG              
                                           1800                           
ACTCCGACGGCTCCTTCTTCCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGC              
                                           1860                           
AGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAGA              
                                           1920                           
AGAGCCTCTCCCTGTCTCCGGGTAAATGAGTGTAGTCTAGAGCTCGCTGATCAGCCTCGA              
                                           1980                           
CTGTGCCTTCTAGTTGCCAGCCATCTGTTGTTTGCCCCTCCCCCGTGCCTTCCTTGACCC              
                                           2040                           
TGGAAGGTGCCACTCCCACTGTCCTTTCCTAATAAAATGAGGAAATTGCATCGCATTGTC              
                                           2100                           
TGAGTAGGTGTCATTCTATTCTGGGGGGTGGGGTGGGGCAGGACAGCAAGGGGGAGGATT              
                                           2160                           
GGGAAGACAATAGCAGGCATGCTGGGGATGCGGTGGGCTCTATGGAACCAGCTGGGGCTC              
                                           2220                           
GAGGGGGGATCTCCCGATCCCCAGCTTTGCTTCTCAATTTCTTATTTGCATAATGAGAAA              
                                           2280                           
AAAAGGAAAATTAATTTTAACACCAATTCAGTAGTTGATTGAGCAAATGCGTTGCCAAAA              
                                           2340                           
AGGATGCTTTAGAGACAGTGTTCTCTGCACAGATAAGGACAAACATTATTCAGAGGGAGT              
                                           2400                           
ACCCAGAGCTGAGACTCCTAAGCCAGTGAGTGGCACAGCATTCTAGGGAGAAATATGCTT              
                                           2460                           
GTCATCACCGAAGCCTGATTCCGTAGAGCCACACCTTGGTAAGGGCCAATCTGCTCACAC              
                                           2520                           
AGGATAGAGAGGGCAGGAGCCAGGGCAGAGCATATAAGGTGAGGTAGGATCAGTTGCTCC              
                                           2580                           
TCACATTTGCTTCTGACATAGTTGTGTTGGGAGCTTGGATAGCTTGGACAGCTCAGGGCT              
                                           2640                           
GCGATTTCGCGCCAAACTTGACGGCAATCCTAGCGTGAAGGCTGGTAGGATTTTATCCCC              
                                           2700                           
GCTGCCATCATGGTTCGACCATTGAACTGCATCGTCGCCGTGTCCCAAAATATGGGGATT              
                                           2760                           
GGCAAGAACGGAGACCTACCCTGGCCTCCGCTCAGGAACGAGTTCAAGTACTTCCAAAGA              
                                           2820                           
ATGACCACAACCTCTTCAGTGGAAGGTAAACAGAATCTGGTGATTATGGGTAGGAAAACC              
                                           2880                           
TGGTTCTCCATTCCTGAGAAGAATCGACCTTTAAAGGACAGAATTAATATAGTTCTCAGT              
                                           2940                           
AGAGAACTCAAAGAAdCACCACGAGGAGCTCATTTTCTTGCCAAAAGTTTGGATGATGCC              
                                           3000                           
TTAAGACTTATTGAACAACCGGAATTGGCAAGTAAAGTAGACATGGTTTGGATAGTCGGA              
                                           3060                           
GGCAGTTCTGTTTACCAGGAAGCCATGAATCAACCAGGCCACCTTAGACTCTTTGTGACA              
                                           3120                           
AGGATCATGCAGGAATTTGAAAGTGACACGTTTTTCCCAGAAATTGATTTGGGGAAATAT              
                                           3180                           
AAACTTCTCCCAGAATACCCAGGCGTCCTCTCTGAGGTCCAGGAGGAAAAAGGCATCAAG              
                                           3240                           
TATAAGTTTGAAGTCTACGAGAAGAAAGACTAACAGGAAGATGCTTTCAAGTTCTCTGCT              
                                           3300                           
CCCCTCCTAAAGCTATGCATTTTTATAAGACCATGCTAGCTTGAACTTGTTTATTGCAGC              
                                           3360                           
TTATAATGGTTACAAATAAAGCAATAGCATCACAAATTTCACAAATAAAGCATTTTTTTC              
                                           3420                           
ACTGCATTCTAGTTGTGGTTTGTCCAAACTCATCAATGTATCTTATCATGTCTGGATCAA              
                                           3480                           
CGATAGCTTATCTGTGGGCGATGCCAAGCACCTGGATGCTGTTGGTTTCCTGCTACTGAT              
                                           3540                           
TTAGAAGCCATTTGCCCCCTGAGTGGGGCTTGGGAGCACTAACTTTCTCTTTCAAAGGAA              
                                           3600                           
GCAATGCAGAAAGAAAAGCATACAAAGTATAAGCTGCCATGTAATAATGGAAGAAGATAA              
                                           3660                           
GGTTGTATGAATTAGATTTACATACTTCTGAATTGAAACTAAACACCTTTAAATTCTTAA              
                                           3720                           
ATATATAACACATTTCATATGAAAGTATTTTACATAAGTAACTCAGATACATAGAAAACA              
                                           3780                           
AAGCTAATGATAGGTGTCCCTAAAAGTTCATTTATTAATTCTACAAATGATGAGCTGGCC              
                                           3840                           
ATCAAAATTCCAGCTCAATTCTTCAACGAATTAGAAAGAGCAATCTGCAAACTCATCTGG              
                                           3900                           
AATAACAAAAAACCTAGGATAGCAAAAACTCTTCTCAAGGATAAAAGAACCTCTGGTGGA              
                                           3960                           
ATCACCATGCCTGACCTAAAGCTGTACTACAGAGCAATTGTGATAAAAACTGCATGGTAC              
                                           4020                           
TGATATAGAAACGGACAAGTAGACCAATGGAATAGAACCCACACACCTATGGTCACTTGA              
                                           4080                           
TCTTCAACAAGAGAGCTAAAACCATCCACTGGAAAAAAGACAGCATTTTCAACAAATGGT              
                                           4140                           
GCTGGCACAACTGGTGGTTATCATGGAGAAGAATGTGAATTGATCCATTCCAATCTCCTT              
                                           4200                           
GTACTAAGGTCAAATCTAAGTGGATCAAGGAACTCCACATAAAACCAGAGACACTGAAAC              
                                           4260                           
TTATAGAGGAGAAAGTGGGGAAAAGCCTCGAAGATATGGGCACAGGGGAAAAATTCCTGA              
                                           4320                           
ATAGAACAGCAATGGCTTGTGCTGTAAGATCGAGAATTGACAAATGGGACCTCATGAAAC              
                                           4380                           
TCCAAAGCTATCGGATCAATTCCTCCAAAAAAGCCTCCTCACTACTTCTGGAATAGCTCA              
                                           4440                           
GAGGCCGAGGCGGCCTCGGCCTCTGCATAAATAAAAAAAATTAGTCAGCCATGCATGGGG              
                                           4500                           
CGGAGAATGGGCGGAACTGGGCGGAGTTAGGGGCGGGATGGGCGGAGTTAGGGGCGGGAC              
                                           4560                           
TATGGTTGCTGACTAATTGAGATGCATGCTTTGCATACTTCTGCCTGCTGGGGAGCCTGG              
                                           4620                           
GGACTTTCCACACCTGGTTGCTGACTAATTGAGATGCATGCTTTGCATACTTCTGCCTGC              
                                           4680                           
TGGGGAGCCTGGGGACTTTCCACACCCTAACTGACACACATTCCACAGAATTAATTCCCG              
                                           4740                           
ATCCCGTCGACCTCGAGAGCTTGGCGTAATCATGGTCATAGCTGTTTCCTGTGTGAAATT              
                                           4800                           
GTTATCCGCTCACAATTCCACACAACATACGAGCCGGAAGCATAAAGTGTAAAGCCTGGG              
                                           4860                           
GTGCCTAATGAGTGAGCTAACTCACATTAATTGCGTTGCGCTCACTGCCCGCTTTCCAGT              
                                           4920                           
CGGGAAACCTGTCGTGCCAGCTGCATTAATGAATCGGCCAACGCGCGGGGAGAGGCGGTT              
                                           4980                           
TGCGTATTGGGCGCTCTTCCGCTTCCTCGCTCACTGACTCGCTGCGCTCGGTCGTTCGGC              
                                           5040                           
TGCGGCGAGCGGTATCAGCTCACTCAAAGGCGGTAATACGGTTATCCACAGAATCAGGGG              
                                           5100                           
ATAACGCAGGAAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGG              
                                           5160                           
CCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCCTGACGAGCATCACAAAAATCGAC              
                                           5220                           
GCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTG              
                                           5280                           
GAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCCT              
                                           5340                           
TTCTCCCTTCGGGAAGCGTGGCGCTTTCTCAATGCTCACGCTGTAGGTATCTCAGTTCGG              
                                           5400                           
TGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCGACCGCT              
                                           5460                           
GCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCAC              
                                           5520                           
TGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGT              
                                           5580                           
TCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGGACAGTATTTGGTATCTGCGCTC              
                                           5640                           
TGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCA              
                                           5700                           
CCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGAT              
                                           5760                           
CTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGGAACGAAAACTCAC              
                                           5820                           
GTTAAGGGATTTTGGTCATGAGATTATCAAAAAGGATCTTCACCTAGATCCTTTTAAATT              
                                           5880                           
AAAAATGAAGTTTTAAATCAATCTAAAGTATATATGAGTAAACTTGGTCTGACAGTTACC              
                                           5940                           
AATGCTTAATCAGTGAGGCACCTATCTCAGCGATCTGTCTATTTCGTTCATCCATAGTTG              
                                           6000                           
CCTGACTCCCCGTCGTGTAGATAACTACGATACGGGAGGGCTTACCATCTGGCCCCAGTG              
                                           6060                           
CTGCAATGATACCGCGAGACCCACGCTCACCGGCTCCAGATTTATCAGCAATAAACCAGC              
                                           6120                           
CAGCCGGAAGGGCCGAGCGCAGAAGTGGTCCTGCAACTTTATCCGCCTCCATCCAGTCTA              
                                           6180                           
TTAATTGTTGCCGGGAAGCTAGAGTAAGTAGTTCGCCAGTTAATAGTTTGCGCAACGTTG              
                                           6240                           
TTGCCATTGCTACAGGCATCGTGGTGTCACGCTCGTCGTTTGGTATGGCTTCATTCAGCT              
                                           6300                           
CCGGTTCCCAACGATCAAGGCGAGTTACATGATCCCCCATGTTGTGCAAAAAAGCGGTTA              
                                           6360                           
GCTCCTTCGGTCCTCCGATCGTTGTCAGAAGTAAGTTGGCCGCAGTGTTATCACTCATGG              
                                           6420                           
TTATGGCAGCACTGCATAATTCTCTTACTGTCATGCCATCCGTAAGATGCTTTTCTGTGA              
                                           6480                           
CTGGTGAGTACTCAACCAAGTCATTCTGAGAATAGTGTATGCGGCGACCGAGTTGCTCTT              
                                           6540                           
GCCCGGCGTCAATACGGGATAATACCGCGCCACATAGCAGAACTTTAAAAGTGCTCATCA              
                                           6600                           
TTGGAAAACGTTCTTCGGGGCGAAAACTCTCAAGGATCTTACCGCTGTTGAGATCCAGTT              
                                           6660                           
CGATGTAACCCACTCGTGCACCCAACTGATCTTCAGCATCTTTTACTTTCACCAGCGTTT              
                                           6720                           
CTGGGTGAGCAAAAACAGGAAGGCAAAATGCCGCAAAAAAGGGAATAAGGGCGACACGGA              
                                           6780                           
AATGTTGAATACTCATACTCTTCCTTTTTCAATATTATTGAAGCATTTATCAGGGTTATT              
                                           6840                           
GTCTCATGAGCGGATACATATTTGAATGTATTTAGAAAAATAAACAAATAGGGGTTCCGC              
                                           6900                           
GCACATTTCCCCGAAAAGTGCCACCT                 6926                           
__________________________________________________________________________

                                  TABLE 3                                 
__________________________________________________________________________
DNA sequence of IL4.Y124D/IgG1 fusion molecule coding region, 1164bp      
SEQ ID No: 3                                                              
__________________________________________________________________________
ATGGGTCTCACCTCCCAACTGCTTCCCCCTCTGTTCTTCCTGCTAGCATGTGCCGGCAAC              
                                           60                             
TTTGTCCACGGACACAAGTGCGATATCACCTTACAGGAGATCATCAAAACTTTGAACAGC              
                                           120                            
CTCACAGAGCAGAAGACTCTGTGCACCGAGTTGACCGTAACAGACATCTTTGCTGCCTCC              
                                           180                            
AAGAACACAACTGAGAAGGAAACCTTCTGCAGGGCTGCGACTGTGCTCCGGCAGTTCTAC              
                                           240                            
AGCCACCATGAGAAGGACACTCGCTGCCTGGGTGCGACTGCACAGCAGTTCCACAGGCAC              
                                           300                            
AAGCAGCTGATCCGATTCCTGAAACGGCTCGACAGGAACCTCTGGGGCCTGGCGGGCTTG              
                                           360                            
AATTCCTGTCCTGTGAAGGAAGCCAACCAGAGTACGTTGGAAAACTTCTTGGAAAGGCTA              
                                           420                            
AAGACGATCATGAGAGAGAAAGACTCAAAGTGTTCGAGCGGTACCGAGCCCAAATCGGCC              
                                           480                            
GACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAACTCCTGGGGGGACCGTCAGTC              
                                           540                            
TTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACA              
                                           600                            
TGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGAC              
                                           660                            
GGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTAC              
                                           720                            
CGGGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAG              
                                           780                            
TGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAA              
                                           840                            
GGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGATGAGCTGACCAAG              
                                           900                            
AACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAG              
                                           960                            
TGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCC              
                                           1020                           
GACGGCTCCTTCTTCCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGG              
                                           1080                           
AACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGC              
                                           1140                           
CTCTCCCTGTCTCCGGGTAAATGA                   1164                           
__________________________________________________________________________

                                  TABLE 4                                 
__________________________________________________________________________
Sequence of encoded IL4.Y124D/IgG1 fusion protein, 387aa                  
SEQ ID No: 4                                                              
__________________________________________________________________________
1  MGLTSQLLPP                                                             
            LFFLLACAGN                                                    
                     FVHGHKCDIT                                           
                              LQEIIKTLNS                                  
                                       LTEQKTLCTE                         
51 LTVTDIFAAS                                                             
            KNTTEKETFC                                                    
                     RAATVLRQFY                                           
                              SHHEKDTRCL                                  
                                       GATAQQFHRH                         
101                                                                       
   KQLIRFLKRL                                                             
            DRNLWGLAGL                                                    
                     NSCPVKEANQ                                           
                              STLENFLERL                                  
                                       KTIMREKDSK                         
151                                                                       
   CSSGTEPKSA                                                             
            DKTHTCPPCP                                                    
                     APELLGGPSV                                           
                              FLFPPKPKDT                                  
                                       LMISRTPEVT                         
201                                                                       
   CVVVDVSHED                                                             
            PEVKFNWYVD                                                    
                     GVEVHNAKTK                                           
                              PREEQYNSTY                                  
                                       RVVSVLTVLH                         
251                                                                       
   QDWLNGKEYK                                                             
            CKVSNKALPA                                                    
                     PIEKTISKAK                                           
                              GQPREPQVYT                                  
                                       LPPSRDELTK                         
301                                                                       
   NQVSLTCLVK                                                             
            GFYPSDIAVE                                                    
                     WESNGQPENN                                           
                              YKTTPPVLDS                                  
                                       DGSFFLYSKL                         
351                                                                       
   TVDKSRWQQG                                                             
            NVFSCSVMHE                                                    
                     ALHNHYTQKS                                           
                              LSLSPGK*                                    
__________________________________________________________________________

                                  TABLE 5                                 
__________________________________________________________________________
DNA sequence of synthetic IgG4 cDNA, 1006bp                               
SEQ ID No: 5                                                              
__________________________________________________________________________
GCTTCCACCAAGGGCCCATCCGTCTTCCCCCTGGCGCCCTGCTCCAGGAGCACCTCCGAG              
                                           60                             
AGCACAGCCGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCG              
                                           120                            
TGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCA              
                                           180                            
GGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACGAAGACC              
                                           240                            
TACACCTGCAACGTAGATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTTGAGTCC              
                                           300                            
AAATATGGTCCCCCATGCCCATCATGCCCAGCACCTGAATTTCTGGGGGGACCATCAGTC              
                                           360                            
TTCCTGTTCCCCCCAAAACCCAAGGACACTCTCATGATCTCCCGGACCCCTGAGGTCACG              
                                           420                            
TGCGTGGTGGTGGACGTGAGCCAGGAAGACCCCGAGGTCCAGTTCAACTGGTACGTGGAT              
                                           480                            
GGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTTCAACAGCACGTAC              
                                           540                            
CGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAACGGCAAGGAGTACAAG              
                                           600                            
TGCAAGGTCTCCAACAAAGGCCTCCCGTCATCGATCGAGAAAACCATCTCCAAAGCCAAA              
                                           660                            
GGGCAGCCCCGAGAGCCACAGGTGTACACCCTGCCCCCATCCCAGGAGGAGATGACCAAG              
                                           720                            
AACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTACCCCAGCGACATCGCCGTGGAG              
                                           780                            
TGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTGG              
                                           840                            
GACGGATCCTTCTTCCTCTACAGCAGGCTAACCGTGGACAAGAGCAGGTGGCAGGAGGGG              
                                           900                            
AATGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACACAGAAGAGC              
                                           960                            
CTCTCCCTGTCTCTGGGTAAATGAGTGTAGTCTAGATCTACGTATG                            
                                           1006                           
__________________________________________________________________________

                                  TABLE 6                                 
__________________________________________________________________________
DNA sequence of IL4.Y124D/IgG4 fusion molecule coding region, 1149bp      
SEQ ID No: 6                                                              
__________________________________________________________________________
ATGGGTCTCACCTCCCAACTGCTTCCCCCTCTGTTCTTCCTGCTAGCATGTGCCGGCAAC              
                                           60                             
TTTGTCCACGGACACAAGTGCGATATCACCTTACAGGAGATCATCAAAACTTTGAACAGC              
                                           120                            
CTCACAGAGCAGAAGACTCTGTGCACCGAGTTGACCGTAACAGACATCTTTGCTGCCTCC              
                                           180                            
AAGAACACAACTGAGAAGGAAACCTTCTGCAGGGCTGCGACTGTGCTCCGGCAGTTCTAC              
                                           240                            
AGCCACCATGAGAAGGACACTCGCTGCCTGGGTGCGACTGCACAGCAGTTCCACAGGCAC              
                                           300                            
AAGCAGCTGATCCGATTCCTGAAACGGCTCGACAGGAACCTCTGGGGCCTGGCGGGCTTG              
                                           360                            
AATTCCTGTCCTGTGAAGGAAGCCAACCAGAGTACGTTGGAAAACTTCTTGGAAAGGCTA              
                                           420                            
AAGACGATCATGAGAGAGAAAGACTCAAAGTGCTCGAGCGAGTCCAAATATGGTCCCCCG              
                                           480                            
TGCCCATCATGCCCAGCACCTGAATTTCTGGGGGGACCATCAGTCTTCCTGTTCCCCCCA              
                                           540                            
AAACCCAAGGACACTCTCATGATCTCCCGGACCCCTGAGGTCACGTGCGTGGTGGTGGAC              
                                           600                            
GTGAGCCAGGAAGACCCCGAGGTCCAGTTCAACTGGTACGTGGATGGCGTGGAGGTGCAT              
                                           660                            
AATGCCAAGACAAAGCCGCGGGAGGAGCAGTTCAACAGCACGTACCGTGTGGTCAGCGTC              
                                           720                            
CTCACCGTCCTGCACCAGGACTGGCTGAACGGCAAGGAGTACAAGTGCAAGGTCTCCAAC              
                                           780                            
AAAGGCCTCCCGTCATCGATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAG              
                                           840                            
CCACAGGTGTACACCCTGCCCCCATCCCAGGAGGAGATGACCAAGAACCAGGTCAGCCTG              
                                           900                            
ACCTGCCTGGTCAAAGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGG              
                                           960                            
CAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGATCCTTCTTC              
                                           1020                           
CTCTACAGCAGGCTAACCGTGGACAAGAGCAGGTGGCAGGAGGGGAATGTCTTCTCATGC              
                                           1080                           
TCCGTGATGCATGAGGCTCTGCACAACCACTACACACAGAAGAGCCTCTCCCTGTCTCTG              
                                           1140                           
GGTAAATGA                                  1149                           
__________________________________________________________________________

                                  TABLE 7                                 
__________________________________________________________________________
Sequence of encoded IL4.Y124D/IgG4 fusion protein, 382aa                  
SEQ ID No: 7                                                              
__________________________________________________________________________
1  MGLTSQLLPP                                                             
            LFFLLACAGN                                                    
                     FVHGHKCDIT                                           
                              LQEIIKTLNS                                  
                                       LTEQKTLCTE                         
51 LTVTDIFAAS                                                             
            KNTTEKETFC                                                    
                     RAATVLRQFY                                           
                              SHHEKDTRCL                                  
                                       GATAQQFHRH                         
101                                                                       
   KQLIRFLKRL                                                             
            DRNLWGLAGL                                                    
                     NSCPVKEANQ                                           
                              STLENFLERL                                  
                                       KTIMREKDSK                         
151                                                                       
   CSSESKYGPP                                                             
            CPSCPAPEFL                                                    
                     GGPSVFLFPP                                           
                              KPKDTLMISR                                  
                                       TPEVTCVVVD                         
201                                                                       
   VSQEDPEVQF                                                             
            NWYVDGVEVH                                                    
                     NAKTKPREEQ                                           
                              FNSTYRVVSV                                  
                                       LTVLHQDWLN                         
251                                                                       
   GKEYKCKVSN                                                             
            KGLPSSIEKT                                                    
                     ISKAKGQPRE                                           
                              PQVYTLPPSQ                                  
                                       EEMTKNQVSL                         
301                                                                       
   TCLVKGFYPS                                                             
            DIAVEWESNG                                                    
                     QPENNYKTTP                                           
                              PVLDSDGSFF                                  
                                       LYSRLTVDKS                         
351                                                                       
   RWQEGNVFSC                                                             
            SVMHEALHNH                                                    
                     YTQKSLSLSL                                           
                              GK*                                         
__________________________________________________________________________

                                  TABLE 8                                 
__________________________________________________________________________
DNA sequence of IgG4 PE variant, 984bp                                    
SEQ ID No: 8                                                              
__________________________________________________________________________
GCTAGTACCAAGGGCCCATCCGTCTTCCCCCTGGCGCCCTGCTCCAGGAGCACCTCCGAG              
                                           60                             
AGCACgGCCGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCG              
                                           120                            
TGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCA              
                                           180                            
GGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACGAAGACC              
                                           240                            
TACACCTGCAACGTAGATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTTGAGTCC              
                                           300                            
AAATATGGTCCCCCATGCCCAcCATGCCCAGCgCCTGAaTTtgaGGGGGGACCATCAGTC              
                                           360                            
TTCCTGTTCCCCCCAAAACCCAAGGACACTCTCATGATCTCCCGGACCCCTGAGGTCACG              
                                           420                            
TGCGTGGTGGTGGACGTGAGCCAGGAAGACCCCGAGGTCCAGTTCAACTGGTACGTGGAT              
                                           480                            
GGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTTCAACAGCACGTAC              
                                           540                            
CGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAACGGCAAGGAGTACAAG              
                                           600                            
TGCAAGGTCTCCAACAAAGGCCTCCCGTCaTCgATCGAGAAAACCATCTCCAAAGCCAAA              
                                           660                            
GGGCAGCCCCGAGAGCCACAGGTGTACACCCTGCCCCCATCCCAGGAGGAGATGACCAAG              
                                           720                            
AACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTACCCCAGCGACATCGCCGTGGAG              
                                           780                            
TGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCC              
                                           840                            
GACGGaTCCTTCTTCCTCTACAGCAGGCTAACCGTGGACAAGAGCAGGTGGCAGGAGGGG              
                                           900                            
AATGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACACAGAAGAGC              
                                           960                            
CTCTCCCTGTCTCTGGGTAAATGA                   984                            
__________________________________________________________________________

                                  TABLE 9                                 
__________________________________________________________________________
DNA sequence of IL4.Y124D/IgG4 PE fusion molecule coding region, 1149bp   
SEQ ID No: 9                                                              
__________________________________________________________________________
ATGGGTCTCACCTCCCAACTGCTTCCCCCTCTGTTCTTCCTGCTAGCATGTGCCGGCAAC              
                                           60                             
TTTGTCCACGGACACAAGTGCGATATCACCTTACAGGAGATCATCAAAACTTTGAACAGC              
                                           120                            
CTCACAGAGCAGAAGACTCTGTGCACCGAGTTGACCGTAACAGACATCTTTGCTGCCTCC              
                                           180                            
AAGAACACAACTGAGAAGGAAACCTTCTGCAGGGCTGCGACTGTGCTCCGGCAGTTCTAC              
                                           240                            
AGCCACCATGAGAAGGACACTCGCTGCCTGGGTGCGACTGCACAGCAGTTCCACAGGCAC              
                                           300                            
AAGCAGCTGATCCGATTCCTGAAACGGCTCGACAGGAACCTCTGGGGCCTGGCGGGCTTG              
                                           360                            
AATTCCTGTCCTGTGAAGGAAGCCAACCAGAGTACGTTGGAAAACTTCTTGGAAAGGCTA              
                                           420                            
AAGACGATCATGAGAGAGAAAGACTCAAAGTGCTCGAGCGAGTCCAAATATGGTCCCCCA              
                                           480                            
TGCCCACCATGCCCAGCgCCTGAATTTGAGGGGGGACCATCAGTCTTCCTGTTCCCCCCA              
                                           540                            
AAACCCAAGGACACTCTCATGATCTCCCGGACCCCTGAGGTCACGTGCGTGGTGGTGGAC              
                                           600                            
GTGAGCCAGGAAGACCCCGAGGTCCAGTTCAACTGGTACGTGGATGGCGTGGAGGTGCAT              
                                           660                            
AATGCCAAGACAAAGCCGCGGGAGGAGCAGTTCAACAGCACGTACCGTGTGGTCAGCGTC              
                                           720                            
CTCACCGTCCTGCACCAGGACTGGCTGAACGGCAAGGAGTACAAGTGCAAGGTCTCCAAC              
                                           780                            
AAAGGCCTCCCGTCaTCgATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAG              
                                           840                            
CCACAGGTGTACACCCTGCCCCCATCCCAGGAGGAGATGACCAAGAACCAGGTCAGCCTG              
                                           900                            
ACCTGCCTGGTCAAAGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGG              
                                           960                            
CAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTGGGACGGaTCCTTCTTC              
                                           1020                           
CTCTACAGCAGGCTAACCGTGGACAAGAGCAGGTGGCAGGAGGGGAATGTCTTCTCATGC              
                                           1080                           
TCCGTGATGCATGAGGCTCTGCACAACCACTACACACAGAAGAGCCTCTCCCTGTCTCTG              
                                           1140                           
GGTAAATGA                                  1149                           
__________________________________________________________________________

                                  TABLE 10                                
__________________________________________________________________________
Sequence of encoded IL4.Y124D/IgG4 PE variant fusion protein, 382aa       
SEQ ID No: 10                                                             
__________________________________________________________________________
1  MGLTSQLLPP                                                             
            LFFLLACAGN                                                    
                     FVHGHKCDIT                                           
                              LQEIIKTLNS                                  
                                       LTEQKTLCTE                         
51 LTVTDIFAAS                                                             
            KNTTEKETFC                                                    
                     RAATVLRQFY                                           
                              SHHEKDTRCL                                  
                                       GATAQQFHRH                         
101                                                                       
   KQLIRFLKRL                                                             
            DRNLWGLAGL                                                    
                     NSCPVKEANQ                                           
                              STLENFLERL                                  
                                       KTIMREKDSK                         
151                                                                       
   CSSESKYGPP                                                             
            CPPCPAPEFE                                                    
                     GGPSVFLFPP                                           
                              KPKDTLMISR                                  
                                       TPEVTCVVVD                         
201                                                                       
   VSQEDPEVQF                                                             
            NWYVDGVEVH                                                    
                     NAKTKPREEQ                                           
                              FNSTYRVVSV                                  
                                       LTVLHQDWLN                         
251                                                                       
   GKEYKCKVSN                                                             
            KGLPSSIEKT                                                    
                     ISKAKGQPRE                                           
                              PQVYTLPPSQ                                  
                                       EEMTKNQVSL                         
301                                                                       
   TCLVKGFYPS                                                             
            DIAVEWESNG                                                    
                     QPENNYKTTP                                           
                              PVLDSDGSFF                                  
                                       LYSRLTVDKS                         
351                                                                       
   RWQEGNVFSC                                                             
            SVMHEALHNH                                                    
                     YTQKSLSLSL                                           
                              GK*                                         
__________________________________________________________________________

__________________________________________________________________________
SEQUENCE LISTING                                                          
(1) GENERAL INFORMATION:                                                  
(iii) NUMBER OF SEQUENCES: 21                                             
(2) INFORMATION FOR SEQ ID NO:1:                                          
(i) SEQUENCE CHARACTERISTICS:                                             
(A) LENGTH: 6367 base pairs                                               
(B) TYPE: nucleic acid                                                    
(C) STRANDEDNESS: double                                                  
(D) TOPOLOGY: circular                                                    
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:                                  
GACGTCGACGGATCGGGAGATCGGGGATCGATCCGTCGACGTACGACTAGTTATTAATAG60            
TAATCAATTACGGGGTCATTAGTTCATAGCCCATATATGGAGTTCCGCGTTACATAACTT120           
ACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGCCCATTGACGTCAATAATG180           
ACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGACGTCAATGGGTGGACTAT240           
TTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCCAAGTACGCCCCCT300           
ATTGACGTCAATGACGGTAAATGGCCCGCCTGGCATTATGCCCAGTACATGACCTTATGG360           
GACTTTCCTACTTGGCAGTACATCTACGTATTAGTCATCGCTATTACCATGGTGATGCGG420           
TTTTGGCAGTACATCAATGGGCGTGGATAGCGGTTTGACTCACGGGGATTTCCAAGTCTC480           
CACCCCATTGACGTCAATGGGAGTTTGTTTTGGCACCAAAATCAACGGGACTTTCCAAAA540           
TGTCGTAACAACTCCGCCCCATTGACGCAAATGGGCGGTAGGCGTGTACGGTGGGAGGTC600           
TATATAAGCAGAGCTGGGTACGTGAACCGTCAGATCGCCTGGAGACGCCATCGAATTCGG660           
TTACCTGCAGATATCAAGCTAATTCGGTACCGAGCCCAAATCGGCCGACAAAACTCACAC720           
ATGCCCACCGTGCCCAGCACCTGAACTCCTGGGGGGACCGTCAGTCTTCCTCTTCCCCCC780           
AAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGA840           
CGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCA900           
TAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGGGTGGTCAGCGT960           
CCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAA1020          
CAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGA1080          
ACCACAGGTGTACACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAGGTCAGCCT1140          
GACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGG1200          
GCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTT1260          
CCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATG1320          
CTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCC1380          
GGGTAAATGAGTGTAGTCTAGAGCTCGCTGATCAGCCTCGACTGTGCCTTCTAGTTGCCA1440          
GCCATCTGTTGTTTGCCCCTCCCCCGTGCCTTCCTTGACCCTGGAAGGTGCCACTCCCAC1500          
TGTCCTTTCCTAATAAAATGAGGAAATTGCATCGCATTGTCTGAGTAGGTGTCATTCTAT1560          
TCTGGGGGGTGGGGTGGGGCAGGACAGCAAGGGGGAGGATTGGGAAGACAATAGCAGGCA1620          
TGCTGGGGATGCGGTGGGCTCTATGGAACCAGCTGGGGCTCGAGGGGGGATCTCCCGATC1680          
CCCAGCTTTGCTTCTCAATTTCTTATTTGCATAATGAGAAAAAAAGGAAAATTAATTTTA1740          
ACACCAATTCAGTAGTTGATTGAGCAAATGCGTTGCCAAAAAGGATGCTTTAGAGACAGT1800          
GTTCTCTGCACAGATAAGGACAAACATTATTCAGAGGGAGTACCCAGAGCTGAGACTCCT1860          
AAGCCAGTGAGTGGCACAGCATTCTAGGGAGAAATATGCTTGTCATCACCGAAGCCTGAT1920          
TCCGTAGAGCCACACCTTGGTAAGGGCCAATCTGCTCACACAGGATAGAGAGGGCAGGAG1980          
CCAGGGCAGAGCATATAAGGTGAGGTAGGATCAGTTGCTCCTCACATTTGCTTCTGACAT2040          
AGTTGTGTTGGGAGCTTGGATAGCTTGGACAGCTCAGGGCTGCGATTTCGCGCCAAACTT2100          
GACGGCAATCCTAGCGTGAAGGCTGGTAGGATTTTATCCCCGCTGCCATCATGGTTCGAC2160          
CATTGAACTGCATCGTCGCCGTGTCCCAAAATATGGGGATTGGCAAGAACGGAGACCTAC2220          
CCTGGCCTCCGCTCAGGAACGAGTTCAAGTACTTCCAAAGAATGACCACAACCTCTTCAG2280          
TGGAAGGTAAACAGAATCTGGTGATTATGGGTAGGAAAACCTGGTTCTCCATTCCTGAGA2340          
AGAATCGACCTTTAAAGGACAGAATTAATATAGTTCTCAGTAGAGAACTCAAAGAACCAC2400          
CACGAGGAGCTCATTTTCTTGCCAAAAGTTTGGATGATGCCTTAAGACTTATTGAACAAC2460          
CGGAATTGGCAAGTAAAGTAGACATGGTTTGGATAGTCGGAGGCAGTTCTGTTTACCAGG2520          
AAGCCATGAATCAACCAGGCCACCTTAGACTCTTTGTGACAAGGATCATGCAGGAATTTG2580          
AAAGTGACACGTTTTTCCCAGAAATTGATTTGGGGAAATATAAACTTCTCCCAGAATACC2640          
CAGGCGTCCTCTCTGAGGTCCAGGAGGAAAAAGGCATCAAGTATAAGTTTGAAGTCTACG2700          
AGAAGAAAGACTAACAGGAAGATGCTTTCAAGTTCTCTGCTCCCCTCCTAAAGCTATGCA2760          
TTTTTATAAGACCATGCTAGCTTGAACTTGTTTATTGCAGCTTATAATGGTTACAAATAA2820          
AGCAATAGCATCACAAATTTCACAAATAAAGCATTTTTTTCACTGCATTCTAGTTGTGGT2880          
TTGTCCAAACTCATCAATGTATCTTATCATGTCTGGATCAACGATAGCTTATCTGTGGGC2940          
GATGCCAAGCACCTGGATGCTGTTGGTTTCCTGCTACTGATTTAGAAGCCATTTGCCCCC3000          
TGAGTGGGGCTTGGGAGCACTAACTTTCTCTTTCAAAGGAAGCAATGCAGAAAGAAAAGC3060          
ATACAAAGTATAAGCTGCCATGTAATAATGGAAGAAGATAAGGTTGTATGAATTAGATTT3120          
ACATACTTCTGAATTGAAACTAAACACCTTTAAATTCTTAAATATATAACACATTTCATA3180          
TGAAAGTATTTTACATAAGTAACTCAGATACATAGAAAACAAAGCTAATGATAGGTGTCC3240          
CTAAAAGTTCATTTATTAATTCTACAAATGATGAGCTGGCCATCAAAATTCCAGCTCAAT3300          
TCTTCAACGAATTAGAAAGAGCAATCTGCAAACTCATCTGGAATAACAAAAAACCTAGGA3360          
TAGCAAAAACTCTTCTCAAGGATAAAAGAACCTCTGGTGGAATCACCATGCCTGACCTAA3420          
AGCTGTACTACAGAGCAATTGTGATAAAAACTGCATGGTACTGATATAGAAACGGACAAG3480          
TAGACCAATGGAATAGAACCCACACACCTATGGTCACTTGATCTTCAACAAGAGAGCTAA3540          
AACCATCCACTGGAAAAAAGACAGCATTTTCAACAAATGGTGCTGGCACAACTGGTGGTT3600          
ATCATGGAGAAGAATGTGAATTGATCCATTCCAATCTCCTTGTACTAAGGTCAAATCTAA3660          
GTGGATCAAGGAACTCCACATAAAACCAGAGACACTGAAACTTATAGAGGAGAAAGTGGG3720          
GAAAAGCCTCGAAGATATGGGCACAGGGGAAAAATTCCTGAATAGAACAGCAATGGCTTG3780          
TGCTGTAAGATCGAGAATTGACAAATGGGACCTCATGAAACTCCAAAGCTATCGGATCAA3840          
TTCCTCCAAAAAAGCCTCCTCACTACTTCTGGAATAGCTCAGAGGCCGAGGCGGCCTCGG3900          
CCTCTGCATAAATAAAAAAAATTAGTCAGCCATGCATGGGGCGGAGAATGGGCGGAACTG3960          
GGCGGAGTTAGGGGCGGGATGGGCGGAGTTAGGGGCGGGACTATGGTTGCTGACTAATTG4020          
AGATGCATGCTTTGCATACTTCTGCCTGCTGGGGAGCCTGGGGACTTTCCACACCTGGTT4080          
GCTGACTAATTGAGATGCATGCTTTGCATACTTCTGCCTGCTGGGGAGCCTGGGGACTTT4140          
CCACACCCTAACTGACACACATTCCACAGAATTAATTCCCGATCCCGTCGACCTCGAGAG4200          
CTTGGCGTAATCATGGTCATAGCTGTTTCCTGTGTGAAATTGTTATCCGCTCACAATTCC4260          
ACACAACATACGAGCCGGAAGCATAAAGTGTAAAGCCTGGGGTGCCTAATGAGTGAGCTA4320          
ACTCACATTAATTGCGTTGCGCTCACTGCCCGCTTTCCAGTCGGGAAACCTGTCGTGCCA4380          
GCTGCATTAATGAATCGGCCAACGCGCGGGGAGAGGCGGTTTGCGTATTGGGCGCTCTTC4440          
CGCTTCCTCGCTCACTGACTCGCTGCGCTCGGTCGTTCGGCTGCGGCGAGCGGTATCAGC4500          
TCACTCAAAGGCGGTAATACGGTTATCCACAGAATCAGGGGATAACGCAGGAAAGAACAT4560          
GTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTT4620          
CCATAGGCTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCG4680          
AAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTC4740          
TCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGT4800          
GGCGCTTTCTCAATGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAA4860          
GCTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCGACCGCTGCGCCTTATCCGGTAACTA4920          
TCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAA4980          
CAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAA5040          
CTACGGCTACACTAGAAGGACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTT5100          
CGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTT5160          
TTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGAT5220          
CTTTTCTACGGGGTCTGACGCTCAGTGGAACGAAAACTCACGTTAAGGGATTTTGGTCAT5280          
GAGATTATCAAAAAGGATCTTCACCTAGATCCTTTTAAATTAAAAATGAAGTTTTAAATC5340          
AATCTAAAGTATATATGAGTAAACTTGGTCTGACAGTTACCAATGCTTAATCAGTGAGGC5400          
ACCTATCTCAGCGATCTGTCTATTTCGTTCATCCATAGTTGCCTGACTCCCCGTCGTGTA5460          
GATAACTACGATACGGGAGGGCTTACCATCTGGCCCCAGTGCTGCAATGATACCGCGAGA5520          
CCCACGCTCACCGGCTCCAGATTTATCAGCAATAAACCAGCCAGCCGGAAGGGCCGAGCG5580          
CAGAAGTGGTCCTGCAACTTTATCCGCCTCCATCCAGTCTATTAATTGTTGCCGGGAAGC5640          
TAGAGTAAGTAGTTCGCCAGTTAATAGTTTGCGCAACGTTGTTGCCATTGCTACAGGCAT5700          
CGTGGTGTCACGCTCGTCGTTTGGTATGGCTTCATTCAGCTCCGGTTCCCAACGATCAAG5760          
GCGAGTTACATGATCCCCCATGTTGTGCAAAAAAGCGGTTAGCTCCTTCGGTCCTCCGAT5820          
CGTTGTCAGAAGTAAGTTGGCCGCAGTGTTATCACTCATGGTTATGGCAGCACTGCATAA5880          
TTCTCTTACTGTCATGCCATCCGTAAGATGCTTTTCTGTGACTGGTGAGTACTCAACCAA5940          
GTCATTCTGAGAATAGTGTATGCGGCGACCGAGTTGCTCTTGCCCGGCGTCAATACGGGA6000          
TAATACCGCGCCACATAGCAGAACTTTAAAAGTGCTCATCATTGGAAAACGTTCTTCGGG6060          
GCGAAAACTCTCAAGGATCTTACCGCTGTTGAGATCCAGTTCGATGTAACCCACTCGTGC6120          
ACCCAACTGATCTTCAGCATCTTTTACTTTCACCAGCGTTTCTGGGTGAGCAAAAACAGG6180          
AAGGCAAAATGCCGCAAAAAAGGGAATAAGGGCGACACGGAAATGTTGAATACTCATACT6240          
CTTCCTTTTTCAATATTATTGAAGCATTTATCAGGGTTATTGTCTCATGAGCGGATACAT6300          
ATTTGAATGTATTTAGAAAAATAAACAAATAGGGGTTCCGCGCACATTTCCCCGAAAAGT6360          
GCCACCT6367                                                               
(2) INFORMATION FOR SEQ ID NO: 2:                                         
(i) SEQUENCE CHARACTERISTICS:                                             
(A) LENGTH: 6926 base pairs                                               
(B) TYPE: nucleic acid                                                    
(C) STRANDEDNESS: double                                                  
(D) TOPOLOGY: circular                                                    
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:                                  
GACGTCGACGGATCGGGAGATCGGGGATCGATCCGTCGACGTACGACTAGTTATTAATAG60            
TAATCAATTACGGGGTCATTAGTTCATAGCCCATATATGGAGTTCCGCGTTACATAACTT120           
ACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGCCCATTGACGTCAATAATG180           
ACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGACGTCAATGGGTGGACTAT240           
TTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCCAAGTACGCCCCCT300           
ATTGACGTCAATGACGGTAAATGGCCCGCCTGGCATTATGCCCAGTACATGACCTTATGG360           
GACTTTCCTACTTGGCAGTACATCTACGTATTAGTCATCGCTATTACCATGGTGATGCGG420           
TTTTGGCAGTACATCAATGGGCGTGGATAGCGGTTTGACTCACGGGGATTTCCAAGTCTC480           
CACCCCATTGACGTCAATGGGAGTTTGTTTTGGCACCAAAATCAACGGGACTTTCCAAAA540           
TGTCGTAACAACTCCGCCCCATTGACGCAAATGGGCGGTAGGCGTGTACGGTGGGAGGTC600           
TATATAAGCAGAGCTGGGTACGTGAACCGTCAGATCGCCTGGAGACGCCATCGAATTCGG660           
TTACCTGCAGATGGGCTGCAGGAATTCCGCATTGCAGAGATAATTGTATTTAAGTGCCTA720           
GCTCGATACAATAAACGCCATTTGACCATTCACCACATTGGTGTGCACCTCCAAGCTTAC780           
CTGCCATGGGTCTCACCTCCCAACTGCTTCCCCCTCTGTTCTTCCTGCTAGCATGTGCCG840           
GCAACTTTGTCCACGGACACAAGTGCGATATCACCTTACAGGAGATCATCAAAACTTTGA900           
ACAGCCTCACAGAGCAGAAGACTCTGTGCACCGAGTTGACCGTAACAGACATCTTTGCTG960           
CCTCCAAGAACACAACTGAGAAGGAAACCTTCTGCAGGGCTGCGACTGTGCTCCGGCAGT1020          
TCTACAGCCACCATGAGAAGGACACTCGCTGCCTGGGTGCGACTGCACAGCAGTTCCACA1080          
GGCACAAGCAGCTGATCCGATTCCTGAAACGGCTCGACAGGAACCTCTGGGGCCTGGCGG1140          
GCTTGAATTCCTGTCCTGTGAAGGAAGCCAACCAGAGTACGTTGGAAAACTTCTTGGAAA1200          
GGCTAAAGACGATCATGAGAGAGAAAGACTCAAAGTGTTCGAGCGGTACCGAGCCCAAAT1260          
CGGCCGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAACTCCTGGGGGGACCGT1320          
CAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGG1380          
TCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACG1440          
TGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCA1500          
CGTACCGGGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGT1560          
ACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAG1620          
CCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGATGAGCTGA1680          
CCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCG1740          
TGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGG1800          
ACTCCGACGGCTCCTTCTTCCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGC1860          
AGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAGA1920          
AGAGCCTCTCCCTGTCTCCGGGTAAATGAGTGTAGTCTAGAGCTCGCTGATCAGCCTCGA1980          
CTGTGCCTTCTAGTTGCCAGCCATCTGTTGTTTGCCCCTCCCCCGTGCCTTCCTTGACCC2040          
TGGAAGGTGCCACTCCCACTGTCCTTTCCTAATAAAATGAGGAAATTGCATCGCATTGTC2100          
TGAGTAGGTGTCATTCTATTCTGGGGGGTGGGGTGGGGCAGGACAGCAAGGGGGAGGATT2160          
GGGAAGACAATAGCAGGCATGCTGGGGATGCGGTGGGCTCTATGGAACCAGCTGGGGCTC2220          
GAGGGGGGATCTCCCGATCCCCAGCTTTGCTTCTCAATTTCTTATTTGCATAATGAGAAA2280          
AAAAGGAAAATTAATTTTAACACCAATTCAGTAGTTGATTGAGCAAATGCGTTGCCAAAA2340          
AGGATGCTTTAGAGACAGTGTTCTCTGCACAGATAAGGACAAACATTATTCAGAGGGAGT2400          
ACCCAGAGCTGAGACTCCTAAGCCAGTGAGTGGCACAGCATTCTAGGGAGAAATATGCTT2460          
GTCATCACCGAAGCCTGATTCCGTAGAGCCACACCTTGGTAAGGGCCAATCTGCTCACAC2520          
AGGATAGAGAGGGCAGGAGCCAGGGCAGAGCATATAAGGTGAGGTAGGATCAGTTGCTCC2580          
TCACATTTGCTTCTGACATAGTTGTGTTGGGAGCTTGGATAGCTTGGACAGCTCAGGGCT2640          
GCGATTTCGCGCCAAACTTGACGGCAATCCTAGCGTGAAGGCTGGTAGGATTTTATCCCC2700          
GCTGCCATCATGGTTCGACCATTGAACTGCATCGTCGCCGTGTCCCAAAATATGGGGATT2760          
GGCAAGAACGGAGACCTACCCTGGCCTCCGCTCAGGAACGAGTTCAAGTACTTCCAAAGA2820          
ATGACCACAACCTCTTCAGTGGAAGGTAAACAGAATCTGGTGATTATGGGTAGGAAAACC2880          
TGGTTCTCCATTCCTGAGAAGAATCGACCTTTAAAGGACAGAATTAATATAGTTCTCAGT2940          
AGAGAACTCAAAGAACCACCACGAGGAGCTCATTTTCTTGCCAAAAGTTTGGATGATGCC3000          
TTAAGACTTATTGAACAACCGGAATTGGCAAGTAAAGTAGACATGGTTTGGATAGTCGGA3060          
GGCAGTTCTGTTTACCAGGAAGCCATGAATCAACCAGGCCACCTTAGACTCTTTGTGACA3120          
AGGATCATGCAGGAATTTGAAAGTGACACGTTTTTCCCAGAAATTGATTTGGGGAAATAT3180          
AAACTTCTCCCAGAATACCCAGGCGTCCTCTCTGAGGTCCAGGAGGAAAAAGGCATCAAG3240          
TATAAGTTTGAAGTCTACGAGAAGAAAGACTAACAGGAAGATGCTTTCAAGTTCTCTGCT3300          
CCCCTCCTAAAGCTATGCATTTTTATAAGACCATGCTAGCTTGAACTTGTTTATTGCAGC3360          
TTATAATGGTTACAAATAAAGCAATAGCATCACAAATTTCACAAATAAAGCATTTTTTTC3420          
ACTGCATTCTAGTTGTGGTTTGTCCAAACTCATCAATGTATCTTATCATGTCTGGATCAA3480          
CGATAGCTTATCTGTGGGCGATGCCAAGCACCTGGATGCTGTTGGTTTCCTGCTACTGAT3540          
TTAGAAGCCATTTGCCCCCTGAGTGGGGCTTGGGAGCACTAACTTTCTCTTTCAAAGGAA3600          
GCAATGCAGAAAGAAAAGCATACAAAGTATAAGCTGCCATGTAATAATGGAAGAAGATAA3660          
GGTTGTATGAATTAGATTTACATACTTCTGAATTGAAACTAAACACCTTTAAATTCTTAA3720          
ATATATAACACATTTCATATGAAAGTATTTTACATAAGTAACTCAGATACATAGAAAACA3780          
AAGCTAATGATAGGTGTCCCTAAAAGTTCATTTATTAATTCTACAAATGATGAGCTGGCC3840          
ATCAAAATTCCAGCTCAATTCTTCAACGAATTAGAAAGAGCAATCTGCAAACTCATCTGG3900          
AATAACAAAAAACCTAGGATAGCAAAAACTCTTCTCAAGGATAAAAGAACCTCTGGTGGA3960          
ATCACCATGCCTGACCTAAAGCTGTACTACAGAGCAATTGTGATAAAAACTGCATGGTAC4020          
TGATATAGAAACGGACAAGTAGACCAATGGAATAGAACCCACACACCTATGGTCACTTGA4080          
TCTTCAACAAGAGAGCTAAAACCATCCACTGGAAAAAAGACAGCATTTTCAACAAATGGT4140          
GCTGGCACAACTGGTGGTTATCATGGAGAAGAATGTGAATTGATCCATTCCAATCTCCTT4200          
GTACTAAGGTCAAATCTAAGTGGATCAAGGAACTCCACATAAAACCAGAGACACTGAAAC4260          
TTATAGAGGAGAAAGTGGGGAAAAGCCTCGAAGATATGGGCACAGGGGAAAAATTCCTGA4320          
ATAGAACAGCAATGGCTTGTGCTGTAAGATCGAGAATTGACAAATGGGACCTCATGAAAC4380          
TCCAAAGCTATCGGATCAATTCCTCCAAAAAAGCCTCCTCACTACTTCTGGAATAGCTCA4440          
GAGGCCGAGGCGGCCTCGGCCTCTGCATAAATAAAAAAAATTAGTCAGCCATGCATGGGG4500          
CGGAGAATGGGCGGAACTGGGCGGAGTTAGGGGCGGGATGGGCGGAGTTAGGGGCGGGAC4560          
TATGGTTGCTGACTAATTGAGATGCATGCTTTGCATACTTCTGCCTGCTGGGGAGCCTGG4620          
GGACTTTCCACACCTGGTTGCTGACTAATTGAGATGCATGCTTTGCATACTTCTGCCTGC4680          
TGGGGAGCCTGGGGACTTTCCACACCCTAACTGACACACATTCCACAGAATTAATTCCCG4740          
ATCCCGTCGACCTCGAGAGCTTGGCGTAATCATGGTCATAGCTGTTTCCTGTGTGAAATT4800          
GTTATCCGCTCACAATTCCACACAACATACGAGCCGGAAGCATAAAGTGTAAAGCCTGGG4860          
GTGCCTAATGAGTGAGCTAACTCACATTAATTGCGTTGCGCTCACTGCCCGCTTTCCAGT4920          
CGGGAAACCTGTCGTGCCAGCTGCATTAATGAATCGGCCAACGCGCGGGGAGAGGCGGTT4980          
TGCGTATTGGGCGCTCTTCCGCTTCCTCGCTCACTGACTCGCTGCGCTCGGTCGTTCGGC5040          
TGCGGCGAGCGGTATCAGCTCACTCAAAGGCGGTAATACGGTTATCCACAGAATCAGGGG5100          
ATAACGCAGGAAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGG5160          
CCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCCTGACGAGCATCACAAAAATCGAC5220          
GCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTG5280          
GAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCCT5340          
TTCTCCCTTCGGGAAGCGTGGCGCTTTCTCAATGCTCACGCTGTAGGTATCTCAGTTCGG5400          
TGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCGACCGCT5460          
GCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCAC5520          
TGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGT5580          
TCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGGACAGTATTTGGTATCTGCGCTC5640          
TGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCA5700          
CCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGAT5760          
CTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGGAACGAAAACTCAC5820          
GTTAAGGGATTTTGGTCATGAGATTATCAAAAAGGATCTTCACCTAGATCCTTTTAAATT5880          
AAAAATGAAGTTTTAAATCAATCTAAAGTATATATGAGTAAACTTGGTCTGACAGTTACC5940          
AATGCTTAATCAGTGAGGCACCTATCTCAGCGATCTGTCTATTTCGTTCATCCATAGTTG6000          
CCTGACTCCCCGTCGTGTAGATAACTACGATACGGGAGGGCTTACCATCTGGCCCCAGTG6060          
CTGCAATGATACCGCGAGACCCACGCTCACCGGCTCCAGATTTATCAGCAATAAACCAGC6120          
CAGCCGGAAGGGCCGAGCGCAGAAGTGGTCCTGCAACTTTATCCGCCTCCATCCAGTCTA6180          
TTAATTGTTGCCGGGAAGCTAGAGTAAGTAGTTCGCCAGTTAATAGTTTGCGCAACGTTG6240          
TTGCCATTGCTACAGGCATCGTGGTGTCACGCTCGTCGTTTGGTATGGCTTCATTCAGCT6300          
CCGGTTCCCAACGATCAAGGCGAGTTACATGATCCCCCATGTTGTGCAAAAAAGCGGTTA6360          
GCTCCTTCGGTCCTCCGATCGTTGTCAGAAGTAAGTTGGCCGCAGTGTTATCACTCATGG6420          
TTATGGCAGCACTGCATAATTCTCTTACTGTCATGCCATCCGTAAGATGCTTTTCTGTGA6480          
CTGGTGAGTACTCAACCAAGTCATTCTGAGAATAGTGTATGCGGCGACCGAGTTGCTCTT6540          
GCCCGGCGTCAATACGGGATAATACCGCGCCACATAGCAGAACTTTAAAAGTGCTCATCA6600          
TTGGAAAACGTTCTTCGGGGCGAAAACTCTCAAGGATCTTACCGCTGTTGAGATCCAGTT6660          
CGATGTAACCCACTCGTGCACCCAACTGATCTTCAGCATCTTTTACTTTCACCAGCGTTT6720          
CTGGGTGAGCAAAAACAGGAAGGCAAAATGCCGCAAAAAAGGGAATAAGGGCGACACGGA6780          
AATGTTGAATACTCATACTCTTCCTTTTTCAATATTATTGAAGCATTTATCAGGGTTATT6840          
GTCTCATGAGCGGATACATATTTGAATGTATTTAGAAAAATAAACAAATAGGGGTTCCGC6900          
GCACATTTCCCCGAAAAGTGCCACCT6926                                            
(2) INFORMATION FOR SEQ ID NO: 3:                                         
(i) SEQUENCE CHARACTERISTICS:                                             
(A) LENGTH: 1164 base pairs                                               
(B) TYPE: nucleic acid                                                    
(C) STRANDEDNESS: double                                                  
(D) TOPOLOGY: linear                                                      
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:                                  
ATGGGTCTCACCTCCCAACTGCTTCCCCCTCTGTTCTTCCTGCTAGCATGTGCCGGCAAC60            
TTTGTCCACGGACACAAGTGCGATATCACCTTACAGGAGATCATCAAAACTTTGAACAGC120           
CTCACAGAGCAGAAGACTCTGTGCACCGAGTTGACCGTAACAGACATCTTTGCTGCCTCC180           
AAGAACACAACTGAGAAGGAAACCTTCTGCAGGGCTGCGACTGTGCTCCGGCAGTTCTAC240           
AGCCACCATGAGAAGGACACTCGCTGCCTGGGTGCGACTGCACAGCAGTTCCACAGGCAC300           
AAGCAGCTGATCCGATTCCTGAAACGGCTCGACAGGAACCTCTGGGGCCTGGCGGGCTTG360           
AATTCCTGTCCTGTGAAGGAAGCCAACCAGAGTACGTTGGAAAACTTCTTGGAAAGGCTA420           
AAGACGATCATGAGAGAGAAAGACTCAAAGTGTTCGAGCGGTACCGAGCCCAAATCGGCC480           
GACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAACTCCTGGGGGGACCGTCAGTC540           
TTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACA600           
TGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGAC660           
GGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTAC720           
CGGGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAG780           
TGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAA840           
GGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGATGAGCTGACCAAG900           
AACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAG960           
TGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCC1020          
GACGGCTCCTTCTTCCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGG1080          
AACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGC1140          
CTCTCCCTGTCTCCGGGTAAATGA1164                                              
(2) INFORMATION FOR SEQ ID NO: 4:                                         
(i) SEQUENCE CHARACTERISTICS:                                             
(A) LENGTH: 387 amino acids                                               
(B) TYPE: amino acid                                                      
(C) STRANDEDNESS:                                                         
(D) TOPOLOGY: linear                                                      
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:                                  
MetGlyLeuThrSerGlnLeuLeuProProLeuPhePheLeuLeuAla                          
151015                                                                    
CysAlaGlyAsnPheValHisGlyHisLysCysAspIleThrLeuGln                          
202530                                                                    
GluIleIleLysThrLeuAsnSerLeuThrGluGlnLysThrLeuCys                          
354045                                                                    
ThrGluLeuThrValThrAspIlePheAlaAlaSerLysAsnThrThr                          
505560                                                                    
GluLysGluThrPheCysArgAlaAlaThrValLeuArgGlnPheTyr                          
65707580                                                                  
SerHisHisGluLysAspThrArgCysLeuGlyAlaThrAlaGlnGln                          
859095                                                                    
PheHisArgHisLysGlnLeuIleArgPheLeuLysArgLeuAspArg                          
100105110                                                                 
AsnLeuTrpGlyLeuAlaGlyLeuAsnSerCysProValLysGluAla                          
115120125                                                                 
AsnGlnSerThrLeuGluAsnPheLeuGluArgLeuLysThrIleMet                          
130135140                                                                 
ArgGluLysAspSerLysCysSerSerGlyThrGluProLysSerAla                          
145150155160                                                              
AspLysThrHisThrCysProProCysProAlaProGluLeuLeuGly                          
165170175                                                                 
GlyProSerValPheLeuPheProProLysProLysAspThrLeuMet                          
180185190                                                                 
IleSerArgThrProGluValThrCysValValValAspValSerHis                          
195200205                                                                 
GluAspProGluValLysPheAsnTrpTyrValAspGlyValGluVal                          
210215220                                                                 
HisAsnAlaLysThrLysProArgGluGluGlnTyrAsnSerThrTyr                          
225230235240                                                              
ArgValValSerValLeuThrValLeuHisGlnAspTrpLeuAsnGly                          
245250255                                                                 
LysGluTyrLysCysLysValSerAsnLysAlaLeuProAlaProIle                          
260265270                                                                 
GluLysThrIleSerLysAlaLysGlyGlnProArgGluProGlnVal                          
275280285                                                                 
TyrThrLeuProProSerArgAspGluLeuThrLysAsnGlnValSer                          
290295300                                                                 
LeuThrCysLeuValLysGlyPheTyrProSerAspIleAlaValGlu                          
305310315320                                                              
TrpGluSerAsnGlyGlnProGluAsnAsnTyrLysThrThrProPro                          
325330335                                                                 
ValLeuAspSerAspGlySerPhePheLeuTyrSerLysLeuThrVal                          
340345350                                                                 
AspLysSerArgTrpGlnGlnGlyAsnValPheSerCysSerValMet                          
355360365                                                                 
HisGluAlaLeuHisAsnHisTyrThrGlnLysSerLeuSerLeuSer                          
370375380                                                                 
ProGlyLys                                                                 
385                                                                       
(2) INFORMATION FOR SEQ ID NO: 5:                                         
(i) SEQUENCE CHARACTERISTICS:                                             
(A) LENGTH: 1006 base pairs                                               
(B) TYPE: nucleic acid                                                    
(C) STRANDEDNESS: double                                                  
(D) TOPOLOGY: linear                                                      
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:                                  
GCTTCCACCAAGGGCCCATCCGTCTTCCCCCTGGCGCCCTGCTCCAGGAGCACCTCCGAG60            
AGCACAGCCGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCG120           
TGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCA180           
GGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACGAAGACC240           
TACACCTGCAACGTAGATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTTGAGTCC300           
AAATATGGTCCCCCATGCCCATCATGCCCAGCACCTGAATTTCTGGGGGGACCATCAGTC360           
TTCCTGTTCCCCCCAAAACCCAAGGACACTCTCATGATCTCCCGGACCCCTGAGGTCACG420           
TGCGTGGTGGTGGACGTGAGCCAGGAAGACCCCGAGGTCCAGTTCAACTGGTACGTGGAT480           
GGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTTCAACAGCACGTAC540           
CGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAACGGCAAGGAGTACAAG600           
TGCAAGGTCTCCAACAAAGGCCTCCCGTCATCGATCGAGAAAACCATCTCCAAAGCCAAA660           
GGGCAGCCCCGAGAGCCACAGGTGTACACCCTGCCCCCATCCCAGGAGGAGATGACCAAG720           
AACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTACCCCAGCGACATCGCCGTGGAG780           
TGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCC840           
GACGGATCCTTCTTCCTCTACAGCAGGCTAACCGTGGACAAGAGCAGGTGGCAGGAGGGG900           
AATGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACACAGAAGAGC960           
CTCTCCCTGTCTCTGGGTAAATGAGTGTAGTCTAGATCTACGTATG1006                        
(2) INFORMATION FOR SEQ ID NO: 6:                                         
(i) SEQUENCE CHARACTERISTICS:                                             
(A) LENGTH: 1149 base pairs                                               
(B) TYPE: nucleic acid                                                    
(C) STRANDEDNESS: double                                                  
(D) TOPOLOGY: linear                                                      
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:                                  
ATGGGTCTCACCTCCCAACTGCTTCCCCCTCTGTTCTTCCTGCTAGCATGTGCCGGCAAC60            
TTTGTCCACGGACACAAGTGCGATATCACCTTACAGGAGATCATCAAAACTTTGAACAGC120           
CTCACAGAGCAGAAGACTCTGTGCACCGAGTTGACCGTAACAGACATCTTTGCTGCCTCC180           
AAGAACACAACTGAGAAGGAAACCTTCTGCAGGGCTGCGACTGTGCTCCGGCAGTTCTAC240           
AGCCACCATGAGAAGGACACTCGCTGCCTGGGTGCGACTGCACAGCAGTTCCACAGGCAC300           
AAGCAGCTGATCCGATTCCTGAAACGGCTCGACAGGAACCTCTGGGGCCTGGCGGGCTTG360           
AATTCCTGTCCTGTGAAGGAAGCCAACCAGAGTACGTTGGAAAACTTCTTGGAAAGGCTA420           
AAGACGATCATGAGAGAGAAAGACTCAAAGTGCTCGAGCGAGTCCAAATATGGTCCCCCA480           
TGCCCATCATGCCCAGCACCTGAATTTCTGGGGGGACCATCAGTCTTCCTGTTCCCCCCA540           
AAACCCAAGGACACTCTCATGATCTCCCGGACCCCTGAGGTCACGTGCGTGGTGGTGGAC600           
GTGAGCCAGGAAGACCCCGAGGTCCAGTTCAACTGGTACGTGGATGGCGTGGAGGTGCAT660           
AATGCCAAGACAAAGCCGCGGGAGGAGCAGTTCAACAGCACGTACCGTGTGGTCAGCGTC720           
CTCACCGTCCTGCACCAGGACTGGCTGAACGGCAAGGAGTACAAGTGCAAGGTCTCCAAC780           
AAAGGCCTCCCGTCATCGATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAG840           
CCACAGGTGTACACCCTGCCCCCATCCCAGGAGGAGATGACCAAGAACCAGGTCAGCCTG900           
ACCTGCCTGGTCAAAGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGG960           
CAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGATCCTTCTTC1020          
CTCTACAGCAGGCTAACCGTGGACAAGAGCAGGTGGCAGGAGGGGAATGTCTTCTCATGC1080          
TCCGTGATGCATGAGGCTCTGCACAACCACTACACACAGAAGAGCCTCTCCCTGTCTCTG1140          
GGTAAATGA1149                                                             
(2) INFORMATION FOR SEQ ID NO: 7:                                         
(i) SEQUENCE CHARACTERISTICS:                                             
(A) LENGTH: 382 amino acids                                               
(B) TYPE: amino acid                                                      
(C) STRANDEDNESS:                                                         
(D) TOPOLOGY: linear                                                      
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:                                  
MetGlyLeuThrSerGlnLeuLeuProProLeuPhePheLeuLeuAla                          
151015                                                                    
CysAlaGlyAsnPheValHisGlyHisLysCysAspIleThrLeuGln                          
202530                                                                    
GluIleIleLysThrLeuAsnSerLeuThrGluGlnLysThrLeuCys                          
354045                                                                    
ThrGluLeuThrValThrAspIlePheAlaAlaSerLysAsnThrThr                          
505560                                                                    
GluLysGluThrPheCysArgAlaAlaThrValLeuArgGlnPheTyr                          
65707580                                                                  
SerHisHisGluLysAspThrArgCysLeuGlyAlaThrAlaGlnGln                          
859095                                                                    
PheHisArgHisLysGlnLeuIleArgPheLeuLysArgLeuAspArg                          
100105110                                                                 
AsnLeuTrpGlyLeuAlaGlyLeuAsnSerCysProValLysGluAla                          
115120125                                                                 
AsnGlnSerThrLeuGluAsnPheLeuGluArgLeuLysThrIleMet                          
130135140                                                                 
ArgGluLysAspSerLysCysSerSerGluSerLysTyrGlyProPro                          
145150155160                                                              
CysProSerCysProAlaProGluPheLeuGlyGlyProSerValPhe                          
165170175                                                                 
LeuPheProProLysProLysAspThrLeuMetIleSerArgThrPro                          
180185190                                                                 
GluValThrCysValValValAspValSerGlnGluAspProGluVal                          
195200205                                                                 
GlnPheAsnTrpTyrValAspGlyValGluValHisAsnAlaLysThr                          
210215220                                                                 
LysProArgGluGluGlnPheAsnSerThrTyrArgValValSerVal                          
225230235240                                                              
LeuThrValLeuHisGlnAspTrpLeuAsnGlyLysGluTyrLysCys                          
245250255                                                                 
LysValSerAsnLysGlyLeuProSerSerIleGluLysThrIleSer                          
260265270                                                                 
LysAlaLysGlyGlnProArgGluProGlnValTyrThrLeuProPro                          
275280285                                                                 
SerGlnGluGluMetThrLysAsnGlnValSerLeuThrCysLeuVal                          
290295300                                                                 
LysGlyPheTyrProSerAspIleAlaValGluTrpGluSerAsnGly                          
305310315320                                                              
GlnProGluAsnAsnTyrLysThrThrProProValLeuAspSerAsp                          
325330335                                                                 
GlySerPhePheLeuTyrSerArgLeuThrValAspLysSerArgTrp                          
340345350                                                                 
GlnGluGlyAsnValPheSerCysSerValMetHisGluAlaLeuHis                          
355360365                                                                 
AsnHisTyrThrGlnLysSerLeuSerLeuSerLeuGlyLys                                
370375380                                                                 
(2) INFORMATION FOR SEQ ID NO: 8:                                         
(i) SEQUENCE CHARACTERISTICS:                                             
(A) LENGTH: 984 base pairs                                                
(B) TYPE: nucleic acid                                                    
(C) STRANDEDNESS: double                                                  
(D) TOPOLOGY: linear                                                      
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:                                  
GCTAGTACCAAGGGCCCATCCGTCTTCCCCCTGGCGCCCTGCTCCAGGAGCACCTCCGAG60            
AGCACGGCCGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCG120           
TGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCA180           
GGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACGAAGACC240           
TACACCTGCAACGTAGATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTTGAGTCC300           
AAATATGGTCCCCCATGCCCACCATGCCCAGCGCCTGAATTTGAGGGGGGACCATCAGTC360           
TTCCTGTTCCCCCCAAAACCCAAGGACACTCTCATGATCTCCCGGACCCCTGAGGTCACG420           
TGCGTGGTGGTGGACGTGAGCCAGGAAGACCCCGAGGTCCAGTTCAACTGGTACGTGGAT480           
GGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTTCAACAGCACGTAC540           
CGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAACGGCAAGGAGTACAAG600           
TGCAAGGTCTCCAACAAAGGCCTCCCGTCATCGATCGAGAAAACCATCTCCAAAGCCAAA660           
GGGCAGCCCCGAGAGCCACAGGTGTACACCCTGCCCCCATCCCAGGAGGAGATGACCAAG720           
AACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTACCCCAGCGACATCGCCGTGGAG780           
TGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCC840           
GACGGATCCTTCTTCCTCTACAGCAGGCTAACCGTGGACAAGAGCAGGTGGCAGGAGGGG900           
AATGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACACAGAAGAGC960           
CTCTCCCTGTCTCTGGGTAAATGA984                                               
(2) INFORMATION FOR SEQ ID NO: 9:                                         
(i) SEQUENCE CHARACTERISTICS:                                             
(A) LENGTH: 1149 base pairs                                               
(B) TYPE: nucleic acid                                                    
(C) STRANDEDNESS: double                                                  
(D) TOPOLOGY: linear                                                      
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9:                                  
ATGGGTCTCACCTCCCAACTGCTTCCCCCTCTGTTCTTCCTGCTAGCATGTGCCGGCAAC60            
TTTGTCCACGGACACAAGTGCGATATCACCTTACAGGAGATCATCAAAACTTTGAACAGC120           
CTCACAGAGCAGAAGACTCTGTGCACCGAGTTGACCGTAACAGACATCTTTGCTGCCTCC180           
AAGAACACAACTGAGAAGGAAACCTTCTGCAGGGCTGCGACTGTGCTCCGGCAGTTCTAC240           
AGCCACCATGAGAAGGACACTCGCTGCCTGGGTGCGACTGCACAGCAGTTCCACAGGCAC300           
AAGCAGCTGATCCGATTCCTGAAACGGCTCGACAGGAACCTCTGGGGCCTGGCGGGCTTG360           
AATTCCTGTCCTGTGAAGGAAGCCAACCAGAGTACGTTGGAAAACTTCTTGGAAAGGCTA420           
AAGACGATCATGAGAGAGAAAGACTCAAAGTGCTCGAGCGAGTCCAAATATGGTCCCCCA480           
TGCCCACCATGCCCAGCGCCTGAATTTGAGGGGGGACCATCAGTCTTCCTGTTCCCCCCA540           
AAACCCAAGGACACTCTCATGATCTCCCGGACCCCTGAGGTCACGTGCGTGGTGGTGGAC600           
GTGAGCCAGGAAGACCCCGAGGTCCAGTTCAACTGGTACGTGGATGGCGTGGAGGTGCAT660           
AATGCCAAGACAAAGCCGCGGGAGGAGCAGTTCAACAGCACGTACCGTGTGGTCAGCGTC720           
CTCACCGTCCTGCACCAGGACTGGCTGAACGGCAAGGAGTACAAGTGCAAGGTCTCCAAC780           
AAAGGCCTCCCGTCATCGATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAG840           
CCACAGGTGTACACCCTGCCCCCATCCCAGGAGGAGATGACCAAGAACCAGGTCAGCCTG900           
ACCTGCCTGGTCAAAGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGG960           
CAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGATCCTTCTTC1020          
CTCTACAGCAGGCTAACCGTGGACAAGAGCAGGTGGCAGGAGGGGAATGTCTTCTCATGC1080          
TCCGTGATGCATGAGGCTCTGCACAACCACTACACACAGAAGAGCCTCTCCCTGTCTCTG1140          
GGTAAATGA1149                                                             
(2) INFORMATION FOR SEQ ID NO: 10:                                        
(i) SEQUENCE CHARACTERISTICS:                                             
(A) LENGTH: 382 amino acids                                               
(B) TYPE: amino acid                                                      
(C) STRANDEDNESS:                                                         
(D) TOPOLOGY: linear                                                      
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10:                                 
MetGlyLeuThrSerGlnLeuLeuProProLeuPhePheLeuLeuAla                          
151015                                                                    
CysAlaGlyAsnPheValHisGlyHisLysCysAspIleThrLeuGln                          
202530                                                                    
GluIleIleLysThrLeuAsnSerLeuThrGluGlnLysThrLeuCys                          
354045                                                                    
ThrGluLeuThrValThrAspIlePheAlaAlaSerLysAsnThrThr                          
505560                                                                    
GluLysGluThrPheCysArgAlaAlaThrValLeuArgGlnPheTyr                          
65707580                                                                  
SerHisHisGluLysAspThrArgCysLeuGlyAlaThrAlaGlnGln                          
859095                                                                    
PheHisArgHisLysGlnLeuIleArgPheLeuLysArgLeuAspArg                          
100105110                                                                 
AsnLeuTrpGlyLeuAlaGlyLeuAsnSerCysProValLysGluAla                          
115120125                                                                 
AsnGlnSerThrLeuGluAsnPheLeuGluArgLeuLysThrIleMet                          
130135140                                                                 
ArgGluLysAspSerLysCysSerSerGluSerLysTyrGlyProPro                          
145150155160                                                              
CysProProCysProAlaProGluPheGluGlyGlyProSerValPhe                          
165170175                                                                 
LeuPheProProLysProLysAspThrLeuMetIleSerArgThrPro                          
180185190                                                                 
GluValThrCysValValValAspValSerGlnGluAspProGluVal                          
195200205                                                                 
GlnPheAsnTrpTyrValAspGlyValGluValHisAsnAlaLysThr                          
210215220                                                                 
LysProArgGluGluGlnPheAsnSerThrTyrArgValValSerVal                          
225230235240                                                              
LeuThrValLeuHisGlnAspTrpLeuAsnGlyLysGluTyrLysCys                          
245250255                                                                 
LysValSerAsnLysGlyLeuProSerSerIleGluLysThrIleSer                          
260265270                                                                 
LysAlaLysGlyGlnProArgGluProGlnValTyrThrLeuProPro                          
275280285                                                                 
SerGlnGluGluMetThrLysAsnGlnValSerLeuThrCysLeuVal                          
290295300                                                                 
LysGlyPheTyrProSerAspIleAlaValGluTrpGluSerAsnGly                          
305310315320                                                              
GlnProGluAsnAsnTyrLysThrThrProProValLeuAspSerAsp                          
325330335                                                                 
GlySerPhePheLeuTyrSerArgLeuThrValAspLysSerArgTrp                          
340345350                                                                 
GlnGluGlyAsnValPheSerCysSerValMetHisGluAlaLeuHis                          
355360365                                                                 
AsnHisTyrThrGlnLysSerLeuSerLeuSerLeuGlyLys                                
370375380                                                                 
(2) INFORMATION FOR SEQ ID NO: 11:                                        
(i) SEQUENCE CHARACTERISTICS:                                             
(A) LENGTH: 30 base pairs                                                 
(B) TYPE: nucleic acid                                                    
(C) STRANDEDNESS: single                                                  
(D) TOPOLOGY: linear                                                      
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11:                                 
CGAACCACTGAATTCCGCATTGCAGAGATA30                                          
(2) INFORMATION FOR SEQ ID NO: 12:                                        
(i) SEQUENCE CHARACTERISTICS:                                             
(A) LENGTH: 35 base pairs                                                 
(B) TYPE: nucleic acid                                                    
(C) STRANDEDNESS: single                                                  
(D) TOPOLOGY: linear                                                      
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12:                                 
CACAAAGATCCTTAGGTACCGCTCGAACACTTTGA35                                     
(2) INFORMATION FOR SEQ ID NO: 13:                                        
(i) SEQUENCE CHARACTERISTICS:                                             
(A) LENGTH: 43 base pairs                                                 
(B) TYPE: nucleic acid                                                    
(C) STRANDEDNESS: single                                                  
(D) TOPOLOGY: linear                                                      
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13:                                 
TCGAGCTCGGTACCGAGCCCAAATCGGCCGACAAAACTCACAC43                             
(2) INFORMATION FOR SEQ ID NO: 14:                                        
(i) SEQUENCE CHARACTERISTICS:                                             
(A) LENGTH: 28 base pairs                                                 
(B) TYPE: nucleic acid                                                    
(C) STRANDEDNESS: single                                                  
(D) TOPOLOGY: linear                                                      
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14:                                 
GTACTGCTCCTCCCGCGGCTTTGTCTTG28                                            
(2) INFORMATION FOR SEQ ID NO: 15:                                        
(i) SEQUENCE CHARACTERISTICS:                                             
(A) LENGTH: 27 base pairs                                                 
(B) TYPE: nucleic acid                                                    
(C) STRANDEDNESS: single                                                  
(D) TOPOLOGY: linear                                                      
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 15:                                 
AATTCGGTTACCTGCAGATATCAAGCT27                                             
(2) INFORMATION FOR SEQ ID NO: 16:                                        
(i) SEQUENCE CHARACTERISTICS:                                             
(A) LENGTH: 27 base pairs                                                 
(B) TYPE: nucleic acid                                                    
(C) STRANDEDNESS: single                                                  
(D) TOPOLOGY: linear                                                      
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 16:                                 
AATTAGCTTGATATCTGCAGGTAACCG27                                             
(2) INFORMATION FOR SEQ ID NO: 17:                                        
(i) SEQUENCE CHARACTERISTICS:                                             
(A) LENGTH: 30 base pairs                                                 
(B) TYPE: nucleic acid                                                    
(C) STRANDEDNESS: single                                                  
(D) TOPOLOGY: linear                                                      
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 17:                                 
CACAAGTGCGATATCACCTTACAGGAGATC30                                          
(2) INFORMATION FOR SEQ ID NO: 18:                                        
(i) SEQUENCE CHARACTERISTICS:                                             
(A) LENGTH: 30 base pairs                                                 
(B) TYPE: nucleic acid                                                    
(C) STRANDEDNESS: single                                                  
(D) TOPOLOGY: linear                                                      
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 18:                                 
CTCGGTACCGCTCGAGCACTTTGAGTCTTT30                                          
(2) INFORMATION FOR SEQ ID NO: 19:                                        
(i) SEQUENCE CHARACTERISTICS:                                             
(A) LENGTH: 30 base pairs                                                 
(B) TYPE: nucleic acid                                                    
(C) STRANDEDNESS: single                                                  
(D) TOPOLOGY: linear                                                      
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 19:                                 
GGTGGACAACTCGAGCGAGTCCAAATATGG30                                          
(2) INFORMATION FOR SEQ ID NO: 20:                                        
(i) SEQUENCE CHARACTERISTICS:                                             
(A) LENGTH: 30 base pairs                                                 
(B) TYPE: nucleic acid                                                    
(C) STRANDEDNESS: single                                                  
(D) TOPOLOGY: linear                                                      
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 20:                                 
TTACGTAGATCTAGACTACACTCATTTACC30                                          
(2) INFORMATION FOR SEQ ID NO: 21:                                        
(i) SEQUENCE CHARACTERISTICS:                                             
(A) LENGTH: 129 amino acids                                               
(B) TYPE: amino acid                                                      
(C) STRANDEDNESS: Not Relevant                                            
(D) TOPOLOGY: linear                                                      
(ii) MOLECULE TYPE: peptide                                               
(iii) HYPOTHETICAL: NO                                                    
(iv) ANTI-SENSE: NO                                                       
(v) FRAGMENT TYPE: N-terminal                                             
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:                                  
HisLysCysAspIleThrLeuGlnGluIleIleLysThrLeuAsnSer                          
151015                                                                    
LeuThrGluGlnLysThrLeuCysThrGluLeuThrValThrAspIle                          
202530                                                                    
PheAlaAlaSerLysAsnThrThrGluLysGluThrPheCysArgAla                          
354045                                                                    
AlaThrValLeuArgGlnPheTyrSerHisHisGluLysAspThrArg                          
505560                                                                    
CysLeuGlyAlaThrAlaGlnGlnPheHisArgHisLysGlnLeuIle                          
65707580                                                                  
ArgPheLeuLysArgLeuAspArgAsnLeuTrpGlyLeuAlaGlyLeu                          
859095                                                                    
AsnSerCysProValLysGluAlaAsnGlnSerThrLeuGluAsnPhe                          
100105110                                                                 
LeuGluArgLeuLysThrIleMetArgGluLysTyrSerLysCysSer                          
115120125                                                                 
Ser                                                                       
__________________________________________________________________________

Claims (9)

We claim:
1. A method of treating a patient suffering from a disease selected from the group consisting of an allergic disease, a T-cell mediated disease and a disease associated with an undesired immune response to an infectious agent, said method comprising the step of:
administering to said patient a therapeutically effective amount of a compound comprising an IL4 mutant or variant in which at least one amino acid at positions 120 to 128 inclusive is different from the amino acid naturally occurring in wild type IL4 fused to at least one human immunoglobulin constant domain.
2. The method according to claim 1 wherein tyrosine naturally occurring at position 124 is replaced with a different amino acid.
3. The method according to claim 1 wherein tyrosine naturally occurring at position 124 is replaced with aspartic acid.
4. The method according to claim 1 wherein said immunoglobulin is of the IgG subclass.
5. The method according to claim 1 wherein said constant domain is the whole or a substantial part of the constant region of the heavy chain of human IgG.
6. The method according to claim 1 wherein said constant domain is the whole or a substantial part of the constant region of the heavy chain of human IgG4.
7. The method according to claim 6 wherein said disease is selected from the group consisting of asthma, rhinitis, conjunctivitis, atopic dermatitis and anaphylaxis.
8. A method of treating a patient suffering from a disease selected from the group consisting of an allergic disease, a T-cell mediated disease and a disease associated with an undesired immune response to an infectious agent, wherein said method comprises the step of:
administering to said patient a therapeutically effective amount of a compound comprising a protein comprising an amino acid sequence selected from the group consisting of SEQ ID NO. 4, SEQ ID NO. 7 and SEQ ID NO. 10.
9. The method according to claim 8 wherein said disease is selected from the group consisting of asthma, rhinitis, conjunctivitis, atopic dermatitis and anaphylaxis.
US08/470,299 1994-07-29 1995-06-06 Therapeutic uses of fusion proteins between mutant IL 4/IL13 antagonists and immunoglobulins Expired - Fee Related US5783181A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9415379 1994-07-29
GB9415379A GB9415379D0 (en) 1994-07-29 1994-07-29 Novel compounds

Publications (1)

Publication Number Publication Date
US5783181A true US5783181A (en) 1998-07-21

Family

ID=10759122

Family Applications (2)

Application Number Title Priority Date Filing Date
US08/470,299 Expired - Fee Related US5783181A (en) 1994-07-29 1995-06-06 Therapeutic uses of fusion proteins between mutant IL 4/IL13 antagonists and immunoglobulins
US10/050,227 Abandoned US20030064481A1 (en) 1994-07-29 2002-01-16 Novel compounds

Family Applications After (1)

Application Number Title Priority Date Filing Date
US10/050,227 Abandoned US20030064481A1 (en) 1994-07-29 2002-01-16 Novel compounds

Country Status (3)

Country Link
US (2) US5783181A (en)
GB (1) GB9415379D0 (en)
ZA (1) ZA956253B (en)

Cited By (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000023472A2 (en) * 1998-10-16 2000-04-27 Biogen, Inc. Interferon-beta fusion proteins and uses
US20030064069A1 (en) * 1999-04-30 2003-04-03 Thompson Julia Elizabeth Specific binding members for TGFbeta1
US20030068320A1 (en) * 2001-03-02 2003-04-10 Christine Dingivan Methods of administering/dosing CD2 antagonists for the prevention and treatment of autoimmune disorders or inflammatory disorders
US20030215421A1 (en) * 1999-07-21 2003-11-20 Mcdonald John R. Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
US6703360B2 (en) 2000-04-07 2004-03-09 Heska Corporation Compositions and methods related to canine IgG and canine IL-13 receptors
US20040265315A1 (en) * 2002-09-05 2004-12-30 Christine Dingivan Methods of preventing or treating T cell malignancies by administering CD2 antagonists
US20050277126A1 (en) * 1998-12-14 2005-12-15 Mary Collins Cytokine receptor chain
US20060063228A1 (en) * 2004-06-09 2006-03-23 Kasaian Marion T Antibodies against human interleukin-13 and uses therefor
US20060073148A1 (en) * 2004-06-17 2006-04-06 Wyeth IL-13 binding agents
US20060140948A1 (en) * 2004-11-17 2006-06-29 Ian Foltz Fully human monoclonal antibodies to IL-13
US7157418B1 (en) 1998-07-22 2007-01-02 Osprey Pharmaceuticals, Ltd. Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
US20070098688A1 (en) * 1998-10-16 2007-05-03 Blake Pepinsky Polymer conjugates of interferon beta-1a and uses
US20070212308A1 (en) * 2006-01-11 2007-09-13 Aerovance, Inc. Methods and compositions for treating asthma in human and non human primates
US20080008648A1 (en) * 2003-12-23 2008-01-10 Tanox, Inc. Treatment of Cancer With a Novel Anti-Il13 Monoclonal Antibody
US20090010874A1 (en) * 2003-08-29 2009-01-08 Aerovance, Inc. Modified il-4 mutein receptor antagonists
US20090068195A1 (en) * 2007-04-23 2009-03-12 Wyeth Methods and compositions for treating and monitoring treatment of il-13-associated disorders
ES2315146A1 (en) * 2003-08-29 2009-03-16 Bayer Pharmaceuticals Corporation Modified il-4 mutein receptor antagonists
US7507706B1 (en) 1998-12-14 2009-03-24 Genetics Institute, Llc Cytokine receptor chain
US20090098142A1 (en) * 2004-06-09 2009-04-16 Kasaian Marion T Methods and compositions for treating and monitoring treatment of IL-13-associated disorders
WO2009052439A2 (en) 2007-10-17 2009-04-23 Elan Pharma International Limited Immunotherapy regimes dependent on apoe status
WO2010141329A1 (en) 2009-06-01 2010-12-09 Medimmune, Llc Molecules with extended half-lives and uses thereof
WO2011020079A1 (en) 2009-08-13 2011-02-17 Calmune Corporation Antibodies against human respiratory syncytial virus (rsv) and methods of use
WO2011020024A2 (en) 2009-08-13 2011-02-17 The Johns Hopkins University Methods of modulating immune function
EP2292663A2 (en) 2006-08-28 2011-03-09 Kyowa Hakko Kirin Co., Ltd. Antagonistic human light-specific human monoclonal antibodies
EP2298806A1 (en) 2002-10-16 2011-03-23 Purdue Pharma L.P. Antibodies that bind cell-associated CA 125/0722P and methods of use thereof
WO2011035205A2 (en) 2009-09-18 2011-03-24 Calmune Corporation Antibodies against candida, collections thereof and methods of use
EP2341060A1 (en) 2000-12-12 2011-07-06 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
WO2012006596A2 (en) 2010-07-09 2012-01-12 Calmune Corporation Anti-human respiratory syncytial virus (rsv) antibodies and methods of use
EP2407548A1 (en) 2006-10-16 2012-01-18 MedImmune, LLC Molecules with reduced half-lives, compositions and uses thereof
WO2013067355A1 (en) 2011-11-04 2013-05-10 Novartis Ag Low density lipoprotein-related protein 6 (lrp6) - half life extender constructs
WO2014018625A1 (en) 2012-07-25 2014-01-30 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies and uses thereof
EP2703007A1 (en) 2007-03-30 2014-03-05 MedImmune, LLC Antibodies with decreased deamidation profiles
WO2014059028A1 (en) 2012-10-09 2014-04-17 Igenica, Inc. Anti-c16orf54 antibodies and methods of use thereof
WO2014197849A2 (en) 2013-06-06 2014-12-11 Igenica Biotherapeutics, Inc. Anti-c10orf54 antibodies and uses thereof
WO2015053871A2 (en) 2013-08-26 2015-04-16 MabVax Therapeutics, Inc. NUCLEIC ACIDS ENCODING HUMAN ANTIBODIES TO SIALYL-LEWISa
WO2015175375A1 (en) 2014-05-13 2015-11-19 Short Jay M Conditionally active biological proteins
WO2015187811A2 (en) 2014-06-04 2015-12-10 MabVax Therapeutics, Inc. Human monoclonal antibodies to ganglioside gd2
EP3026123A1 (en) 2006-04-27 2016-06-01 Klaritos, Inc. Method and kit for predicting antibody therapy
WO2016139482A1 (en) 2015-03-03 2016-09-09 Kymab Limited Antibodies, uses & methods
US9738702B2 (en) 2014-03-14 2017-08-22 Janssen Biotech, Inc. Antibodies with improved half-life in ferrets
US9920120B2 (en) 2013-09-13 2018-03-20 Genentech, Inc. Methods and compositions comprising purified recombinant polypeptides
US9945858B2 (en) 2013-09-13 2018-04-17 Genentech, Inc. Compositions and methods for detecting and quantifying host cells protein in cell lines and recombinant polypeptide products
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
WO2019073069A1 (en) 2017-10-13 2019-04-18 Boehringer Ingelheim International Gmbh Human antibodies to thomsen-nouvelle (tn) antigen
US10428145B2 (en) 2015-09-29 2019-10-01 Celgene Corporation PD-1 binding proteins and methods of use thereof
US10513699B2 (en) 2014-09-03 2019-12-24 Bioatla, Llc Discovering and producing conditionally active biologic proteins in the same eukaryotic cell production hosts
EP3590539A1 (en) 2014-03-04 2020-01-08 Kymab Limited Antibodies, uses & methods
WO2020016459A1 (en) 2018-07-20 2020-01-23 Pierre Fabre Medicament Receptor for vista
US10548954B2 (en) 2010-07-09 2020-02-04 Bioverativ Therapeutics Inc. Factor IX polypeptides and methods of use thereof
US10751414B2 (en) 2016-09-19 2020-08-25 Celgene Corporation Methods of treating psoriasis using PD-1 binding antibodies
US10766959B2 (en) 2014-12-11 2020-09-08 Pierre Fabre Medicament Anti-C10ORF54 antibodies and uses thereof
US10766958B2 (en) 2016-09-19 2020-09-08 Celgene Corporation Methods of treating vitiligo using PD-1 binding antibodies
EP3738981A1 (en) 2014-01-24 2020-11-18 NGM Biopharmaceuticals, Inc. Antibodies binding beta klotho domain 2 and methods of use thereof
US10844122B2 (en) 2015-05-06 2020-11-24 Janssen Biotech, Inc. Prostate specific membrane antigen (PSMA) bispecific binding agents and uses thereof
EP3763740A1 (en) 2011-01-26 2021-01-13 Celldex Therapeutics, Inc. Anti-kit antibodies and uses thereof
EP3888690A2 (en) 2014-05-16 2021-10-06 MedImmune, LLC Molecules with altered neonate fc receptor binding having enhanced therapeutic and diagnostic properties
WO2022147463A2 (en) 2020-12-31 2022-07-07 Alamar Biosciences, Inc. Binder molecules with high affinity and/ or specificity and methods of making and use thereof
US11472876B2 (en) 2015-11-02 2022-10-18 Bioatla, Inc. Conditionally active polypeptides
US11642398B2 (en) 2013-03-15 2023-05-09 Bioverativ Therapeutics Inc. Factor IX polypeptide formulations
WO2023131901A1 (en) 2022-01-07 2023-07-13 Johnson & Johnson Enterprise Innovation Inc. Materials and methods of il-1beta binding proteins
WO2024013727A1 (en) 2022-07-15 2024-01-18 Janssen Biotech, Inc. Material and methods for improved bioengineered pairing of antigen-binding variable regions

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0396387A2 (en) * 1989-05-05 1990-11-07 Research Development Foundation A novel antibody delivery system for biological response modifiers
WO1991001004A1 (en) * 1989-07-06 1991-01-24 Seragen, Inc. Hybrid molecules
US5349053A (en) * 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4137333A1 (en) * 1991-11-13 1993-05-19 W Prof Dr Sebald THERAPEUTIC AGENTS THAT ARE ANTAGONISTS OR PARTIAL AGONISTS OF THE HUMAN INTERLEUKIN 4 OR CONTAIN THEM, HIL-4-MUTANT PROTEINS AND METHOD FOR THE PRODUCTION THEREOF
DE4423131A1 (en) * 1994-07-01 1996-01-04 Bayer Ag New hIL-4 mutant proteins as antagonists or partial agonists of human interleukin 4

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0396387A2 (en) * 1989-05-05 1990-11-07 Research Development Foundation A novel antibody delivery system for biological response modifiers
WO1991001004A1 (en) * 1989-07-06 1991-01-24 Seragen, Inc. Hybrid molecules
US5349053A (en) * 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Krese et al. EMBO 11(9) 1992, pp.3237 3244. *
Krese et al. EMBO11(9) 1992, pp.3237-3244.

Cited By (144)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7157418B1 (en) 1998-07-22 2007-01-02 Osprey Pharmaceuticals, Ltd. Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
US7166702B1 (en) 1998-07-22 2007-01-23 Osprey Pharmaceuticals, Ltd. Cytotoxic conjugates comprising a chemokine receptor targeting agent
US7192736B2 (en) 1998-07-22 2007-03-20 Osprey Pharmaceuticals, Ltd. Nucleic acid molecules encoding cytotoxic conjugates that contain a chemokine receptor targeting agent
US20110160126A1 (en) * 1998-07-22 2011-06-30 Mcdonald John R Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
WO2000023472A2 (en) * 1998-10-16 2000-04-27 Biogen, Inc. Interferon-beta fusion proteins and uses
US7446173B2 (en) 1998-10-16 2008-11-04 Biogen Idec Ma Inc. Polymer conjugates of interferon beta-1A and uses
US7527946B2 (en) 1998-10-16 2009-05-05 Biogen Idec Ma Inc., Interferon-beta-1a-immunoglobulin fusion proteins and uses
US20070098688A1 (en) * 1998-10-16 2007-05-03 Blake Pepinsky Polymer conjugates of interferon beta-1a and uses
US6800735B2 (en) 1998-10-16 2004-10-05 Biogen, Inc. Interferon-beta fusion proteins and uses
US20090286958A1 (en) * 1998-10-16 2009-11-19 Biogen Idec Ma Inc. Interferon-beta fusion proteins and uses
US20050214253A1 (en) * 1998-10-16 2005-09-29 Adrian Whitty Interferon-beta fusion proteins and uses
US20090104150A1 (en) * 1998-10-16 2009-04-23 Blake Pepinsky Polymer conjugates of interferon Beta-1a and uses
WO2000023472A3 (en) * 1998-10-16 2000-08-31 Biogen Inc Interferon-beta fusion proteins and uses
US9314534B2 (en) 1998-10-16 2016-04-19 Biogen Ma Inc. Polymer conjugates of interferon beta-1A and uses
US7553487B2 (en) 1998-12-14 2009-06-30 Genetics Institute, Llc Method and compositions for treating asthma
US20050277126A1 (en) * 1998-12-14 2005-12-15 Mary Collins Cytokine receptor chain
US7507706B1 (en) 1998-12-14 2009-03-24 Genetics Institute, Llc Cytokine receptor chain
US20030091566A1 (en) * 1999-04-30 2003-05-15 Thompson Julia Elizabeth Specific binding members for TGFbeta1
US20030064069A1 (en) * 1999-04-30 2003-04-03 Thompson Julia Elizabeth Specific binding members for TGFbeta1
US7151169B2 (en) 1999-04-30 2006-12-19 Cambridge Antibody Technology Limited Specific binding members for TGFβ1
US20030215421A1 (en) * 1999-07-21 2003-11-20 Mcdonald John R. Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
US6703360B2 (en) 2000-04-07 2004-03-09 Heska Corporation Compositions and methods related to canine IgG and canine IL-13 receptors
US7378275B2 (en) 2000-04-07 2008-05-27 Heska Corporation Canine IL-13 receptor alpha-1 subunit nucleic acid molecules
US20080287665A1 (en) * 2000-04-07 2008-11-20 Mccall Catherine A CANINE IgG NUCLEIC ACID MOLECULES
US20040142372A1 (en) * 2000-04-07 2004-07-22 Mccall Catherine A. Compositions and methods related to canine IgG and canine IL-13 receptors
EP2357187A1 (en) 2000-12-12 2011-08-17 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
EP2354149A1 (en) 2000-12-12 2011-08-10 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
EP2341060A1 (en) 2000-12-12 2011-07-06 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
EP3569610A2 (en) 2000-12-12 2019-11-20 Medlmmune, LLC Molecules with extended half lives, compositions and uses thereof
US20070025990A1 (en) * 2001-03-02 2007-02-01 Medimmune, Inc. Methods of administering/dosing CD2 antagonists for the prevention and treatment of autoimmune disorders or inflammatory disorders
US20030068320A1 (en) * 2001-03-02 2003-04-10 Christine Dingivan Methods of administering/dosing CD2 antagonists for the prevention and treatment of autoimmune disorders or inflammatory disorders
US20040265315A1 (en) * 2002-09-05 2004-12-30 Christine Dingivan Methods of preventing or treating T cell malignancies by administering CD2 antagonists
EP2298806A1 (en) 2002-10-16 2011-03-23 Purdue Pharma L.P. Antibodies that bind cell-associated CA 125/0722P and methods of use thereof
EP3301114A1 (en) 2002-10-16 2018-04-04 Purdue Pharma LP Fusion polypeptides of antibodies that bind cell-associated ca 125/o722p
EP2891666A1 (en) 2002-10-16 2015-07-08 Purdue Pharma L.P. Antibodies that bind cell-associated CA 125/O722P and methods of use thereof
ES2315146A1 (en) * 2003-08-29 2009-03-16 Bayer Pharmaceuticals Corporation Modified il-4 mutein receptor antagonists
US20090010874A1 (en) * 2003-08-29 2009-01-08 Aerovance, Inc. Modified il-4 mutein receptor antagonists
US7785580B2 (en) 2003-08-29 2010-08-31 Aerovance, Inc. Modified IL-4 mutein receptor antagonists
US20110014199A1 (en) * 2003-12-23 2011-01-20 Sek Chung Fung Novel anti-il 13 antibodies and uses thereof
US20080008648A1 (en) * 2003-12-23 2008-01-10 Tanox, Inc. Treatment of Cancer With a Novel Anti-Il13 Monoclonal Antibody
US8734801B2 (en) 2003-12-23 2014-05-27 Genentech, Inc. Anti-IL13 antibodies and uses thereof
US8734797B2 (en) 2003-12-23 2014-05-27 Genentech, Inc. Anti-IL13 antibodies and uses thereof
US7674459B2 (en) 2003-12-23 2010-03-09 Genentech, Inc. Treatment of cancer with a novel anti-IL13 monoclonal antibody
US11434287B2 (en) 2003-12-23 2022-09-06 Genentech, Inc. Anti-IL13 antibodies and uses thereof
US20090214523A1 (en) * 2003-12-23 2009-08-27 Genentech, Inc. Novel anti-IL13 antibodies and uses thereof
US20100266494A1 (en) * 2003-12-23 2010-10-21 Genentech, Inc. Treatment of cancer with novel anti-il13 monoclonal antibodies
US8318160B2 (en) 2003-12-23 2012-11-27 Genentech, Inc. Treatment of cancer with novel anti-IL13 monoclonal antibodies
US9067994B2 (en) 2003-12-23 2015-06-30 Genentech, Inc. Anti-IL13 antibodies and uses thereof
US9605065B2 (en) 2003-12-23 2017-03-28 Genentech, Inc. Anti-IL13 antibodies and uses thereof
US8088618B2 (en) 2003-12-23 2012-01-03 Genentech, Inc. Anti-IL 13 antibodies and uses thereof
US8067199B2 (en) 2003-12-23 2011-11-29 Genentech, Inc. Anti-IL13 antibodies and uses thereof
US8221752B2 (en) 2004-06-09 2012-07-17 Wyeth Llc Antibodies against human interleukin-13 and uses therefor
US20090098142A1 (en) * 2004-06-09 2009-04-16 Kasaian Marion T Methods and compositions for treating and monitoring treatment of IL-13-associated disorders
US7615213B2 (en) 2004-06-09 2009-11-10 Wyeth Antibodies against human interleukin-13 and pharmaceutical compositions thereof
US20100129360A1 (en) * 2004-06-09 2010-05-27 Wyeth Llc Antibodies against human interleukin-13 and uses therefor
US20060063228A1 (en) * 2004-06-09 2006-03-23 Kasaian Marion T Antibodies against human interleukin-13 and uses therefor
US20060073148A1 (en) * 2004-06-17 2006-04-06 Wyeth IL-13 binding agents
US20090274705A1 (en) * 2004-06-17 2009-11-05 Wyeth Il-13 binding agents
US7501121B2 (en) 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
US7943342B2 (en) 2004-06-17 2011-05-17 Wyeth Llc Nucleic acids encoding IL-13 binding agents
US7994302B2 (en) 2004-11-17 2011-08-09 Amgen Inc. Fully human monoclonal antibodies to IL-13
US20060140948A1 (en) * 2004-11-17 2006-06-29 Ian Foltz Fully human monoclonal antibodies to IL-13
US7585500B2 (en) 2004-11-17 2009-09-08 Amgen Inc. Fully human monoclonal antibodies to IL-13
WO2007082068A3 (en) * 2006-01-11 2008-07-31 Aerovance Inc Methods and compositions for treating asthma in human and non human primates
US7947648B2 (en) 2006-01-11 2011-05-24 Aerovance, Inc. Methods for treating asthma in human and non human primates using IL-4 mutant compositions
US20110158939A1 (en) * 2006-01-11 2011-06-30 Aerovance, Inc. Methods and Compositions for Treating Asthma in Human and Nonhuman Primates
US20070212308A1 (en) * 2006-01-11 2007-09-13 Aerovance, Inc. Methods and compositions for treating asthma in human and non human primates
EP3026123A1 (en) 2006-04-27 2016-06-01 Klaritos, Inc. Method and kit for predicting antibody therapy
EP2484696A1 (en) 2006-08-28 2012-08-08 Kyowa Hakko Kirin Co., Ltd. Antagonistic human light-specific human monoclonal antibodies
EP2292663A2 (en) 2006-08-28 2011-03-09 Kyowa Hakko Kirin Co., Ltd. Antagonistic human light-specific human monoclonal antibodies
EP2407548A1 (en) 2006-10-16 2012-01-18 MedImmune, LLC Molecules with reduced half-lives, compositions and uses thereof
EP2703007A1 (en) 2007-03-30 2014-03-05 MedImmune, LLC Antibodies with decreased deamidation profiles
US20090068195A1 (en) * 2007-04-23 2009-03-12 Wyeth Methods and compositions for treating and monitoring treatment of il-13-associated disorders
EP2952524A1 (en) 2007-10-17 2015-12-09 Janssen Sciences Ireland UC Immunotherapy regimes dependent on apoe status
WO2009052439A2 (en) 2007-10-17 2009-04-23 Elan Pharma International Limited Immunotherapy regimes dependent on apoe status
WO2010141329A1 (en) 2009-06-01 2010-12-09 Medimmune, Llc Molecules with extended half-lives and uses thereof
US20110076268A1 (en) * 2009-08-13 2011-03-31 Robert Anthony Williamson Antibodies against human respiratory syncytial virus (RSV) and methods of use
US9365638B2 (en) 2009-08-13 2016-06-14 Crucell Holland B. V. Antibodies against human respiratory syncytial virus (RSV) and methods of use
US9988437B2 (en) 2009-08-13 2018-06-05 Janssen Vaccines & Prevention B.V. Anti-human Respiratory Syncytial Virus (RSV) antibodies and methods of use
US8568719B2 (en) 2009-08-13 2013-10-29 Crucell Holland B.V. Antibodies against human respiratory syncytial virus (RSV) and methods of use
EP3381937A2 (en) 2009-08-13 2018-10-03 The Johns Hopkins University Methods of modulating immune function
WO2011020079A1 (en) 2009-08-13 2011-02-17 Calmune Corporation Antibodies against human respiratory syncytial virus (rsv) and methods of use
WO2011020024A2 (en) 2009-08-13 2011-02-17 The Johns Hopkins University Methods of modulating immune function
US9403900B2 (en) 2009-08-13 2016-08-02 Crucell Holland B.V. Anti-human respiratory syncytial virus (RSV) antibodies and methods of use
WO2011035205A2 (en) 2009-09-18 2011-03-24 Calmune Corporation Antibodies against candida, collections thereof and methods of use
WO2012006596A2 (en) 2010-07-09 2012-01-12 Calmune Corporation Anti-human respiratory syncytial virus (rsv) antibodies and methods of use
US10561714B2 (en) 2010-07-09 2020-02-18 Bioverativ Therapeutics Inc. Factor IX polypeptides and methods of use thereof
US10548954B2 (en) 2010-07-09 2020-02-04 Bioverativ Therapeutics Inc. Factor IX polypeptides and methods of use thereof
US10568943B2 (en) 2010-07-09 2020-02-25 Bioverativ Therapeutics Inc. Factor IX polypeptides and methods of use thereof
US9139642B2 (en) 2010-07-09 2015-09-22 Crucell Holland B.V. Anti-human respiratory syncytial virus (RSV) antibodies and methods of use
US10898554B1 (en) 2010-07-09 2021-01-26 Bioverativ Therapeutics Inc. Factor IX polypeptides and methods of use thereof
EP3763740A1 (en) 2011-01-26 2021-01-13 Celldex Therapeutics, Inc. Anti-kit antibodies and uses thereof
WO2013067355A1 (en) 2011-11-04 2013-05-10 Novartis Ag Low density lipoprotein-related protein 6 (lrp6) - half life extender constructs
EP3252075A1 (en) 2011-11-04 2017-12-06 Novartis AG Low density lipoprotein-related protein 6 (lrp6) - half life extender constructs
EP3290442A1 (en) 2011-11-04 2018-03-07 Novartis AG Low density lipoprotein-related protein 6 (lrp6) half-life extender constructs
WO2014018625A1 (en) 2012-07-25 2014-01-30 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies and uses thereof
EP3381943A1 (en) 2012-07-25 2018-10-03 Celldex Therapeutics, Inc. Anti-kit antibodies and uses thereof
EP4063391A1 (en) 2012-07-25 2022-09-28 Celldex Therapeutics, Inc. Anti-kit antibodies and uses thereof
WO2014059028A1 (en) 2012-10-09 2014-04-17 Igenica, Inc. Anti-c16orf54 antibodies and methods of use thereof
US11642398B2 (en) 2013-03-15 2023-05-09 Bioverativ Therapeutics Inc. Factor IX polypeptide formulations
WO2014197849A2 (en) 2013-06-06 2014-12-11 Igenica Biotherapeutics, Inc. Anti-c10orf54 antibodies and uses thereof
US10100123B2 (en) 2013-06-06 2018-10-16 Pierre Fabre Medicament Anti-C10orf54 antibodies and uses thereof
US10414823B2 (en) 2013-06-06 2019-09-17 Pierre Fabre Medicament Anti-C10orf54 antibodies and uses thereof
US10421818B2 (en) 2013-06-06 2019-09-24 Pierre Fabre Medicament Anti-C10orf54 antibodies and uses thereof
US9475874B2 (en) 2013-08-26 2016-10-25 MabVax Therapeutics, Inc. Nucleic acids encoding human antibodies to sialyl-lewisa
EP3906945A2 (en) 2013-08-26 2021-11-10 BioNTech Research and Development, Inc. Nucleic acids encoding human antibodies to sialyl-lewis a
WO2015053871A2 (en) 2013-08-26 2015-04-16 MabVax Therapeutics, Inc. NUCLEIC ACIDS ENCODING HUMAN ANTIBODIES TO SIALYL-LEWISa
US10494429B2 (en) 2013-09-13 2019-12-03 Genentech, Inc. Compositions comprising purified anti-abeta monoclonal antibodies
US9920120B2 (en) 2013-09-13 2018-03-20 Genentech, Inc. Methods and compositions comprising purified recombinant polypeptides
US9945858B2 (en) 2013-09-13 2018-04-17 Genentech, Inc. Compositions and methods for detecting and quantifying host cells protein in cell lines and recombinant polypeptide products
US10597446B2 (en) 2013-09-13 2020-03-24 Genentech, Inc. Method of treatment comprising purified recombinant IL-13 antibody
US11667706B2 (en) 2013-09-13 2023-06-06 Genentech, Inc. Methods of purifying recombinant anti-abeta antibodies
US11519912B2 (en) 2013-09-13 2022-12-06 Genentech, Inc. Compositions and methods for detecting and quantifying host cell protein in cell lines and recombinant polypeptide products
US10597447B2 (en) 2013-09-13 2020-03-24 Genentech, Inc. Compositions comprising purified recombinant IL-13 antibody
US10822404B2 (en) 2013-09-13 2020-11-03 Genentech, Inc. Methods and compositions comprising purified recombinant polypeptides
US10788494B2 (en) 2013-09-13 2020-09-29 Genentech, Inc. Compositions and methods for detecting and quantifying host cell protein in cell lines and recombinant polypeptide products
EP3738981A1 (en) 2014-01-24 2020-11-18 NGM Biopharmaceuticals, Inc. Antibodies binding beta klotho domain 2 and methods of use thereof
EP3590539A1 (en) 2014-03-04 2020-01-08 Kymab Limited Antibodies, uses & methods
US9738702B2 (en) 2014-03-14 2017-08-22 Janssen Biotech, Inc. Antibodies with improved half-life in ferrets
WO2015175375A1 (en) 2014-05-13 2015-11-19 Short Jay M Conditionally active biological proteins
US10329556B2 (en) 2014-05-13 2019-06-25 Bioatla, Llc Conditionally active biological proteins
EP3888690A2 (en) 2014-05-16 2021-10-06 MedImmune, LLC Molecules with altered neonate fc receptor binding having enhanced therapeutic and diagnostic properties
US11760809B2 (en) 2014-06-04 2023-09-19 BioNTech SE Human monoclonal antibodies to ganglioside GD2
US9856324B2 (en) 2014-06-04 2018-01-02 MabVax Therapeutics, Inc. Human monoclonal antibodies to ganglioside GD2
WO2015187811A2 (en) 2014-06-04 2015-12-10 MabVax Therapeutics, Inc. Human monoclonal antibodies to ganglioside gd2
US10906988B2 (en) 2014-06-04 2021-02-02 Biontech Research And Development, Inc. Human monoclonal antibodies to ganglioside GD2
EP3868405A1 (en) 2014-06-04 2021-08-25 BioNTech Research and Development, Inc. Human monoclonal antibodies to ganglioside gd2
US10513699B2 (en) 2014-09-03 2019-12-24 Bioatla, Llc Discovering and producing conditionally active biologic proteins in the same eukaryotic cell production hosts
US11873339B2 (en) 2014-12-11 2024-01-16 Pierre Fabre Medicament Anti-C10orf54 antibodies and uses thereof
US10766959B2 (en) 2014-12-11 2020-09-08 Pierre Fabre Medicament Anti-C10ORF54 antibodies and uses thereof
EP3800202A1 (en) 2014-12-11 2021-04-07 Pierre Fabre Medicament Anti-c10orf54 antibodies and uses thereof
EP4137157A1 (en) 2015-03-03 2023-02-22 Kymab Limited Antibodies, uses and methods
WO2016139482A1 (en) 2015-03-03 2016-09-09 Kymab Limited Antibodies, uses & methods
US10844122B2 (en) 2015-05-06 2020-11-24 Janssen Biotech, Inc. Prostate specific membrane antigen (PSMA) bispecific binding agents and uses thereof
US10428145B2 (en) 2015-09-29 2019-10-01 Celgene Corporation PD-1 binding proteins and methods of use thereof
US11472876B2 (en) 2015-11-02 2022-10-18 Bioatla, Inc. Conditionally active polypeptides
US10766958B2 (en) 2016-09-19 2020-09-08 Celgene Corporation Methods of treating vitiligo using PD-1 binding antibodies
US10751414B2 (en) 2016-09-19 2020-08-25 Celgene Corporation Methods of treating psoriasis using PD-1 binding antibodies
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
WO2019073069A1 (en) 2017-10-13 2019-04-18 Boehringer Ingelheim International Gmbh Human antibodies to thomsen-nouvelle (tn) antigen
WO2020016459A1 (en) 2018-07-20 2020-01-23 Pierre Fabre Medicament Receptor for vista
WO2022147463A2 (en) 2020-12-31 2022-07-07 Alamar Biosciences, Inc. Binder molecules with high affinity and/ or specificity and methods of making and use thereof
WO2023131901A1 (en) 2022-01-07 2023-07-13 Johnson & Johnson Enterprise Innovation Inc. Materials and methods of il-1beta binding proteins
WO2024013727A1 (en) 2022-07-15 2024-01-18 Janssen Biotech, Inc. Material and methods for improved bioengineered pairing of antigen-binding variable regions

Also Published As

Publication number Publication date
GB9415379D0 (en) 1994-09-21
ZA956253B (en) 1997-01-08
US20030064481A1 (en) 2003-04-03

Similar Documents

Publication Publication Date Title
US5783181A (en) Therapeutic uses of fusion proteins between mutant IL 4/IL13 antagonists and immunoglobulins
EP0770135A1 (en) Novel compounds
AU668423B2 (en) Bispecific immunoadhesins
JP2644794B2 (en) A new type of colony stimulating factor-1
US5457038A (en) Natural killer stimulatory factor
JP3507507B2 (en) Hybrid of interferon-α and immunoglobulin linked via non-immunogenic peptide
AU678787B2 (en) Methods of preparing soluble, oligomeric proteins
US5451521A (en) Procoagulant proteins
US7361738B2 (en) Megakaryocyte stimulating factors
US20070104680A1 (en) Antibodies to natural killer stimulatory factor
EP0230107A1 (en) Mammalian interleukin-4
KR20150127185A (en) AGLYCOSYLATED Fc-CONTAINING POLYPEPTIDES
KR20020018197A (en) EXPRESSION AND EXPORT OF INTERFERON-ALPHA PROTEINS AS Fc FUSION PROTEINS
WO1994010308A9 (en) Methods of preparing soluble, oligomeric proteins
WO1997000319A2 (en) Chimeric leptin fused to immunoglobulin domain and use
KR19990063653A (en) Chemokine inhibitors
EP0342206A1 (en) Human interleukin-3 proteins
EP0425536A1 (en) Nonglycosylated human interleukin-3 compositions
WO1997023639A1 (en) Process for producing biologically active fused proteins
AU620537B2 (en) Human interleukin-4 muteins
JPH07149800A (en) New soluble human fc-gamma iii receptors, their preparation,pharmaceutical compositions containing them, their use as medicines and their use for diagnosis
AU1196402A (en) Novel compounds
AU2140699A (en) Novel compounds
JP3652365B6 (en) Natural killer stimulating factor
IE68876B1 (en) Thrombin-binding substance and process for preparing the same

Legal Events

Date Code Title Description
AS Assignment

Owner name: SMITHKLINE BEECHAM CORPORATION, PENNSYLVANIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:YOUNG, PETER RONALD;SHATZMAN, ALLAN RICHARD;BROWNE, MICHAEL JOSEPH;AND OTHERS;REEL/FRAME:007630/0269;SIGNING DATES FROM 19950626 TO 19950705

Owner name: SMITHKLINE BEECHAM CORPORATION, UNITED KINGDOM

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:YOUNG, PETER RONALD;SHATZMAN, ALLAN RICHARD;BROWNE, MICHAEL JOSEPH;AND OTHERS;REEL/FRAME:007630/0269;SIGNING DATES FROM 19950626 TO 19950705

FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

FPAY Fee payment

Year of fee payment: 4

REMI Maintenance fee reminder mailed
LAPS Lapse for failure to pay maintenance fees
STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Lapsed due to failure to pay maintenance fee

Effective date: 20060721